Risk Prediction Models and Visualizations for Hepatorenal Syndrome by Koola, Jejo David
  
RISK PREDICTION MODELS AND VISUALIZATIONS 
FOR HEPATORENAL SYNDROME 
 
 
By 
 
Jejo David Koola 
 
 
Thesis 
 
Submitted to the Faculty of the 
 
Graduate School of Vanderbilt University 
 
in partial fulfillment of the requirements 
 
for the degree of 
 
 
MASTER OF SCIENCE 
 
 
in 
 
Biomedical Informatics 
 
December 15, 2018 
 
Nashville, Tennessee 
 
 
 
 
 
 
Approved: 
 
Michael E. Matheny, M.D., M.S., M.P.H. 
 
Bradley Malin, Ph.D. 
 
Daniel Fabbri, Ph.D. 
  
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2018 by Jejo D. Koola 
All Rights Reserved 
  
 iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to my mother, for her  
support and her unwavering faith in me. 
  
 iv 
ACKNOWLEDGEMENTS 
 
I would like to sincerely thank my thesis committee for their support in completing this project. I 
would like to especially thank Dr. Michael Matheny for his amazing mentoring, help, and 
guidance in helping me take my first steps in Biomedical Informatics and a physician scientist 
career. I would also like to thank Dr. Brad Malin and Dr. Daniel Fabbri who supported me with 
guidance and insightful comments regarding this work. Thank you for giving me the chance to 
make this an unforgettable experience.  
My work would not have been possible without the generous financial support of the Department 
of Veterans Affairs and the Advanced Fellowship Program in Medical Informatics through the 
Office of Academic Affiliations. Additionally, I whole heartedly thank the Department of 
Biomedical Informatics, Vanderbilt University for their generous financial in-kind support in 
allowing me to obtain this Master’s.  
My work wouldn’t have been possible without the help of so many other people who were 
involved in this project. Thank you to the faculty, staff, and fellow students at the Department of 
Veterans Affairs. Most specifically, I would like to thank Dr. Ruth Reeves, Dr. Glenn Gobbel, 
Jason Denton, Dax Westerman, Vincent Messina, and Dr. Freneka Minter. Thank you also to the 
faculty, staff, and students of the Department of Biomedical Informatics at Vanderbilt 
University. Specifically, I would like to thank Dr. Kevin Johnson, Dr. Cynthia Gadd, and Ms. 
Rischelle Jenkins. 
Finally, I would like to thank my parents and my sister for supporting me and encouraging me 
throughout this experience and work. 
 v 
TABLE OF CONTENTS 
 
Page 
ACKNOWLEDGEMENTS ........................................................................................................... iv 
TABLE OF CONTENTS ................................................................................................................ v 
LIST OF TABLES ....................................................................................................................... viii 
LIST OF FIGURES ....................................................................................................................... ix 
Chapter I: Introduction .................................................................................................................... 1 
Clinical Background ................................................................................................................... 1 
Cirrhosis Complications.......................................................................................................... 2 
Hepatorenal Syndrome (HRS) ................................................................................................ 4 
Informatics Background.............................................................................................................. 5 
Data Driven Phenotyping ........................................................................................................ 5 
Use of Natural Language Processing Products in Phenotyping & Risk Modeling ................ 6 
Risk Prediction Models ........................................................................................................... 8 
Assessment of Performance (Discrimination / Calibration) ............................................... 9 
Feature Generation & Selection .......................................................................................... 9 
Information Visualization ......................................................................................................... 10 
Cognitive Principles of Visualization ................................................................................... 11 
Taxonomy of Visualization................................................................................................... 11 
General Paradigm of Visualization ....................................................................................... 12 
Temporal Visualizations ....................................................................................................... 13 
Challenge of Big Data ........................................................................................................... 14 
Application in Clinical Informatics ...................................................................................... 14 
Prior HRS Informatics Research ............................................................................................... 15 
Thesis Objective........................................................................................................................ 16 
Chapter II: Phenotyping Hepatorenal Syndrome .......................................................................... 19 
Chapter Objective ..................................................................................................................... 19 
Materials and Methods .............................................................................................................. 19 
Study Population ................................................................................................................... 19 
Data Collection ..................................................................................................................... 19 
Cohort Selection.................................................................................................................... 19 
Outcome ................................................................................................................................ 20 
Predictor Variables................................................................................................................ 20 
 vi 
Natural Language Processing ............................................................................................... 21 
Final Phenotyping Model Development ............................................................................... 22 
NLP Dimensionality Reduction and Phenotyping Model Assessment................................. 22 
Results ....................................................................................................................................... 23 
Discussion ................................................................................................................................. 29 
Limitations ............................................................................................................................ 30 
Conclusion ............................................................................................................................ 30 
Chapter III: Risk Prediction Models for Hepatorenal Syndrome ................................................. 32 
Chapter Objective ..................................................................................................................... 32 
Patients and Methods ................................................................................................................ 32 
Study population ................................................................................................................... 32 
Data Collection ..................................................................................................................... 32 
Cohort Selection.................................................................................................................... 32 
Outcome ................................................................................................................................ 33 
Predictor Variables................................................................................................................ 33 
Model Development.............................................................................................................. 35 
Model Assessment ................................................................................................................ 35 
Results ....................................................................................................................................... 35 
Discussion ................................................................................................................................. 38 
Chapter IV: Information Visualization for Model Analysis ......................................................... 41 
Chapter Objective ..................................................................................................................... 41 
Methods..................................................................................................................................... 41 
Workflow Observation.......................................................................................................... 41 
Design Rationale and Tools .................................................................................................. 41 
Data Sets ............................................................................................................................... 42 
Methods on using clustering to look at model performance ................................................. 42 
Results ....................................................................................................................................... 44 
Timeline Visualization .......................................................................................................... 44 
Clustering to analyze model performance ............................................................................ 44 
ClusterView  Visualization ................................................................................................... 47 
Layout ............................................................................................................................... 47 
User Interaction ................................................................................................................. 49 
Discussion ................................................................................................................................. 50 
Chapter V: Conclusions ................................................................................................................ 51 
 vii 
Limitations ................................................................................................................................ 52 
Future Directions ...................................................................................................................... 52 
References ..................................................................................................................................... 54 
Appendix A: Details on Phenotyping Algorithms ........................................................................ 71 
Appendix B: Details on Risk Prediction Algorithms .................................................................. 143 
 
        
 viii 
LIST OF TABLES 
 
 
Table                                                                                                                                          Page  
Table 1: Diagnostic criteria for Hepatorenal Syndrome. ................................................................ 4 
Table 2: Patterns of information visualization and their relationships to data size and 
dimensionality. .............................................................................................................................. 12 
Table 3: Tasks in Shneiderman’s Paradigm of Data Visualization. ............................................. 13 
Table 4: Summary of Hepatorenal Syndrome Risk Prediction Papers. ........................................ 17 
Table 5: Diagnostic criteria for Hepatorenal Syndrome from the International Ascites Club. .... 20 
Table 6: Characteristics of the cohort of cirrhotic patients with and without HRS as determined 
by chart review. ............................................................................................................................. 23 
Table 7: Evaluation of dimension reduction techniques for handling Natural Language 
Processing outputs for phenotyping. ............................................................................................. 25 
Table 8: Discrimination and calibration performance of the five models to phenotype 
Hepatorenal Syndrome.................................................................................................................. 26 
Table 9: Odds ratios and confidence intervals for the logistic regression model based on 100 
bootstrap samples. ......................................................................................................................... 27 
Table 10: Error analysis of false positive and false negatives using the logistic regression model 
on the test set at three different thresholds. ................................................................................... 28 
Table 11: Breakdown of the candidate predictor variables used in the Hepatorenal Syndrome risk 
prediction model. .......................................................................................................................... 34 
Table 12: Characteristics of patients with and without HRS. ....................................................... 35 
Table 13: Odds ratios for the general estimating equations model predicting HRS for variables 
selected by penalized logistic regression. ..................................................................................... 38 
Table 14: Discrimination and calibration statistics for each cluster along with 95% confidence 
intervals obtained by bootstrap sampling. .................................................................................... 45 
 
 
  
 ix 
LIST OF FIGURES 
 
 
Figure                                                                                                                                        Page  
Figure 1: Change in prevalence of chronic liver disease in the United States from 1988 to 2008. 2 
Figure 2: Change in prevalence of cirrhosis etiology for Veterans Affairs patients from 2001 to 
2013................................................................................................................................................. 2 
Figure 3: Survival estimates for controls, subjects with compensated cirrhosis, and subjects with 
decompensated cirrhosis. ................................................................................................................ 3 
Figure 4: Steps leading to Hepatorenal Syndrome. ........................................................................ 4 
Figure 5: Hypothetical phenotyping elements for Hepatorenal Syndrome. ................................... 6 
Figure 6: Description of workflow and modules within the clinical Text Analysis Knowledge 
Extraction System (cTAKES) NLP system. ................................................................................... 8 
Figure 7: Examples of pre-attentive/gestalt properties in visual processing. ............................... 12 
Figure 8: Workflow describing Natural Language Processing pipeline. ...................................... 22 
Figure 9: Discrimination (Panel A), via the ROC curve, and calibration (Panel B), via smoothed 
observed-to-expected probability plots, for the five different various models for phenotyping 
Hepatorenal Syndrome phenotyping models. ............................................................................... 26 
Figure 10: Cohort selection process from an initial sample of all inpatient admissions after 
applying exclusion criteria. ........................................................................................................... 33 
Figure 11: Observed-to-expected probability plot from the GEE model. Each point represents a 
decile within the predicted probability. ........................................................................................ 37 
Figure 12: Example clinical course visualization for a patient with alcoholic cirrhosis. ............. 43 
Figure 13: Example comparison of two patients with different clinical trajectories as depicted by 
the clinical course visualization tool. ............................................................................................ 43 
Figure 14: Visual representation of each patient cluster. .............................................................. 47 
Figure 15: Layout of statistics visualization tool. ......................................................................... 48 
Figure 16: 7x7 Self Organizing Map with the 49 clusters of observations. Each cluster has an 
outer ring color coded to the risk model's performance (AUC) within that cluster. ..................... 48 
Figure 17: Statistics visualization user interface workflow. ......................................................... 49 
 
 
 1 
CHAPTER I: INTRODUCTION 
 
In 2012 the Institute of Medicine (now the National Academy of Medicine) released a desiderata 
for a learning healthcare system, where evidence informs practice and practice informs 
evidence.1 Though the randomized clinical trial (RCT) serves as the gold standard for informing 
clinical decisions, flaws exist in terms of achieving recruitment, overly stringent 
inclusion/exclusion criteria, and lack of patient-centered decision making.2,3 Moreover, the 
majority of medical decisions may not be informed by randomized controlled trials; a recent 
review found that only 19% of Class I cardiology guidelines have Level A evidence.4  
Clinicians often have questions when caring for patients but do not pursue answers to many of 
them.5 Observational cohort studies have grown as an important complement to RCTs allowing 
comparative effectiveness research and patient-centered trials.6 This thesis centers on leveraging 
observational cohort data to create and interpret models improving healthcare for cirrhosis patients. 
CLINICAL BACKGROUND 
Cirrhosis, a late stage of chronic liver damage where scarring replaces hepatic tissue, carries 
significant morbidity and mortality due to decreased mental, physical, and biochemical function.  
The prevalence is estimated between 400,000 and 3,000,000 persons in the United States, and the 
disease causes 44,000 deaths annually.7–11  Over fifteen etiologies exist, including 
hemochromatosis, Wilson’s disease, autoimmune hepatitis, and primary biliary cirrhosis.12  In 
the United States, the most common causes are alcohol abuse, viral hepatitis, and nonalcoholic 
fatty liver disease (NAFLD).12–14 Due to increasing obesity and diabetes in the US, the 
prevalence of NAFLD has been growing (from 5.5% in the original National Health and 
Nutrition Examination Survey up to 11% in 2008, refer to Figure 1).8 Because cirrhosis may 
remain latent for years, only autopsy or late sequelae implicate the diagnosis in 20-30% percent 
of cases.15–19   
The Department of Veterans Affairs (VA) faces an increasing burden of chronic liver disease due 
to substance use disorders, chronic viral hepatitis, and increasing numbers of patients with 
NAFLD. The VA’s patients face a higher burden of substance abuse, particularly among Iraq and 
Afghanistan veterans where the prevalence has been estimated at 11%.20 Overall, 90-100% of 
alcoholics develop liver steatosis, 10-35% develop alcoholic fibrosis and/or hepatitis, and 10% 
develop cirrhosis.21 The VA is the largest single provider of Hepatitis C Virus (HCV) care in the 
US, and has approximately 186,000 patients have chronic active HCV.22 Refer to Figure 2 for a 
description of the changes in VA cirrhosis etiology prevalence. These dramatic increases in 
overall prevalence of cirrhosis at the VA will impact the VHA system with greatly increased 
costs due to complications occurring from end-stage liver disease. 
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Figure 1: Change in prevalence of chronic liver disease in the United States from 1988 to 
2008. 
Data obtained from Younossi et al.8 
  
Figure 2: Change in prevalence of cirrhosis etiology for Veterans Affairs patients from 
2001 to 2013.  
Data obtained from Beste et al.22 Note: HCV: Hepatitis C Virus; HBV: Hepatitis B Virus: PBC: Primary Biliary 
Cirrhosis; AIH: Autoimmune Hepatitis; PSC: Primary Sclerosing Cholangitis; ALD: Alcoholic Liver Disease; 
NAFLD: Non-Alcoholic Fatty Liver Disease. 
 
CIRRHOSIS COMPLICATIONS 
Cirrhosis impacts the health care system broadly because of the breadth and severity of end-stage 
liver disease complications. Complications stem from liver synthetic dysfunction and portal 
hypertension. Synthetic dysfunction causes coagulation disorders, low serum albumin, low 
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platelet counts, and hepatic encephalopathy.23 Portal hypertension, increased pressure in the 
veins that carry blood from the gastrointestinal tract to the liver, leads to ascites, varices, renal 
failure, gastrointestinal bleeding, and spontaneous bacterial peritonitis.24 Because many 
medications are metabolized by the liver, cirrhosis can cause heightened medication sensitivity 
and toxicity.25 Once a cirrhotic patient develops a complication they follow a significantly 
different disease trajectory. The median survival for a cirrhotic patient without a complication is 
10 years, however, once a patient becomes decompensated, i.e. develops a complication, their 
median survival drops to four years.26 Refer to Figure 3 for a description of the survival curve.  
Figure 3: Survival estimates for controls, subjects with compensated cirrhosis, and subjects 
with decompensated cirrhosis. 
Data taken from Fleming et al.26 
 
The only cure for cirrhosis is liver transplant. However because livers are a scarce resource, 
relatively few are transplanted annually. In 2016, 7,841 livers were transplanted with 13,725 
patients still on the waiting list at the end of the year.27 Patients are candidates for liver 
transplant once their Model for End-stage Liver Disease (MELD) score, a measure of overall 
liver dysfunction, is ≥ 15. Patients may qualify for earlier liver transplant if they have certain 
exceptional conditions, such as hepatocellular carcinoma. Liver transplantation is contraindicated 
in select cases such as severe extra-hepatic disease, acquired immunodeficiency syndrome, and 
persistent non-adherence with medical care. Because transplantation is expensive and livers are 
scarce, patients must undergo an extensive pre-transplant evaluation that includes exhaustive 
laboratory testing, cardiopulmonary assessment, cancer screening, infectious diseases evaluation, 
and psychosocial appraisal. Guidelines recommend all patients with a MELD > 10 be referred 
for liver transplant evaluation to initiate pre-transplant evaluation and substance-abuse 
counseling (if needed). One particular complication, renal failure, heralds poor survival and 
warrants urgent transplant evaluation. 
Patients with cirrhosis are particularly prone to renal failure from multiple etiologies. Causes 
include hypovolemia from diuretics, medication toxicity, parenchymal renal disease such viral 
hepatitis induced cryoglobulinemia, and changes in the circulatory system due to cirrhosis. 
Cirrhotics with renal failure have a higher mortality and increased frequency of complications 
compared to cirrhotics without renal failure.28 Acute renal failure is also a common occurrence 
in patients hospitalized with cirrhosis, occurring 20% of the time.29 The deadliest form of renal 
failure in cirrhosis is termed Hepatorenal Syndrome. 
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HEPATORENAL SYNDROME (HRS) 
Hepatorenal syndrome (HRS), is a particularly challenging complication of end-stage cirrhosis, 
and represents an archetype of multi-organ failure.30–32  HRS represents functional kidney 
dysfunction due to intense renal vasoconstriction with concomitant splanchnic vasodilation.  
Diagnosing HRS requires exclusion of other kidney disorders, absence of shock, no concurrent 
or recent treatment with nephrotoxic drugs, and no improvement in serum creatinine after at least 
two days of diuretic withdrawal and volume expansion with albumin.30   
Table 1: Diagnostic criteria for Hepatorenal Syndrome. 
Renal biopsy often does not show intrinsic disease nor sufficient tissue damage to explain the 
amount of dysfunction.  Hepatorenal Syndrome’s underlying etiology is understood to be a 
cumulative effect of multiple clinical conditions starting with progressive portal hypertension 
causing splanchnic vasodilation resulting in lowered intravascular perfusion pressures to the 
kidneys. Subsequent neurohormonal compensation leads to sodium and water retention resulting 
in ascites. Further degradation in effective blood flow to the kidneys, potentially brought on by 
an acute insult such as an infection, leads to Hepatorenal Syndrome. Refer to Figure 4. 
Figure 4: Steps leading to Hepatorenal Syndrome. 
Note: RAAS: Renin-Angiotensin Aldosterone System. 
 
The disorder is broadly divided into two types, I and II, based mainly on rate of progression and 
a few clinical indicators.  The median survival for Type I HRS is two weeks, and is six months 
for Type II HRS.31,33,34  Over a five year span, 39% of cirrhotic patients will experience HRS.35 
The definitive treatment for HRS is liver transplant,30,31,34 but several case series suggest that 
only 4.5 – 35% of patients (median 18.5%) receive a liver36–41 due to HRS’ high mortality and 
organ scarcity.42,43  The standard of care includes several temporizing and palliative measures 
Cirrhosis with ascites 
Serum creatinine > 1.5 mg/dl (old guidelines) OR diagnosis of AKI using established 
guideline agency AKI criteria (new guidelines) 
No improvement of serum creatinine after at least 2 days with diuretic withdrawal and volume 
expansion with albumin. The recommended dose of albumin is 1 g/kg of body weight per day 
up to a maximum of 100 g/day. 
Absence of shock 
No current or recent treatment with nephrotoxic drugs 
Absence of parenchymal kidney disease as indicated by proteinuria 500 mg/day, micro-
hematuria (50 red blood cells per high power field) and/or abnormal renal ultrasonography. 
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including vasopressors,30,31,34 dialysis,44 Molecular Adsorbent Recirculating System (MARS) 
therapy,45,46 Transjugular Intrahepatic Portosystemic Shunt (TIPS),47,48 and hospice.49,50 
However, there is large variability in survival among these patients, particularly those with Type 
II HRS. Some patients may benefit from early identification and initiation of some medical 
treatments.   
Temporizing measures such as dialysis do not change overall survival, and as such there is 
increasing focus on palliative treatment, which may still result in net improvements in patient 
satisfaction and quality of life in this time period.  Earlier diagnosis would be beneficial to 
initiate timely triaging or specific treatments for HRS, including the use of vasopressor and 
somatostatin agonists, albumin expansion, dialysis, expedite evaluation for transplantation, or 
referral for palliative care.  Several studies have shown that renal function prior to the initiation 
of vasopressor therapy is predictive of response,51–53 particularly a creatinine less than 3.0 
mg/dL.54 The International Ascites Club has stressed earlier diagnosis and treatment of HRS in 
its updated 2015 guidelines.55 Moreover, increasing changes in serum creatinine from baseline 
have shown linear increases in hospitalization costs amongst patients admitted with acute kidney 
injury (AKI) from $4,886 for an increase ≥ 0.3 mg/dl up to $22,023 for an increase ≥ 2.0 
mg/dl.56  
INFORMATICS BACKGROUND 
DATA DRIVEN PHENOTYPING 
Electronic health record (EHR) phenotyping helps identify sufficiently large cohorts to perform 
observational studies that inform clinical care in a wide variety of domains; refer to Shivade et 
al. and Xu et al. for a review.57,58  Phenotyping is especially important as larger observational 
cohort datasets have been generated due to collaboration from multiple institutions.59,60 EHR 
phenotyping has been applied to various conditions including cancer,61–63 diabetes,64 heart 
failure,65 rheumatoid arthritis,66 cataracts,67 drug side effects,68 pneumonia,69 asthma,70  and 
hypertension.71   
Phenotyping has not been applied to acute kidney injury (AKI), a common acute complication 
sometimes necessitating hospitalization and a challenging problem because of the close overlap 
between multiple causes of kidney injury. There are more than ten causes of AKI;72 and in 
observational cohort studies, though laboratory markers can be used for some etiologies, the 
majority of etiologies are represented by the International Classification of Diseases (ICD) code. 
Using ICD-9 codes alone is well known to have limited sensitivity and sub-optimal specificity.73 
Hepatorenal syndrome is a serious form of AKI that can occur among patients with cirrhosis, and 
stands as an archetype of multi-organ failure.30–32 Refer to Figure 5 for some EHR elements that 
may be used to identify patients with HRS. 
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Figure 5: Hypothetical phenotyping elements for Hepatorenal Syndrome. 
Note: ICD: International Classification of Diseases. 
 
Rule based systems serve as the most basic phenotyping model. The simplest rule based systems 
employ a single ICD code to identify a cohort, e.g. ICD-9 code 571.2 for alcoholic cirrhosis. 
Typical rule-based systems apply other constraints (such as age, biological sex, laboratory value 
thresholds, etc.) in a sequence of steps. Rule-based systems can be a priori defined, either by 
medical experts or based on healthcare guidelines. Conversely, they can be automatically derived 
using, for example, a decision tree algorithm. The pros of a rule-based system include their ease 
in interpretation, implementation speed, and they tend to yield good results on limited datasets. 
Because rule-based systems often rely on structured data elements that are universal in EHRs, 
they are also more portable. Examples of rule-based systems include rules for reporting quality 
metrics to guideline agencies, e.g. National Quality Forum74 measure #001875 which identifies 
individuals with hypertension based on age, blood pressure readings, and ICD codes. 
Unlike rule-based systems, systems utilizing machine learning and statistical analysis attempt a 
data-driven approach to identifying a phenotype. Popular machine learning models employed in 
these systems include support vector machines,66 random forest,76 and Bayesian algorithms.77 
Statistical methods for classification, such as logistic regression, are not infrequently used for 
phenotyping when the overall number of variables is small.78 As EHR datasets have grown, 
particularly in the number of variables available for model construction, machine learning 
algorithms have overtaken rule-based and statistical algorithms.  
Algorithm development has given way to phenotyping system design. Phenotyping systems 
attempt to generate reproducible phenotyping algorithms that can be shared and validated across 
systems. Examples include the Electronic Medical Records and Genomics (eMERGE) 
network,59 Strategic Health IT Advanced Research Projects (SHARP),79 and the Cross 
Institutional Translational Research (CICTR).80 Rule-based algorithms are naturally easier to 
share across systems and can be posted online, e.g. on PheKB.org.60 Important questions remain 
about using free text from clinical notes and variable selection in phenotyping. 
USE OF NATURAL LANGUAGE PROCESSING PRODUCTS IN PHENOTYPING & RISK MODELING 
Phenotyping applications leverage multiple information sources from the EHR, with clinical text 
playing an increasingly important role. Clinical text, as recorded by healthcare providers usually 
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during routine care of patients, can contain data inexpressible in a structured format, tedious to 
express in structured formats, or more nuanced then that which is contained in structured data.81 
Natural Language Processing (NLP) of clinical text plays a crucial role in converting free text 
into computable structured data.66,82,83 NLP systems may proceed along one of two workflows. 
One choice is to build a custom NLP pipeline and train the system to identify specific 
phrases/concepts within the documents. This process frequently requires painstaking annotation 
of a document corpus at the phrase level. Because the concepts of interest are a priori defined 
using domain knowledge, this method will produce a more parsimonious feature set and the 
results likely will have higher specificity.  
Conversely, one may utilize an “out-of-the-box” NLP system that attempts to identify all medical 
concepts within the documents. Natural Language Processing has increasingly turned to 
replacing raw text with standardized concepts from ontologies such as the Unified Medical 
Language System (UMLS).84 Natural Language Processing pipelines from clinical Text Analysis 
Knowledge Extraction System (cTAKES),85 MedLEE,86 and MetaMap87 allow for replacing free 
text concepts with UMLS concept unique identifiers (CUIs). Refer to Figure 6 for an example of 
the steps taken by the cTAKES pipeline to convert free text into computable CUIs. The 
workflow for using these systems for model development is often different, with annotation more 
likely to be performed at the document or at the patient level. In either case, some sort of manual 
chart review is required; however, depending on resources and level of domain knowledge one 
workflow may be superior to the other. Because the “out-of-the-box” approach is often non-
specific, i.e. it attempts to identify all medical terms in the text, some sort of post-processing is 
required. This post-processing often requires dimension-reduction and/or machine learning to 
match the identified concepts with the document- or patient-level annotation. 
Phenotyping has traditionally been a time intensive process, often requiring the assistance of 
domain experts. As a result, increasing emphasis has recently been placed on automated 
methods, termed high throughput phenotyping, requiring less domain knowledge.88–90 These 
high throughput methods have focused on using NLP to augment the phenotyping process.91–93 
To date, however, they have only been validated on chronic medical conditions. Performance 
may be biased due to the much higher data density for chronic conditions, particularly in terms 
of clinical text. 
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Figure 6: Description of workflow and modules within the clinical Text Analysis 
Knowledge Extraction System (cTAKES) NLP system.  
Note: Taken from apache.org.94 DT: determiner; NN: noun; VBD: verb, past tense; IN: preposition; NNP: proper 
noun; WDT: Wh-determiner; VBD: RB: adverb; VB: verb, base form; NNS: noun, plural; PRP$: possessive 
pronoun; NP: noun phrase; VB: verb phrase; Unified Medical Language System (UMLS). 
RISK PREDICTION MODELS 
Risk prediction models increasingly complement clinical reasoning and decision making in 
modern medicine.  Models have been developed to predict a wide array of outcomes including 
ICU mortality95, various types of cancer96–98, quality control99, post-acute coronary syndrome 
outcomes100,  and other forms of acute kidney injury.101–105  
Traditional views of medicine incorporated the ideal of the master clinician who, through years 
of experience and inductive reasoning, could appropriately diagnose and treat patients. This view 
of physician healthcare delivery changed in the 20th century, most notably with the birth of 
Gordon Guyatt’s “Evidence Based Medicine.”106 However, its seeds had taken root much earlier. 
Possibly the first use of rigorous modeling in healthcare had to do with population tracking and 
prediction. Verhulst developed the logistic equation to describe population growth in 1845.107 
The logistic function had subsequent uses from the U.S. Food Administration to model food 
shortages during World War I.108 Eventually, Cox would publish his seminal work on logistic 
regression.109 Though rigorous modeling was nipping at the heels of medicine in the early 20th 
century, the majority of scientific thinking, communication, and training were still grounded in 
inductive knowledge.  
Perhaps one of the earliest changes to this dogma occurred with the Framingham Heart Study 
started in 1948 in the town of Framingham, Massachusetts.110 A cohort of 5,209 subjects were 
followed prospectively to quantify various heart disease risk factors. However, the subsequent 
multivariable survival model was too complex for everyday use and it was not until a simpler, 
point-based formula allowed the Framingham Risk Score to be employed in routine clinical 
care.111 Other early forays into risk models include the Child-Turcotte-Pugh score112,113 to 
predict surgical mortality in cirrhotic patients, Maddrey’s discriminant function for alcoholic 
hepatitis,114 and Ranson’s criteria for pancreatitis mortality.115 Though these were early forays 
into risk prediction models in medicine, it was not until the 1980s when the field exploded with 
several new models.116–119 
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Nevertheless, modeling was invariably expert driven, partially as a commentary on the climate in 
medicine at the time, but also as a matter of necessity. These models were usually based on 
carefully conducted prospective studies where the variables had to be prespecified and 
reasonable to collect. The concept of “data mining,” and its promise, was coined in the 1990s 
with the increasing reliance on large database systems in finance, transportation, and 
communication.120 Data-driven medicine did not really become a concept until two important 
events in the 21st century, sequencing of the human genome and the HITECH Act, which 
introduced a tremendous amount of data into healthcare. With the proliferation of EHRs, risk 
modeling became more complex as it consumed vastly more information,105,121–124 and even 
allowed EHR incorporation of predictions at the point of care.125–128 These EHR driven, point-of-
care risk models have led to probabilistic clinical decision support (CDS), as opposed to 
reporting a binary outcome, making calibration all the more important. 
Assessment of Performance (Discrimination / Calibration) 
For a risk prediction model to be clinically useful, one must consider both its discrimination as 
well as its calibration.129 Discrimination refers to the model’s ability to distinguish individuals 
who experienced the outcome from those who remained event free. Calibration refers to 
agreement between the probability of developing the outcome as estimated by the model and the 
observed outcome frequencies. Although clinical decision rules have often focused on a model’s 
discriminative ability (e.g., instituting a statin medication in high cardiovascular risk patients)130, 
proper calibration is required when multiple decision options are available at differing levels of 
risk (e.g., management of a solitary pulmonary nodule found on computed tomography).131 
Moreover, model performance degrades when used in a cohort outside of its development, 
making careful validation of discrimination and calibration essential.132 
Several statistics are available to summarize discrimination for binary classification models, 
which tend to be the most common in healthcare, including the c-index133 and the area under the 
receiver operator characteristic curve (AUC). One may best assess calibration graphically by 
plotting observed outcome frequencies against mean predicted probabilities within subgroups of 
the observations, usually split by deciles of predicted probabilities.134 The plot can be 
supplemented with formal statistical testing for goodness of fit, frequently done using the 
Hosmer-Lemeshow (HL) test. However, because the HL test applies the chi-square distribution, 
whose power scales with the sample size,135 the null hypothesis for the HL-test may be accepted 
under a small sample size, but rejected under a large sample size.136  
Newer measures of discrimination and calibration have been developed. Discrimination has been 
reframed as a reclassification task, i.e. how well does a new model correctly classify 
observations that the old model misclassified. Two metrics for measuring reclassification include 
the Net Reclassification Index (NRI) and the Integrated Discrimination Index.129 The NRI may 
be interpreted as the net improvement in the true positive rate plus the net improvement in the 
false positive rate under the new model. The NRI may be measured at specific thresholds of 
interest of the underlying model, which may be more informative than a global measure such as 
the AUC. Healthcare delivery is often interested in model performance at certain cutpoints.  
Feature Generation & Selection 
Feature selection and generation are common steps in data pre-processing. Feature selection 
hopes to identify a relevant subset of the original features; whereas, feature generation creates 
new features (optionally replacing some original features) to enhance model performance. 
 10 
Feature selection has always been essential to produce parsimonious models, prevent loss of 
statistical power, and prevent overfitting. However, as the amount of healthcare data has 
exploded feature selection has gained in importance. Traditional healthcare models were often 
created with 5 – 20 a priori selected variables; however, newer data-driven models may have 
hundreds of potential variables. Popular clinical NLP systems can generate hundreds to 
thousands of features from reviewed documents.85–87,137 Often, dimensionality reduction is 
necessary to either make the classification task more tractable or improve performance.138,139  
Perhaps the most common traditional selection method has been forward selection and backward 
elimination (FBS). Forward/backward selection has drawbacks, however; particularly in large 
datasets with many variables or collinearity among its predictors.140 Newer methods include 
using random forest classifier based variable importance and 141 penalized logistic 
regression.142,143 For very high dimensional data, which is more common in biomedical datasets, 
penalized logistic regression methods such as LASSO and elastic net appear to work well.144 
Though one may produce an adequate model via the original feature set, often times one must 
consider feature generation as both a way to perform dimension reduction and identify novel 
relationships. Feature generation methods such as a priori specifying interaction terms, Principle 
Component Analysis (PCA),145 and Latent Discriminant Analysis (LDA)146 serve an important 
role in discovering underlying structure. Methods such as PCA and LDA have the added benefit 
of reducing the feature space.  
A relatively recent dimensionality reduction technique involves a distributed vector 
representation of words, or word embeddings, which has shown good performance in many NLP 
tasks.147,148 Google’s word2vec, an increasingly popular embedding algorithm,149 has been 
generalized to vector representations of an entire document (termed doc2vec).150 Although word 
embeddings have been used to improve classification in healthcare tasks,151–153 it is still 
relatively new to assess improvement in phenotyping. Zhang et al. assessed word embedding’s 
benefit in identifying phrases suggestive of psychiatric illness,154 and Turner et al used word 
embedding to identify an overall phenotype for Systemic Lupus Erythematosus.155 However, 
they applied it to chronic conditions and used raw text. 
Regardless of whether one is interested in feature selection or feature generation, the primary 
goal is to improve model accuracy. However, and this is particularly true in data-driven methods, 
a secondary measure of importance is understandability.156 Validation of the model not only 
requires statistical measures such as discrimination and calibration, but also 
biological/physiological plausibility. Feature generation methods such as PCA, latent 
discriminant analysis, and neural networks may obscure understandability of the model.157 In 
this regard, knowledge driven variable selection tends to be superior.  
INFORMATION VISUALIZATION 
The surge of Electronic Health Records, and its resulting zettabyte of data,158 allows us to realize 
the vision of the learning healthcare system. Despite the growth of observational cohort studies, 
challenges still remain bringing the knowledge from the bench-to-the-bedside.  Observational 
cohort studies employ data for secondary use, i.e. data collected for other purposes. The most 
common secondary use scenario is data collected as part of routine clinical care.159 However, 
due to cognitive and perceptual limitations, healthcare providers need increasing help to digest 
the vast amounts of information generated during clinical care.  Information visualization can be 
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defined as “the process of transforming data, information, and knowledge into visual form 
making use of humans’ natural visual capabilities.”160 Bertin, a pioneer in information 
visualization, defined it as, “… finding the artificial memory that best supports our natural means 
of perception.”161 Ultimately it is the depiction of information using spatial or graphical 
representations, to facilitate comparison, pattern recognition, change detection, and other 
cognitive skills by making use of the visual system.  It is important to differentiate scientific 
visualization from information visualization. Scientific visualization’s goals are to depict 
scientific data, often physically based, over a compact domain. Information visualization often 
deals with abstract data types mapped onto abstract domains.162  
COGNITIVE PRINCIPLES OF VISUALIZATION 
There are two basic cognitive principles in visualization, pre-attentive properties and gestalt 
properties.161 Pre-attentive processing occurs without need for focusing attention. Tasks which 
are completed in less than 250 milliseconds are considered pre-attentive.  As reference, a non-
exhaustive list of the various pre-attentive properties that have been studied in Information 
Visualization include length, width, size, curvature, number, terminators, intersection, closure, 
color, intensity, flicker, motion, binocular luster, stereoscopic depth, 3D depth curves, and 
lighting direction (See Figure 7 for examples).163  Accurate application of pre-attentive 
properties can communicating information rapidly, as a pre-attentive task takes the same amount 
of time irrespective of the number of distractors.164 The gestalt properties are forms or patterns 
that transcend the stimuli used to create them. They include proximity, similarity, enclosure, 
closure, continuity, and connection. In Information Visualization, proximity, similarity, and 
enclosure tend to play larger roles. 
TAXONOMY OF VISUALIZATION 
Visualization techniques can be subdivided into a few different types. Certain methods may be 
more appropriate for particular types of data.165,166 Table 2 describes some of the patterns of 
information visualization and the data sizes and dimensionality for which they are suited.  
Geometric visualization is one of the most common and has the closest resemblance to Scientific 
Visualization. A classic example is the use of hierarchical parallel coordinates, which allows the 
plotting of multiple variables within one figure.167 Iconographic visualization techniques have 
gained more popularity as a means of communicating complex information to lay people.168 
Pixel based visualizations allow display of very large datasets by mapping multi-dimensional 
datapoints onto a single pixel within a larger diagram.169 Hierarchical display visualizations 
allow the user to see underlying relationships within the data; the Treemap is a popular tool to 
demonstrate hierarchical relationships and semantic information.170 Network visualizations are 
common in displaying non-hierarhical relationships within a wide area of research, including 
social relationships and bioinformatics.171,172   
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Figure 7: Examples of pre-attentive/gestalt properties in visual processing. 
Each panel demonstrates a different pre-attentive property. A: orientation; B: length; C: closure; D: size; E: 
curvature; F: color; G: density; H: shape. Panels C, F, and G also demonstrate gestalt properties of closure, 
similarity, and proximity, respectively. Taken from Healey.173  
 
Table 2: Patterns of information visualization and their relationships to data size and 
dimensionality.  
GENERAL PARADIGM OF VISUALIZATION 
Ben Shneiderman constructed a paradigm of visualization, divided into tasks and data types. 
Tasks includes: (1) provide an overview; (2) zoom into relevant detail; (3) filter; (4) provide 
details-on-demand; (5) relate what is being viewed to the bigger picture; (6) be able to provide a 
history of actions; and (7) extract relevant details.174 Shneiderman also suggested (possibly 
orthogonal) data-types that in some ways mirror the taxonomy presented in Table 2. In 
particular, he considered data to be: 1-dimensional (1-D), 2-D, 3-D, Multi-dimensional, 
Temporal, Hierarchical, and Networked. Naturally, certain visualization techniques work well 
 
Data 
Size 
Dimensions Examples 
Geometric Large to 
very 
large 
Medium to 
high 
Scatter matrix, PCA, factor analysis, MDS, 
GridViz, Hierarchical Parallel Coordinates 
Icon Small to 
medium 
Medium to 
high 
Chernoff faces, color icons, driftweed, shape 
coding, sound icons 
Pixel Large to 
very 
large 
Medium Circle Segments, Recursive Pattern, Space 
Filling Curves 
Hierarchical Small to 
medium 
Low to 
medium 
TreeMap, Dimensional Stacking, Worlds-
within-Worlds 
Graph Medium Low NetMap, NetViz, SocialNet 
Hybrid Variable Variable Variable 
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with certain data types in Shneiderman’s hierarchy, e.g. Hierarchical Parallel Coordinates for 
multi-dimensional data and a TreeMap for hierarchical data. Table 3 outlines Shneiderman’s 
visualization “tasks” and methods to effectuate these tasks. 
Table 3: Tasks in Shneiderman’s Paradigm of Data Visualization. 
Tasks Example Methods 
Overview Fisheye distortion 
Zoom Brushing 
Filter Dynamic querying 
Details-on-Demand Pop-up windows 
Relate LifeLines175 
History Undo/Redo controls 
Extract Image export 
Visualization is increasingly interactive, especially when dealing with large datasets with 
multidimensional data. Central paradigms in dealing with complex data sets, as is often 
encountered in healthcare, are multiple coordinated views and dynamic queries.176,177 Dynamic 
queries allow the user to interact with the visualization in a pragmatic manner: (1) visual 
presentation of the query’s components; (2) visual presentation of results; (3) rapid, incremental, 
and reversible control; (4) selection by pointing; and (5) immediate, continuous feedback.  
TEMPORAL VISUALIZATIONS 
Temporal visualizations seek to identify patterns in time-dependent data changes. Several 
general purpose visualization tools have been developed to explore temporal changes in data.178–
181 Healthcare temporal visualization has tackled time series182–184 and event series data.175,185–
187 Time series data often have issues with scale and data density, particularly in healthcare. 
Berry et al.179 used “brushing,” a technique that allows the user to examine a data segment in 
greater detail by serially highlight and zooming in on areas of interest. Another technique used to 
zoom in on detail is “distortion visualization.” Kincaid180 applies distortion allowing the user to 
employ a “fish-eye lens” type effect. Doing so allows the user to view detail about a specific part 
of the time-line, while still maintaining global perspective.  
Different layouts can help alleviate some of the challenges of temporal data. Multi-
dimensionality is a common hurdle with healthcare data. Multi-dimensionality makes visualizing 
temporal data all the more difficult. Some basic solutions to the problem include utilizing 
interactivity to allow the user to select subsets of variables to display, such as in Rind et al.182 
Another design principle combines “multiple coordinated views,” i.e. different perspectives of 
the same data, to handle multi-dimensionality. Zhao et al.181 uses a radial layout, but combines it 
with alternate linear views offering different perspectives of the data. Disease specific views, a 
common design in healthcare visualizations of patient data, attempt to align the patient’s disease 
course, usually summarized by a numeric measure, compared to treatment interventions.183 
Brodbeck et al.,184 for example, utilizes a simple linear view but juxtaposes estimates of lung 
function with breathing treatments in patients with obstructive pulmonary disease.   
Though frequently healthcare visualizations attempt to plot data regarding a single patient, 
another common theme is plotting data of multiple patients together on the same visualization in 
an attempt to identify patterns. One of the earliest multi-patient visualizations is the seminal 
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work by Plaisant et al. with LifeLines.175 Plaisant expanded on this work by tackling a common 
problem with temporal visualization of healthcare data: often healthcare data records discrete 
events, e.g. medication refills; however, these discrete events are semantically part of a 
continuous temporal period, i.e. the time from when the healthcare provider starts prescribing the 
medication to when it stops. Wang et al.187 operationalized an iterative method to combine 
events to visualize patterns in patients with heparin-induced thrombocytopenia. Meyer186 
updated the prior work to assess patterns in medication use for patients with obstructive lung 
disease.  
CHALLENGE OF BIG DATA 
Big Data offers unique challenges for Information Visualization. Both the scale of data and the 
dimensionality provide challenges for constructing effective visual analytic tools. Two major 
approaches have emerged to handle these challenges: distortion and non-distortion based 
approaches. Non-distortion based approaches primarily focus on presenting a part of the data at 
any one time using scrolling or paging access, providing hierarchical access, and structure 
specific presentation. Distortion based approaches try to preserve the global data presentation on 
the macro scale, while zooming into the relevant area of interest on the micro scale. One 
common distortion based visualization is the Fisheye Lens, which zooms in on a local area of the 
visualization, compressing the areas not of interest, though they are still displayed on screen.188  
The prior discussed paradigms of dynamic queries and multiple coordinated views can also help 
the user explore and interpret very large datasets. 
APPLICATION IN CLINICAL INFORMATICS 
Complex informatics solutions have had difficulty gaining traction in routine clinical practice 
because of esoteric analytic techniques and outputs.  Information visualization, a field devoted to 
conveying complex data, can address these shortcomings.165,177   Visual Analytics in healthcare 
has been used for improving radiology interpretation,169,189 investigating temporality,185,187,190–
193 explaining social networks,171 analyzing spatial patterns,194,195 documenting workflows,177 
identify latent structure,176 and analyzing high dimensional data.196,197  Research on uncertainty 
visualization has predominated within geographic information science, geographic visualization, 
and scientific visualization fields.198–203  
Though visualizing risk prediction and uncertainty has received some attention for patient-facing 
tools,168,204 physician-facing clinical decision support (CDS) at the point of care has received 
sparse investigation.205 Most visualizations in medical practice are designed to be used “off-
line.” Because medical decision making rarely has an obvious correct answer, further research in 
uncertainty visualization for CDS would be beneficial.   
Visualization has also been utilized to better understand patient cohorts. For example, Mane et 
al.205 employed visualization to better understand results in comparative effectiveness trials to 
make decisions in psychiatry. Early efforts have also used visualization to show clinicians 
“Patients-like-me” cohorts.206  An essential component of these kinds of studies is ensuring that 
one has an appropriate cohort of patients. Research studies are often done under the assumption 
that a cohort of patients based on fairly rudimentary principles are relatively uniform. As 
discussed in simple rule-based phenotyping algorithms, a common assumption is that if one 
selects a group of patients with Hepatorenal Syndrome via simple structured data (e.g., ICD-9 
code) the cohort will be rather homogenous.  
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However, this assumption often does not hold. The case mix (i.e. the heterogeneity of subjects in 
the population) used to develop the model affects both discrimination and calibration.207,208 
More importantly, population heterogeneity can hide subgroups for which the risk model 
underperforms (e.g. pharmacogenomic model based dosing of warfarin209 and a geriatric 
mortality model210 did worse in African Americans and the EuroSCORE cardiac surgery 
mortality model performed worse for high-risk subgroups).211  
The process of finding a cohort of similar patients goes by many names, including phenotyping, 
matching, cohort discovery, etc. Matching is an increasingly popular method to improve causal 
inference in observational studies.212 Matching attempts to reduce the bias inherently involved in 
observational studies because of measured and unmeasured confounders.213 The end result is a 
matched group of study subjects that could theoretically have been produced by a randomized 
control trial. However, traditional matching methods may cause spurious results based on the 
methodologies.214,215 
Information Visualization, when combined with clustering, may help identify true pockets of 
heterogeneity. Clustering has been applied to various medical problems such as identifying 
disease subtypes70,216,217 and risk stratifying patients.218,219 At its heart, Information 
Visualization aims at making the user an active participant in identifying patterns in the data, 
which may be undiagnosed by a computational algorithm. For example Gotz et al.220 clustered 
patients into similar groups, then attempted to visualize common clinical trajectories. The goal 
being to use the group’s trajectory to predict a new patient’s outcomes.  
PRIOR HRS INFORMATICS RESEARCH 
Current HRS mortality risk models suffer from one or more flaws: they were developed prior to 
the current standard of care (particularly the use of vasopressors);35 they were developed with 
modest sample sizes;37,39,221–224 used specialized, non-routine laboratory tests;221 did not include 
Type I and Type II HRS;39,222,225 or they were limited to a small, a priori set of variables.39,222  
Refer to Table 4 for a summary of risk prediction studies involving HRS. Because Hepatorenal 
Syndrome exhibits different phenotypes, risk model performance may vary widely among sub 
groups.95,226,227  
Several of the studies in Table 4 use an outdated definition of HRS, either the 200730 or the 1996 
International Ascites Club criteria.228 Most of the studies do not perform any validation of their 
risk model, whether internal or external. The listed studies had a median subject size of 64 (IQR: 
41 – 105) and they evaluated a median of 7.5 variables (IQR: 1 – 16.5) in univariate testing. 
Studies that performed multivariable model building invariably only included 3 – 5 variables. 
Nevertheless, several smaller studies show promising avenues for investigation. Several studies 
have investigated the beneficial use of Transjugular Intrahepatic Portosystemic Shunts (TIPS), a 
common procedure performed in cirrhotics. The use of beta-blockers, a common medication 
used in cirrhosis, has also come under scrutiny.  
For example Guevara et al.229 assessed vascular hemodynamics in 7 patients before and after 
TIPS placement, resulting in (expected) reduced portal pressures and favorable metabolite 
profiles. Testino et al.230 assessed the role of TIPS in 9 patients with severe alcoholic hepatitis 
and HRS, and identified favorable outcomes in this small sample study. Brensing et al.231 
prospectively followed 41 non-transplanted cirrhotics with HRS who received TIPS, and also 
recorded favorable short-term hemodynamic and long-term outcomes. Regardless all three 
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studies show the limitation of studying TIPS in HRS patients as no one study or TIPS specialized 
center has enough patients for sufficient inference due to the usually restrictive nature of TIPS 
selection. Sersté et al.232 performed a single-center study involving 151 patients with refractory 
ascites (often a precursor to HRS) and found poorer survival. Mandorfer et al.233 retrospectively 
analyzed 607 patients with spontaneous bacterial peritonitis and identified increased risk of HRS. 
Because beta-blockers are the standard of care for many patients with cirrhosis (to prevent 
variceal bleeding), there is significant confounding and retrospective studies require larger 
numbers to tease out any potential causal effect. To the best of our knowledge, no study has 
evaluated the necessity of stopping a beta-blocker when a patient develops HRS.  
In both of these cases improved phenotyping efforts could advance the field by building larger 
observational cohort datasets. Additionally, phenotyping could be deployed for real-time 
identification of HRS patients as current practice guidelines often leave the diagnosis in doubt 
early in the illness’s trajectory. Biomedical informatics tools and techniques may help advance 
risk prediction for HRS by allowing a significantly larger candidate predictor pool, improving 
accuracy, and allowing for other data types such as NLP augmented clinical text. Medical 
informatics solutions have been sought to improve cirrhosis care; however, these methods 
invariably rely on structured data and ignore social determinants of illness. 
THESIS OBJECTIVE 
Because of the prior small sample sizes of patient cohorts and complexity of the disease, there 
has been little work in attempting to use clinical informatics and data science to identify and 
characterize individual phenotypes within the overall syndrome of HRS.  In addition, there are 
opportunities to attempt to create early detection algorithms in order to identify and potentially 
triage and manage patients at high risk for developing HRS in the near term.  Lastly, 
interpretation of complex, high density clinical data is a challenge in health care, particularly as 
data collection and data become harder and harder to interpret and efficiently manage, and there 
are needs for interactive visualizations to help present actionable clinical information in a way 
that is believable, accepted, and actionable for clinicians.   Within the context of the use case for 
HRS, we aim to explore some of these challenges. 
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Table 4: Summary of Hepatorenal Syndrome Risk Prediction Papers. 
Note: PC: Prospective cohort; RC: Retrospective cohort; RCT: Randomized Controlled Trial; IAC: International Ascites Club. 
Author 
(Year) 
Study 
Type 
N Inclusion Criteria Exclusion Criteria # of 
Var 
Outcome Definition Event Rate 
Ginès 
(1993)35 
PC 234 Cirrhosis with ascites GI hemorrhage within 1 month of 
admission, hepatic encephalopathy 
or bacterial infection at the time of 
study, hepatocellular carcinoma, 
respiratory, cardiac, or renal 
diseases. 
39 Development of HRS by 
criteria similar to 1996 IAC 
criteria228 
56 (24%) 
Gungor 
(2014)221 
PC 64 Group 1: Healthy control 
Group 2: serum creatinine value <1.5 
mg/dl. 
Group 3: Type-2 HRS (serum 
creatinine >1.5 mg/dl) 
Group 4: Type-1 HRS (serum 
creatinine >2.5 mg/dl) 
 
Group 2: renal dysfunction, active 
infection or malignancy 
Groups 3/4: shock, fluid losses, 
active infection, and patients who 
did not fulfil HRS diagnostic 
6 6-month Mortality 28 (43.7%) 
Maddukuri 
(2014)39 
RC 59 2007 IAC criteria for HRS,30 
received vasoconstrictors plus 
albumin 
No baseline creatinine, received 
dialysis within 3 days of therapy, 
received liver transplant within 3 
days of therapy, died within 3 days 
of therapy 
1 Treatment response, defined 
as decrease in serum 
creatinine gen-erally to a 
level < 1.5 mg/dl 
15 (25.4%) 
Martinez 
(2012)222 
RC 68 2007 IAC criteria for HRS Type 130 None provided 9 Death or discharge from 
hospital 
Median survival: 
13 days 
Salerno 
(2011)224 
PC 253 (76 
w/ 
HRS) 
Cirrhosis patients admitted with renal 
failure (creatinine > 1.5 mg/dl) 
Age < 18 years, prior kidney or 
liver transplant 
21 3-month mortality 58 (76%) 
Alessandria 
(2005)37 
RC 105 1996 IAC criteria for HRS228 
 
None specified 15 Mortality 78 (74%) 
Barreto 
(2014)225 
PC 70 2007 IAC criteria for HRS30 and 
infection 
Admitted for elective diagnostic or 
therapeutic procedures, history of 
liver and/or kidney transplantation, 
hemodialysis before admission. 
27 Treatment response, 
mortality 
Treatment 
response: 23 
(33%), 3-month 
mor-tality: 53 
(75%) 
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Author 
(Year) 
Study 
Type 
N Inclusion Criteria Exclusion Criteria # of 
Var 
Outcome Definition Event Rate 
Krag 
(2010)234 
 
PC 24 Alcoholic cirrhosis with ascites 
without HRS type 1 by 2007 IAC 
criteria30 
GI hemorrhage within the week 
before the study, spontaneous 
bacterial peritonitis, 
insulin-dependent diabetes, acute or 
chronic intrinsic 
renal or cardiovascular diseases, 
arterial hypertension, 
abnormal electrocardiogram or any 
acute 
medical conditions such as 
infections or acute 
heart or lung diseases, alcohol 
abstinence for 6 weeks was required 
 
1 Development of type 1 HRS 
within 3 months, 12-month 
mortality 
Type 1 hrs: 4 
(16.7%), death: 9 
(37.5%) 
Mandorfer 
(2014)233 
 
RC 165 Cirrhosis with ascites who received 
their first paracentesis 
Non-liver causes of ascites 1 Development of HRS within 
90 days of SBP 
development 
29 (18%) 
Sersté 
(2010)232 
 
RC 151 Cirrhotic patients with refractory 
ascites 
Not specified 15 Mortality 97 (64.2%), 
median survival: 8 
months 
Ghosh 
(2013)52 
 
RCT 46 Type 2 HRS based on IAC 2007 
criteria30 
Severe coronary 
artery disease, sepsis in, HCC, 
diabetic nephropathy 
 
17 HRS reversal 34 (74%); 17 in 
intervention group 
A and 17 in group 
B 
Guevara 
(1998)229 
 
PC 7 Type 1 HRS patients by 1996 IAC 
criteria228 
None described. 1 Improvement in renal 
function 
7 (100%) 
Brensing 
(2000)235 
PC 41 HRS patients by 1996 IAC criteria228 
ineligible for transplant 
Transplant eligibility 5 Multiple outcomes. 3-month 
survival 
63% 
Testino 
(2012)230 
 
PC 9 Severe Alcoholic hepatitis with HRS Ongoing infections, malignancy, 
symptomatic cardiac or respiratory 
diseases, GI hemorrhage in the last 
week 
1 Improvement in renal 
function 
Unclear, 
presumably all 
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CHAPTER II: PHENOTYPING HEPATORENAL SYNDROME 
 
CHAPTER OBJECTIVE 
In this study, we sought first to assess the performance characteristics of ICD-9-CM codes for 
determining HRS occurring during a patient hospitalization.  We then evaluated commonly used 
machine learning methods and dimensionality reduction techniques among a large number of 
variables derived from EHR structured data and NLP processed outputs in order to develop 
probabilistic predictions for phenotyping HRS during hospitalization of patients that have both 
cirrhosis and acute kidney injury.   We report on the performance of these methods by comparing 
each of the HRS predictors to a reference standard of clinical patient chart reviews. 
MATERIALS AND METHODS 
STUDY POPULATION 
We analyzed a retrospective cohort of patients hospitalized from among 124 medical centers in 
the Department of Veterans Affairs (VA) between January 1, 2005 and December 31, 2013.  The 
VA is an integrated care network that includes acute inpatient hospitals, outpatient primary care 
and sub-specialist clinics, outpatient pharmacies, rehabilitation facilities, long-term care facilities 
and domiciliaries.  All VA personnel use the same EHR, Veterans Information Systems and 
Technology Architecture/Computerized Patient Record System (ViSTa/CPRS), for 
documentation and administration of clinical care.236 The institutional review board and research 
and development committees of the Tennessee Valley Health Care System VA Medical Center, 
Nashville, TN, approved this study. 
DATA COLLECTION 
All data were collected from the EHR and accessed via the national Corporate Data Warehouse.  
The clinical data included vital signs, laboratory data, inpatient and outpatient medication data, 
narrative text notes, ICD-9 codes for diagnoses, and Current Procedural Terminology (CPT) 
codes for procedures. 
COHORT SELECTION 
We examined a cohort of patients hospitalized at a VA facility during the study years. We 
included all hospitalizations for patients who had a cirrhosis diagnosis (based on a history of two 
outpatient or one inpatient) ICD-9 code (571.2 or 571.5) and had AKI during their 
hospitalization with a maximum inpatient creatinine of at least 1.5 mg/dl. The maximum 
inpatient creatinine cutoff was used to be compliant with International Ascites Club criteria for 
HRS (Refer to Table 5).30 We excluded hospitalizations where the patient was on dialysis prior 
to admission, did not have at least one serum creatinine value within the year prior to admission 
or during the inpatient stay, who had a diagnosis of HRS prior to the hospitalization, who had a 
prior hospitalization with AKI, or who were discharged in less than forty eight hours.  
We performed stratified sampling based on presence/absence of an ICD-9 code for HRS, level of 
kidney injury, and level of liver disease.  Acute Kidney Injury was defined by the Kidney 
Disease: Improving Global Outcomes (KDIGO) guidelines: with Stage I being a defined as a rise 
in creatinine of ≥0.3 mg/dl from baseline; Stage II being defined as a doubling of serum 
creatinine from baseline; and Stage III being defined as a tripling of serum creatinine or initiation 
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of dialysis. Severity of liver disease was defined by the Model for End Stage Liver Disease 
(MELD) score: a combination of three laboratory values: the serum creatinine, international 
normalized ratio, and platelet count. We sampled in blocks of twelve: six patients were selected 
if they had an ICD-9 code for HRS (572.4) anytime during their hospitalization; six patients 
(without an HRS ICD-9 code) were selected based on two levels of kidney injury (KDIGO Stage 
I versus KDIGO Stages II and III) and three levels of MELD (< 20, >= 20, and unable to 
calculate). We randomly selected a total of 42 blocks (504 inpatient admissions) to serve as the 
gold standard cohort.  
Table 5: Diagnostic criteria for Hepatorenal Syndrome from the International Ascites 
Club. 
OUTCOME 
Two physician annotators reviewed the 504 hospitalizations reviewing all clinical notes, relevant 
laboratory values, medications, and radiology reports to assign each hospitalization into one of 
five categories: HRS Type I, HRS Type II, HRS Type Indeterminate, Maybe HRS, and Not 
HRS. Reviewers were instructed to differentiate Type I, Type II, and Not HRS based on 
International Ascites Club criteria.30 Type Indeterminate was reserved for cases where the 
reviewer felt the patient had enough evidence for HRS, but could not differentiate between Type 
I and II; whereas, Maybe HRS was reserved for cases of clinical uncertainty. We employed a 
practice phase where the two annotators worked in blocks of twelve patients until the inter-
annotator agreement was  0.8. Disagreements on the 504 patient set were adjudicated by a 
board certified nephrologist. We report the inter-annotator agreement for the 504 charts that were 
reviewed. To reduce the problem to a two-class classification measure, we combined HRS Type 
I, Type II, Type Indeterminate, and Maybe HRS into a “Yes HRS” category. We performed a 
sensitivity analysis to examine classification performance after excluding “Maybe HRS” from 
model building and validation. 
PREDICTOR VARIABLES 
We included 649 variables from the structured data in the EHR, including demographics (3), 
laboratory values (92), vital signs (21), home medications (99), inpatient medications (116), 
medical history (129), inpatient diagnoses and procedures (176), and four other miscellaneous 
variables. To the structured data we added nine engineered variables comprised of the patient’s 
creatinine response to various events during hospitalization. Variable engineering was performed 
Criteria 
Cirrhosis with ascites 
Serum creatinine > 1.5 mg/dl 
No improvement of serum creatinine after at least 2 days with diuretic withdrawal and volume 
expansion 
Absence of shock 
No current treatment with nephrotoxic drugs 
Absence of parenchymal kidney disease 
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using the training set and validated on the test set prior to inclusion. A detailed summary of these 
variables and associated definitions are included in Online Appendix A.1 and A.2.  To the 
structured variables, we added variables from natural language processing of the clinical notes as 
outlined in the next section. 
With the exception of cirrhosis-related or nephrotoxic medications (e.g., lactulose, rifaximin, 
albumin, norepinephrine, cyclosporine), which were coded as separate variables, all medications 
were represented by their corresponding VA drug class code (e.g., “cephalosporin 3rd 
generation”). The VA drug class codes are available publicly through the VA National Drug 
File.237 With the exception of three prehospitalization laboratory variables, the inpatient 
laboratory values and vital signs were summarized by their maximum, minimum, and mean or 
median. Missing values for laboratory test results were filled in using Markov Chain Monte 
Carlo multiple imputation using a subset of co-morbid conditions, medications, and procedures 
(See Online Appendix A.3).238 
NATURAL LANGUAGE PROCESSING 
We filtered all available clinical notes based on authorship by first including only physicians and 
advanced practice providers, and then excluding specialties unlikely to address hepatic pathology 
(podiatry, ophthalmology, and dentistry).  We converted the documents into a string of CUIs 
mapped to the UMLS (version 2013AB)84 using the clinical Text Analysis Knowledge 
Extraction System (cTAKES) version 3.2.85 To manage the large number of unique CUIs and 
data sparsity, based on inspection and evaluation of instability of modeling within the training 
data, we first filtered the output by removing CUIs with a less than 2% or greater than 90% 
prevalence among documents. All CUI counts were log transformed. From this data, we 
evaluated nine different dimensionality reduction techniques: (1) using the full set of CUIs; (2) 
CUIs limited by semantic type; (3) CUIs aggregated by semantic similarity; (4) document 
embedding using the raw text; (5) document embedding using CUIs; (6) an a priori selection of 
CUIs based on domain knowledge; (7) Yu’s Automated Feature Extraction for Phenotyping 
(AFEP);93 (8) Yu’s Surrogate-Assisted Feature Extraction (SAFE); 92 and (9) principal 
component analysis (PCA).  We refer the reader to Online Appendix Tables A.4, A.5, and A.8 
for the list of semantic type filters, a priori selected CUIs, and AFEP/SAFE selected CUIs, 
respectively. 
To aggregate CUIs by semantic similarity we first limited by semantic type and then constructed 
a pairwise similarity matrix using the Information Content based on the Leacock and Chodorow 
distance measure, which has been shown to exhibit good performance when compared against 
other semantic similarity measures.239 We subsequently performed k-medoids clustering to find 
groups of similar CUIs. Seventy clusters were chosen using the gap statistic and the “1-standard-
error” rule.240 For models (4) and (5) we used the Distributed Memory Model of Paragraph 
Vectors (doc2vec)150 as implemented by the python gensim package.241 We utilize the term 
“document embedding,” as opposed to “word embedding,” signifying doc2vec’s ability to 
consume variable length text, and therefore obviate the need to combine word vectors. Similar to 
Turner et al.155 we pre-processed raw text by removing non-alpha numeric characters and 
eliminating stopwords before using the doc2vec algorithm to generate vectors. No processing of 
the CUIs was performed other than the default parameters within cTAKES. For PCA, we kept 
sufficient components (395) to explain 95% of the variance. Refer to Figure 8 for the workflow. 
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Figure 8: Workflow describing Natural Language Processing pipeline. 
Note: cTAKES: clinical Text Analysis Knowledge Extraction System; CUI: Concept Unique Identifier; AFEP: 
Automated Feature Extraction for Phenotyping; SAFE: Surrogate-Assisted Feature Extraction; PCA: Principal 
Component Analysis 
 
FINAL PHENOTYPING MODEL DEVELOPMENT 
We tested five different classification models: logistic regression (LR), support vector machines 
(SVM), gradient boosting (GBM), random forest, and naïve Bayes. For LR and naïve Bayes we 
first performed variable selection using penalized LR, using the L1 penalty (Least Absolute 
Shrinkage and Selection Operator—LASSO), to select a subset of the predictor variables.42 For 
the remainder of the models we used the full set of predictor variables. The hyperparameters for 
SVM, GBM, and random forest were optimized using five-fold cross validation on the training 
set. A Gaussian distribution was assumed for naïve Bayes. 
NLP DIMENSIONALITY REDUCTION AND PHENOTYPING MODEL ASSESSMENT 
We assessed the NLP dimensionality reduction techniques by constructing an SVM model using 
only the NLP variables with HRS as the outcome measure. The Radial Basis Function served as 
the SVM kernel and hyperparameters, C and γ, were optimized using grid search and 5-fold 
cross validation.  While it is possible that the dimensionality reduction techniques may perform 
differently using an alternative model assessment method, we elected to test NLP variables with 
an SVM model because we wanted to utilize a method that had a low bias and few assumptions 
about the model parameter development, to allow for complex interactions to be discoverable in 
the CUI data.  While this can result in high variance, we limited the values of C in the grid search 
to prevent very small C values that would increase the variance and over-fitting to observed data.  
In addition, this machine learning framework has been shown to work well with NLP 
variables.57,242,243  
Performance of the NLP dimension reduction technique and the final phenotyping algorithm 
were calculated using bootstrapping (100 bootstrap samples) to estimate discrimination (area 
under the receiver operating characteristic [ROC] curve [AUC], F1-measure, precision, recall) 
and calibration (slope and intercept of the best fit line through the observed to predicted 
probability plot and Brier score) metrics.129,244 We defined statistical significance as non-
crossing of the 95% bootstrapped confidence intervals. We compared the discriminatory 
performance of the machine learning algorithms to the ICD-9 code. 
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We conducted an error analysis using the best machine learning method and studied the false 
positives and false negatives. We looked at false positives and false negatives at three cut-points 
for the probabilistic phenotype: the optimal sensitivity and specificity based on Youden’s index, 
sensitivity of 0.95, and specificity of 0.95. For each of these scenarios, we examined the 
annotators’ notes on the gold standard to understand why the errors occurred.  
RESULTS 
Based on manual annotation there were 87 cases with Type I HRS, 19 with Type II HRS, 16 with 
Type Indeterminate, 88 with Maybe HRS, and 294 without HRS. Table 6 shows a summary of 
the cohort after the case annotations were dichotomized as noted in the methods, resulting in a 
total of 210 (41.7%) hospitalizations with HRS.  Eighty cases were adjudicated, yielding a 
weighted Cohen’s kappa of 0.83. Males represented 98.2% of the total admissions, with a 
median age of 61. White patients accounted for the majority of hospital admissions (71.1%). The 
sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of a 
discharge ICD-9 code for HRS were 57.6%, 88.8%, 78.6%, and 74.6%, respectively. The 
sensitivity, specificity, PPV, and NPV of an HRS ICD-9 code at any time during hospitalization 
were 87.1%, 76.5%, 72.6%, and 89.3%, respectively. 
Table 6: Characteristics of the cohort of cirrhotic patients with and without HRS as 
determined by chart review. 
1 Note: A patient may have more than one etiology of cirrhosis, hence percentages add up to greater than 100%. 
Characteristic HRS  Diagnosis (n = 
210) 
No HRS Diagnosis (n = 
294) 
DEMOGRAPHICS 
   Age, mean (SD) 60 (7.9) 62 (10.2) 
   Gender (male), n (%) 208 (99.0%) 292 (99.3%) 
   Race, n (%)   
      White 154 (73.3%) 201 (68.4%) 
      Black 28 (13.3%) 65 (22.1%) 
      Other 28 (13.3%) 28 (9.5%) 
PRE-ADMISSION CHARACTERISTICS 
   Cirrhosis Etiology, n (%)1   
      Alcoholic 130 (61.9%) 151 (51.4%) 
      Viral (Hepatitis B and C) 112 (53.3%) 130 (44.2%) 
      NAFLD 31 (14.7%) 41 (13.9%) 
   Congestive Heart Failure, n (%) 19 (9.0%) 61 (20.7%) 
   Diabetes Mellitus, n (%) 59 (28.1%) 122 (41.5%) 
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Characteristic HRS  Diagnosis (n = 
210) 
No HRS Diagnosis (n = 
294) 
   Chronic Kidney Disease, n (%) 20 (9.5%) 54 (18.4%) 
   Prior Cirrhosis Complications, n (%)   
      Hepatic Encephalopathy 75 (35.7%) 61 (20.7%) 
      Varices 58 (27.6%) 66 (22.4%) 
      SBP 30 (14.3%) 19 (6.5%) 
      Ascites 122 (58.1%) 132 (44.9%) 
      Hepatocellular Carcinoma 28 (13.3%) 22 (7.5%) 
   Baseline Creatinine, mean (SD) 1.04 (0.42) 1.15 (0.49) 
INDEX HOSPITALIZATION CHARACTERISTICS 
   Maximum Creatinine, mean (SD) 4.16 (2.10) 2.75 (1.50) 
   Maximum Blood Urea Nitrogen, 
mean (SD) 
78.2 (49.0) 49.9 (26.0) 
   Average Sodium,  mean (SD) 132.6 (5.7) 135.8 (5.0) 
   Average Bilirubin, mean (SD) 12.7 (11.5) 4.4 (6.2) 
   Average Albumin, mean (SD) 2.4 (0.6) 2.6 (0.7) 
   Average INR, mean (SD) 2.0 (0.7) 1.7 (0.7) 
   Admission MELD, mean (SD) 26.3 (8.4) 20.5 (7.1) 
   Discharge HRS ICD-9 Code, n (%) 170 (81.0%) 63 (21.4%) 
 
There were a total of 23,415 distinct CUIs within the entire document corpus, and a total of 
6,985 distinct CUIs after initial frequency filtering. Limiting based on semantic type reduced the 
total number of distinct CUIs to 2082. The median number of CUIs per cluster was 12 (IQR: 5 – 
18). AFEP and SAFE selected thirty-six and three CUIs, respectively. Table 7 presents the total 
number of variables and evaluation results for each of the nine NLP strategies. Document 
embedding using CUIs (AUC of 0.79, 95% CI: 0.79 – 0.80) significantly improved performance 
compared to embedding using raw text (AUC of 0.66, 95% CI 0.66 – 0.67). The a priori CUI 
selection, semantically informed clustering, and the high-throughput phenotyping methods 
(SAFE and AFEP) had statistically similar performance (AUC of 0.81 – 0.82). The a priori CUI 
set was selected for further analysis due to their clinical relevance and ease of interpretation. 
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Table 7: Evaluation of dimension reduction techniques for handling Natural Language 
Processing outputs for phenotyping. 
Note: ¥: the counts for these models are doubled because they include both the positive assertion and the negative 
assertion; AFEP and SAFE include an extra variable for note count. AFEP: Automated Feature Extraction for 
Phenotyping; SAFE: Surrogate-Assisted Feature Extraction; CUI: Concept Unique Identifier; AUC: Area Under the 
Curve. 
Combining the structured and NLP variables, there were a total of 701 candidate predictors. 
LASSO selected 21 variables. The results of the model comparisons are shown in Table 8. 
Logistic regression had the best performance in terms of AUC, though modest performance in 
terms of calibration. Figure 9 (Panel A) shows the ROC curves with 95% confidence intervals 
for the 5 methods. The sensitivity and specificity are also plotted for the HRS ICD-9 code (both 
for a discharge ICD-9 code and any ICD-9 code during the inpatient stay). Logistic regression 
dominated the other methods and was superior to using just the ICD-9 code. Figure 9 (Panel B) 
shows the smoothed calibration curves for the different methods based on Van Hoorde et al.244 
Though calibration appears relatively uniform for regression, GBM, SVM, and random forest 
based on the Brier score; the calibration curve shows GBM and SVM had superior performance. 
As part of our sensitivity analysis, appendix Table A.6 shows the classifier performance after 
building the five classifiers after excluding “Maybe HRS” from the model building and 
validation. We note slight improvement for regression (AUC of 0.94); however, we elected to 
maintain “Maybe HRS” within the model to account for edge cases. By varying the probability 
threshold, the user may include/exclude clinically uncertain cases. Appendix Table A.7 shows 
model performance using the SAFE CUIs for comparison. Overall model performance for 
Model No. of 
Variables 
Precision Recall F-measure AUC 
Full CUI Set 13,970¥ 0.56 (0.55, 
0.57) 
0.84 (0.83, 
0.84) 
0.68 (0.67, 
0.70) 
0.74 (0.74, 
0.75) 
Semantic Type 
Limited CUI Set 
4,164¥ 0.63 (0.62, 
0.64) 
0.80 (0.79, 
0.81) 
0.70 (0.68, 
0.71) 
0.73 (0.72, 
0.73) 
AFEP 37 0.66 (0.65, 
0.67) 
0.84 (0.83, 
0.86) 
0.74 (0.73, 
0.74) 
0.82 (0.81, 
0.82) 
SAFE 4 0.73 (0.72, 
0.74) 
0.79 (0.78, 
0.80) 
0.76 (0.75, 
0.76) 
0.82 (0.81, 
0.82) 
Principal Component 
Analysis 
395 0.53 (0.52, 
0.54) 
0.77 (0.74, 
0.80) 
0.61 (0.60, 
0.63) 
0.57 (0.56, 
0.57) 
Document 
Embedding with Raw 
Text 
500 0.58 (0.57, 
0.59) 
0.65 (0.62, 
0.67) 
0.60 (0.59, 
0.61) 
0.66 (0.66, 
0.67) 
Document 
Embedding with CUIs 
500 0.66 (0.65, 
0.67) 
0.79 (0.78, 
0.81) 
0.72 (0.71, 
0.72) 
0.79 (0.79, 
0.80) 
Clustered CUIs 140¥ 0.72 (0.71, 
0.73) 
0.78 (0.77, 
0.79) 
0.73 (0.72, 
0.73) 
0.82 (0.81, 
0.82) 
A priori CUIs 52¥ 0.66 (0.65, 
0.67) 
0.84 (0.83, 
0.85) 
0.74 (0.73, 
0.74) 
0.81 (0.80, 
0.81) 
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logistic regression is largely unchanged, though the individual variables selected by LASSO 
identify more structured variables to make up for the fewer NLP variables. 
Table 8: Discrimination and calibration performance of the five models to phenotype 
Hepatorenal Syndrome. 
Note: Slope and Intercept refer to the parameters of the best-fit line through the observed-to-predicted probability 
plot; AUC: Area Under the Curve 
Model AUC (95% CI) Slope (95% CI) Intercept (95% CI) Brier Score (95% 
CI) 
Logistic 
Regression 
0.93 (0.92, 0.93) 0.68 (0.65, 0.71) 0.18 (0.13, 0.24) 0.11 (0.11, 0.11) 
Gradient 
Boosting 
0.88 (0.88,0.88) 1.26 (1.21, 1.31) 0.15 (0.10, 0.20) 0.14 (0.13, 0.14) 
Naïve Bayes 0.73 (0.72, 0.74) 0.04 (0.03, 0.04) -0.41 (-0.53, -0.29) 0.32 (0.30, 0.33) 
Random Forest 0.91 (0.91, 0.91) 2.01 (1.95, 2.06) 0.29 (0.24, 0.35) 0.13 (0.13, 0.13) 
Support Vector 
Machine 
0.90 (0.90, 0.91) 0.74 (0.71, 0.77) -0.12 (-0.17, -0.07) 0.13 (0.12, 0.13) 
Figure 9: Discrimination (Panel A), via the ROC curve, and calibration (Panel B), via 
smoothed observed-to-expected probability plots, for the five different various models for 
phenotyping Hepatorenal Syndrome phenotyping models. 
Note: The grey square represents performance for a Hepatorenal Syndrome ICD-9 code anytime during the 
admission. The grey circle represents a Hepatorenal Syndrome ICD-9 code as a discharge diagnosis. LR: Logistic 
Regression; SVM: Support Vector Machine; GBM: Gradient Boosting Machine; NB: Naïve Bayes; RF: Random 
Forest 
Panel A 
 
Panel B 
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Table 9 reports the odds ratios for the variables used in the LR model. Significant variables 
predictive of HRS include an ICD-9 code for HRS, NLP mention of HRS, inpatient use of 
midodrine, the peak serum creatinine after the first 48 hours of admission, and the average mean 
corpuscular hemoglobin concentration (MCHC). Variables predictive of other causes of renal 
failure include an ICD-9 code for acute tubular necrosis (ATN), NLP mention of shock, high 
urine sodium, a significant difference between the maximum inpatient serum creatinine versus at 
discharge, and higher serum sodium. 
Table 9: Odds ratios and confidence intervals for the logistic regression model based on 100 
bootstrap samples. 
Note: INR: International Normalized Ratio; MCHC: Mean Corpuscular Hemoglobin Concentration; NLP: Natural 
Language Processing; HRS: Hepatorenal Syndrome; ATN: Acute Tubular Necrosis; NAFLD: Non-alcoholic Fatty 
Liver Disease 
Variable Odds Ratio 
(95% CI) 
Variable Odds Ratio 
(95% CI) 
Inpatient Labs - Temporal - 
Average Serum 
Sodium 
0.67 (0.64, 
0.70) 
Creatinine Diff.  
(max inpt. to 
discharge) 
0.21 (0.20, 0.23) 
Average Urine Sodium 0.73 (0.70, 
0.77) 
Creatinine Diff.  
(1st 48 hours vs. 
rest of stay) 
0.55 (0.51, 0.60) 
Average Bicarbonate 0.79 (0.76, 
0.83) 
Peak Creatinine 
After First 48h 
1.78 (1.66, 1.91) 
Minimum Albumin 0.84 (0.81, 
0.88) 
  
Average Glucose 0.94 (0.90, 
0.97) 
ICD 9 Codes - 
Average Total Bilirubin 1.15 (1.09, 
1.20) 
Inpatient ATN 0.40 (0.36, 0.45) 
Minimum INR 1.16 (1.11, 
1.21) 
Inpatient NAFLD 1.07 (1.03, 1.11) 
Average Blood Urea 
Nitrogen 
1.16 (1.07, 
1.26) 
Inpatient Ascites 1.59 (1.51, 1.67) 
Minimum Blood Urea 
Nitrogen 
1.77 (1.63, 
1.93) 
Inpatient HRS 9.98 (9.12, 
10.93) 
Average MCHC 1.96 (1.87, 
2.05) 
  
  NLP - 
Inpatient Medications - (+) Shock 0.21 (0.20, 0.23) 
Midodrine 3.24 (2.89, 
3.62) 
(+) Paracentesis 1.37 (1.30, 1.43) 
  (+) HRS 1.78 (1.67, 1.90) 
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Table 10 reports our error analysis at three levels of cut-offs: optimal using Youden’s index, high 
sensitivity, and high specificity. As expected, false positives versus false negatives dominate at 
higher sensitivity and higher specificity, respectively. False positives at high sensitivity are 
primarily caused by the algorithm’s inability to detect improvement with fluid administration, 
separating chronic kidney disease from HRS, and other causes of AKI in cirrhotics. At higher 
specificity, false negatives are caused by high urine sodium, chronic kidney disease, and 
competing diagnoses.  At an optimal threshold, the majority of errors stemmed from an inability 
to identify improvement with fluid administration. Insufficient information caused errors at all 
cut-points, though a relatively small percentage of errors. 
Table 10: Error analysis of false positive and false negatives using the logistic regression 
model on the test set at three different thresholds. 
Note: FP: False Positive; FN: False Negative; CKD: Chronic Kidney Disease; ATN: Acute Tubular Necrosis; GI: 
Gastrointestinal; HIVAN: Human Immunodeficiency Virus Associated Nephropathy  
Sensitivity = 
0.95 
Specificity = 
0.95 
Optimal 
Threshold  
(Youden’s 
Index) 
 
FP 
(n=21) 
FN 
(n=3) 
FP 
(n=3) 
FN 
(n=15) 
FP 
(n=9) 
FN 
(n=5) 
High Urine Sodium 
 
2 
 
3 
 
2 
Improved with fluids 9 
 
1 1 5 
 
CKD 4 
  
2 
 
2 
Competing Diagnosis (sepsis) 
   
2 
 
1 
Competing Diagnosis (contrast) 1 
   
1 
 
Competing Diagnosis (ATN) 1 
 
1 
 
1 
 
Competing Diagnosis 
(hypotension or shock) 
1 
  
2 1 
 
Competing Diagnosis (multiple) 1 
  
1 
  
Competing Diagnosis (GI Bleed) 1 
  
1 
  
Competing Diagnosis (HIVAN) 1 
     
Insufficient Information 1 1 1 3 1 
 
Error in Underlying Data 1      
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DISCUSSION 
This research demonstrates that it is possible to create a high performance probabilistic 
phenotyping algorithm to detect cases of HRS. This is one of the first efforts to phenotype AKI 
etiology, a condition that effects up to 2% of hospitalized patients.245 Penalized LR achieved the 
best performance with an AUC of 0.93 (95% CI: 0.92-0.93). NLP significantly boosted the 
performance of the model from an AUC of 0.82 (95% CI: 0.81-0.83). The sensitivity and 
specificity of an ICD-9 code anytime during the hospitalization were 87.1% and 76.5%, 
respectively; whereas, a discharge ICD-9 code had a sensitivity and specificity of 57.6% and 
88.8%, respectively. At Youden’s index, the LR algorithm would have a sensitivity of 85.4% and 
a specificity of 84.0%. The probabilistic phenotyping algorithm allows one to alter the thresholds 
for varying levels of sensitivity and specificity depending on the needs of the user.  
Optimizing the algorithm required handling the large number of NLP variables. Automated 
dimensionality reduction in NLP based classification has been shown to improve performance in 
multiple studies.246–248 Increasing effort has been placed on high-throughput phenotyping to 
perform automated feature selection/dimension reduction, though to date they have been 
primarily tested in chronic conditions where the data density is much higher. In our study, 
manual NLP variable selection using domain knowledge performed similarly to dimensionality 
reduction using SAFE, AFEP, and semantic similarity informed clustering.  Manual variable 
selection has been shown to perform favorably in other studies.61,67 For instance, Chen et. al. 
showed that a feature set selected by domain experts outperformed a data driven approach in 
phenotyping algorithms for Rheumatoid Arthritis, Colorectal Cancer, and Venous 
Thromboembolism.249   
Although embeddings have been used for phenotyping tasks, we demonstrate its performance in 
acute illness and using CUIs instead of raw text.154,155 Turner et al. showed their word 
embedding task using raw text outperformed bag-of-words models but did not outperform 
machine learning models using CUIs. We show that CUI based models (including embedding) 
outperform embedding models using free text. Increasing effort is being applied to mapping free 
text to a domain ontology for purposes of improving a wide variety of NLP tasks246,250 and 
constructing shareable, computable clinical data warehouses.251  
Though machine learning algorithms are increasingly popular for cohort identification,57 our 
study showed superior performance with penalized LR. Regression has been used for 
phenotyping efforts78 and, in at least one risk prediction study comparing regression to machine 
learning models, regression performed better.105 Machine learning methods such as support 
vector machines and random forests tend to perform well on classification tasks where multiple 
interactions exist between the predictor variables, which suggests that complex interactions may 
not have been highly prevalent in these data.   Additionally, despite the better discriminatory 
power of the logistic regression model, calibration was better with gradient boosting and support 
vector machines, which suggests that for some cut-points performance may still favor the 
machine learning methods. 
The most important variable based on odds ratio was the HRS ICD-9 code. Inpatient codes for 
ascites also significantly increased the probability of HRS. This makes pathophysiologic sense 
because development of ascites and HRS are tightly related, particularly in HRS Type II. 
Inpatient administration of midodrine, a medication that increases the blood pressure, was 
significantly predictive of HRS. This is also a logical finding because midodrine is used in only a 
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few contexts in medicine and one of them is treatment of HRS. NLP variables that were 
predictive of HRS include mention of HRS and mention of paracentesis (removal of accumulated 
fluid in the abdomen), which is indicative of the presence of clinically significant ascites. 
Predictors with good negative predictive value for HRS include variables that indicate less 
severe portal hypertension (increased blood pressure in the abdominal blood vessels), other 
causes of acute kidney injury (ATN and shock), and significant improvement in creatinine levels 
at time of discharge.   
To better understand failure points and edge cases, we performed an error analysis, revealing 
three common themes. First, errors were made in the system assessing response to fluid 
administration. In essence, this is a temporal pattern recognition problem. Though some temporal 
type variables were included in the model, they were insufficient to capture the full variation of 
response waveforms. Second, there were challenges differentiating HRS from other causes of 
kidney failure in cirrhotics. HRS is commonly one of several competing diagnoses in clinical 
practice when diagnosing the etiology of AKI in cirrhosis. The phenotyping system performed 
well in most cases. Finally, insufficient information caused a low level of persistent error across 
all cut-points. While this is unavoidable when using retrospective data, it may be mitigated when 
using the system prospectively. Importantly, our probabilistic phenotyping model allows the user 
to tailor the cutoff to the intended use: higher sensitivity for clinical decision support and higher 
specificity for defining cohorts in secondary data use analyses. 
LIMITATIONS 
There are some limitations to this research that are worth highlighting for refinement and 
extension of this investigation. First, this is a retrospective observational cohort and there were 
gaps in documentation that likely lowered ascertainment from chart review for the phenotype. 
Second, the VA data may not be representative of other clinical environments due to the slightly 
older average age and predominance of men. The other clinical variables, however, are not 
significantly different than other studies published regarding HRS.37,52,53 We only performed 
internal validation; however, we aimed to increase generalizability by sampling across a broad 
range of kidney injury and liver disease. Moreover, all variables are common to other electronic 
health records, and the selected variables make pathophysiologic sense. Third, several significant 
predictors were ICD-9 codes, but with the transition to ICD-10 in the US, the algorithm’s 
performance cannot be assured. At the same time, it is worth noting that there are one-to-one 
mappings for two of the important ICD-9 codes (ATN and HRS) based on the General 
Equivalent Maps (GEMs) framework.252 The code sets defining non-alcoholic fatty liver disease 
and ascites would require additional validation.  
NLP dimension reduction was assessed with SVM, and it is possible that an alternate method 
may have ranked the methods in a different order. We did not test expectation-maximization 
methods of clustering, such as Gaussian mixture modeling, for dimension reduction as we do not 
know the inherent probability distribution of the data. Lastly, a more thoughtful exploration of 
mapping temporal changes using established methods may have improved performance.253–255 
CONCLUSION 
This study demonstrated the utility of a probabilistic phenotype that used machine learning based 
methods to retrospectively classify patients with HRS. Though we focused on one form of AKI 
due to its high mortality, lessons learned could be applied to phenotyping other forms of kidney 
injury. Domain knowledge and several automated dimension reduction methods demonstrated 
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similar performance for identifying acute illness. Penalized logistic regression identified a 
parsimonious set of features with excellent performance. Unlike the fixed sensitivity and 
specificity of the HRS ICD-9 code, this probabilistic model can be used at multiple set points 
depending on the use case (e.g., a bias towards specificity or sensitivity). Future directions 
include external validation and identifying HRS cohorts for predictive analytics, clinical decision 
making, and population management. 
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CHAPTER III: RISK PREDICTION MODELS FOR HEPATORENAL SYNDROME 
 
CHAPTER OBJECTIVE 
Risk prediction models increasingly complement clinical reasoning and decision making in 
modern medicine.  Within the domain of HRS risk prediction, prior models focused on 
predicting the long-term risk of developing HRS (6 months to 2 years) with none predicting 
short-term risk during hospitalization, which could be useful to support immediate decision 
making regarding treatment.  In this study, we developed and internally validated an HRS risk 
prediction algorithm using data available in the peri-admission window of patient hospitalization 
among a large nationwide veteran cohort of patients.  We sought to develop an algorithm to 
support clinical decision making and initiate treatment earlier, thus improving anticipated 
outcomes. 
PATIENTS AND METHODS 
STUDY POPULATION 
We analyzed a retrospective cohort of patients hospitalized from among 122 medical centers in 
the U.S. Department of Veterans Affairs (VA) between January 1, 2005 and December 31, 2013.  
The VA is an integrated care network that includes acute inpatient hospitals, outpatient care 
services, and long-term care facilities.  All VA personnel use the same EHR, Veterans 
Information Systems and Technology Architecture/Computerized Patient Record System 
(ViSTa/CPRS), for documentation and administration of clinical care.20 The institutional review 
board and research and development committees of the Tennessee Valley Health Care System 
VA Medical Center, Nashville, TN, approved this study. 
DATA COLLECTION 
All data were collected from the EHR and accessed via the national corporate data warehouse.  
The clinical data included International Classification of Diseases - version 9 (ICD-9) codes for 
diagnoses, Current Procedural Terminology (CPT) codes for procedures, vital signs, laboratory 
data, and inpatient and outpatient medication data. 
COHORT SELECTION 
We included patients who had a cirrhosis diagnosis (based on a history of two outpatient or one 
inpatient) ICD-9 code (571.2 or 571.5) and had AKI on admission.  AKI on admission was 
defined according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines to be 
an absolute rise in serum creatinine of at least 0.3 mg/, relative rise of 50%, or the new initiation 
of dialysis in a patient.256 Baseline creatinine was defined as the average outpatient creatinine 
from values collected from 365 days to 7 days prior to admission257 and peak creatinine was 
defined as the maximum creatinine between -24 and +24 hours of admission.  
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Figure 10: Cohort selection process from an initial sample of all inpatient admissions after 
applying exclusion criteria. 
 
We excluded patients who were: (1) on dialysis prior to admission; (2) did not have at least one 
serum creatinine value within the year prior to admission; (3) did not have an admission 
creatinine; or (4) died within 24 hours of hospitalization. We also excluded patients from two 
VA facilities that had no laboratory measurements in the available source data. Furthermore, we 
excluded patients who received both octreotide and midodrine within 24 hours of hospitalization 
as this combination was pathognomonic for the treatment of HRS—indicating that a presumptive 
diagnosis was established at time of admission. We did not exclude other treatments for HRS 
(e.g., norepinephrine) because they could be used to treat alternate diseases (e.g., sepsis). We 
refer the reader to Figure 10 for a breakdown of the cohort selection process. 
OUTCOME 
The main outcome of interest was the presence of an ICD-9 code for HRS (572.4) during 
hospitalization or at the time of discharge, and the patient must have had a documented history of 
ascites or presented with ascites. See Appendix 1 for details regarding validation of the HRS 
ICD-9 code and ascites status ascertainment. If patients did not meet the ascites requirement, 
then they were assigned to the non-HRS AKI group (even if their EHR contained an ICD-9 code 
for HRS). 
PREDICTOR VARIABLES 
We started with a total of 404 variables during the pre-admission (all data up to -24 hours of 
admit) and the admission timeframe (-24 to +24 hours of admit). We included data -24 hours 
prior to admit as part of the admission timeframe to incorporate emergency room data.  Refer to 
Table 11 for a breakdown of the variables. Since by definition 100% of HRS patients have 
ascites, the complication was excluded from the candidate predictor pool. A detailed summary of 
these variables and associated definitions are included in Appendix 2. 
Initial Adult Hospitalization Cohort (n = 5,754,861) 
Exclude Patients Without Cirrhosis (n = 5,496,046) 
Exclude Patients Without Baseline Creatinine (n = 24,787) 
Exclude Patients Without AKI (n = 163,020) 
Exclude LOS < 24 hours (n = 30,798) 
Exclude Death < 24 hours (n = 1,579) 
Exclude VA Facilities w/out Data (n = 1,245) 
Exclude Patients Receiving Midodrine and 
Octreotide(n = 1,029) 
Exclude Patients Without Admit Creatinine (n = 15,098) 
Final Cohort (n = 35,412) 
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Table 11: Breakdown of the candidate predictor variables used in the Hepatorenal 
Syndrome risk prediction model. 
(Note: KDIGO: Kidney Diseases Improving Global Outcomes; MELD: Model for End Stage Liver Disease; SBP: 
Spontaneous Bacterial Peritonitis) 
With the exception of cirrhosis-related medications (e.g., lactulose, rifaximin, albumin, 
norepinephrine, and vasopressin), which were coded as separate variables, all medications were 
represented by their corresponding VA drug class code (e.g., “cephalosporin 3rd generation”). 
The VA drug class codes are available publicly through the VA National Drug File.237 Except 
for the baseline creatinine value, the remaining laboratory values corresponded to the 23 most 
commonly collected test results on inpatient admission. We summarized the inpatient laboratory 
values and vital signs as the average value during the admission timeframe, SBP was defined 
either by administrative code or > 250 neutrophils/mm3 in ascites fluid.  We eliminated any 
categorical variables that were present for less than 0.2% of admissions or showed perfect 
collinearity. The remaining 287 variables are outlined in Appendix 2. Missing values for race 
were replaced with “Unknown.” Missing values for laboratory values were filled in using 
multiple imputation using a subset of co-morbid conditions, medications, and procedures (as 
Variable Group Number of Variables in Group 
Pre-Admission Timeframe (all data up to -24 hours of admit) 
Demographics 3 
Comorbid conditions 64 
Cirrhosis etiologies 3 
h/o Cirrhosis complications 5 
Home medications 142 
Paracentesis within 3 days of 
admission 
1 
# of paracenteses within past 90 days 1 
Admission Timeframe (-24 to +24  hours of admit) 
Inpatient medications 137 
Laboratory values 24 
Vital signs 12 
Procedures (including paracentesis) 6 
KDGIO renal failure stage 1 
MELD score 1 
SBP diagnosed at admission 1 
Total IV Fluids 1 
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outlined in Appendix 3).238,258  Missing vital signs and ages were imputed with the median 
admission values from the entire cohort. 
MODEL DEVELOPMENT 
We performed a penalized logistic regression, using the L1 penalty (Least Absolute Shrinkage 
and Selection Operator — LASSO) , to select a subset of the predictor variables.42 Refer to 
Appendix 1 for details on the variable selection procedure. We subsequently used the variables 
identified by the LASSO procedure in a generalized estimating equations (GEE) model clustered 
by patient using an exchangeable covariance structure, which adjusted for correlation due to the 
multiple admissions per patient.259 Finally, we produced a traditional point-based scoring model, 
similar to the Framingham risk study,260 based on the statistically significant variables from the 
GEE model. 
MODEL ASSESSMENT 
We reported the AUC of the GEE model with a 95% confidence interval (CI) calculated from the 
bootstrap samples and variable odds ratios.129  We assessed model calibration using the Brier 
score (range from 0 to 1, where 0 implies perfect calibration), slope and intercept of the 
regression line between O/E probabilities, and an O/E  probability plot.261 We performed two 
sensitivity analyses: first, excluding hospitalizations where patients received vasopressin or 
norepinephrine on admission; second, excluding patients who could possibly have cardiorenal 
syndrome. Finally, we compared our model to a baseline that included only the Model for End-
Stage Liver Disease (MELD) score as a predictor. All statistical analysis was performed using 
the R statistical programming suite, version 3.2.2. 
RESULTS 
After applying the inclusion and exclusion criteria, we identified 19,146 patients comprising 
35,412 inpatient admissions. Hospitalization characteristics of patients with and without HRS 
diagnosis are summarized in Table 12.  There was a median of one admission per patient with an 
interquartile range of one to two admissions, and a maximum of 23 admissions for one patient. 
The distribution of admissions is shown in Appendix 5. Males represented 98.2% of the total 
admissions, with a median age of 61. White patients accounted for the majority of hospital 
admissions (71.1%). The event rate for hospitalized HRS was 2,258 (6.4%). 
Table 12: Characteristics of patients with and without HRS. 
Characteristic HRS  Diagnosis 
(n=2435) 
No HRS Diagnosis 
(n=32977) 
Age, mean (SD) 61 (7.8) 63 (9.2) 
Gender (male), n (%) 2392 (98.2%) 32393 (98.2%) 
Race, n (%)   
   White 1796 (73.8%) 23372 (70.9%) 
   Black 388 (15.9%) 6803 (20.6%) 
   Other 251 (10.3%) 2802 (8.5%) 
Etiology, n (%)   
   Alcoholic 1488 (61.1%) 17513 (53.1%) 
   Viral (Hep B and C) 1337 (54.9%) 17211 (52.2%) 
   NAFLD 497 (20.4%) 4893 (14.8%) 
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Table 13 presents the 26 out of 287 variables selected by LASSO and the corresponding odds 
ratios from the GEE model. Not unexpectedly, the MELD score increased the probability of HRS 
(per 1-point increase, OR 1.16, 95% CI: 1.14 - 1.17). Other strong predictors included KDIGO 
Stage II renal failure (OR 1.23, 95% CI: 1.08 - 1.39), hepatic encephalopathy (OR 1.58, 95% CI: 
1.43 - 1.75), diagnosis of SBP at time of admission (OR 1.57, 95% 1.37 – 1.81), and a 
paracentesis on the day of admission (OR 1.50, 95% CI: 1.35 - 1.68). Medication exposure to 
drugs the VA classifies as ‘Non Opioid Analgesics’ (primarily aspirin) significantly reduced the 
likelihood of HRS (OR 0.73, 95% CI: 0.64 - 0.83). Of the ‘Non Opioid Analgesic’ group, 167 
out of 9,986 admissions had acute tubular necrosis (ATN), by ICD-9 code, versus 476 out of 
25,426 admissions (p=0.22), which suggested that the difference was not borne out of non-
steroidal anti-inflammatory drug induced AKI. The risk model had an AUC of 0.84 (95% CI: 
0.83 – 0.85), a Brier score of 0.053 (95% CI: 0.050—0.055), slope of 0.98 (95% CI: 0.92—
1.04), intercept of -0.04 (95% CI: -0.20—-0.12) and the O/E calibration curve is shown in Figure 
11. When converting the model to a traditional point-based scoring model, points ranged from 0 
to 55 (median 19, IQR: 14 – 25). Using the point-based model preserved discrimination (AUC of 
0.82), though calibration was significantly worse (slope and intercept of the calibration line and 
Brier score of -3.50, 1.00, and 0.30, respectively). Refer to Appendix 6 for details.  
The two sensitivity analyses as outlined in the Methods did not change the results of the LASSO 
variable selection or significantly affect the odds ratios from the GEE model. See Appendix 7 for 
KDIGO Renal Failure Stage, n 
(%) 
  
   Stage I 1092 (44.8%) 22828 (69.2%) 
   Stage II 670 (27.5%) 5243 (15.9%) 
   Stage III 673 (27.6%) 4906 (14.9%) 
Congestive Heart Failure, n (%) 398 (16.3%) 9774 (29.6%) 
Diabetes Mellitus, n (%) 950 (39.0%) 17030 (51.6%) 
Chronic Kidney Disease, n (%) 872 (35.8%) 12713 (38.5%) 
h/o Cirrhosis Complications, n 
(%) 
  
   Hepatic Encephalopathy 1289 (52.9%) 10357 (31.4%) 
   Varices 859 (35.3%) 8270 (25.1%) 
   SBP 592 (24.3%) 4099 (12.4%) 
   Ascites 1936 (79.5%) 17959 (54.5%) 
   Hepatocellular Carcinoma 352 (14.5%) 3782 (11.5%) 
Baseline Creatinine, mean (SD) 1.30 (0.60) 1.57 (1.42) 
Admit Creatinine, mean (SD) 2.96 (1.74) 2.41 (1.82) 
Admit Blood Urea Nitrogen,  
mean (SD) 
51.0 (27.1) 39.6 (25.5) 
Admit Sodium, mean (SD) 131.8 (6.4) 134.4 (5.7) 
Admit Bilirubin, mean (SD) 7.5 (9.1) 3.0 (4.8) 
Admit Albumin, mean (SD) 2.3 (0.7) 2.5 (0.9) 
Admit INR, mean (SD) 1.8 (0.7) 1.6 (0.7) 
Admit MELD, mean (SD) 26.5 (7.4) 19.5 (6.5) 
Admit Mean Arterial Pressure,  
mean (SD) 
94.8 (14.1) 101.2 (16.3) 
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details. The MELD score-only model had an AUC of 0.76 (95% CI: 0.75—0.78), Brier score of 
0.056 (95% CI: 0.053—0.059), slope of 1.00 (95% CI: 0.91—1.09), and intercept of 0.00 (95% 
CI: -0.23—0.24). We also investigated performance for two patient populations for whom 
clinical suspicion of HRS is typically low. First, in patients with an admission MELD score < 15 
(roughly corresponding to Child-Pugh Classification A), the model had an AUC of 0.82. Second, 
in patients with a history of CKD and who did not present with SBP, the model had an AUC of 
0.85.  
Figure 11: Observed-to-expected probability plot from the GEE model. Each point 
represents a decile within the predicted probability. 
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Table 13: Odds ratios for the general estimating equations model predicting HRS for 
variables selected by penalized logistic regression. 
Risk Factor GEE Odds Ratio 
(95% CI) 
Admit Intravenous Fluids / 1000 mL 0.93 (0.90 - 0.97) 
Admit MELD 1.15 (1.14 - 1.17) 
Baseline Creatinine 0.79 (0.75 - 0.84) 
Admit Sodium 0.99 (0.98 - 0.99) 
Admit Bicarbonate 0.98 (0.97 - 0.99) 
Admit Blood Urea Nitrogen 1.01 (1.00 - 1.01) 
Admit Glucose 1.00 (1.00 - 1.00) 
Admit Mean Corpuscular Hemoglobin Conc. 1.06 (1.01 - 1.11) 
Admit Mean Corpuscular Hemoglobin 1.00 (0.99 - 1.02) 
Admit Alkaline Phosphatase 1.00 (1.00 - 1.00) 
Admit Partial Thromboplastin Time 1.00 (0.99 - 1.00) 
Admit International Normalized Ratio 0.56 (0.50 - 0.64) 
Admit Systolic Blood Pressure 1.00 (0.99 - 1.00) 
Admit Temperature 0.98 (0.89 - 1.07) 
Admit Weight 1.00 (1.00 - 1.00) 
Admit Maximum Temperature 0.98 (0.92 - 1.05) 
# Paracentesis in 90 days Pre-Admit 1.09 (1.07 - 1.12) 
KDIGO Stage II (vs. KDIGO Stage I as 
baseline) 1.26 (1.12 - 1.41) 
KDIGO Stage III (vs. KDIGO Stage I as 
baseline) 1.02 (0.88 - 1.18) 
Ascites 1.65 (1.46 - 1.86) 
Coronary Artery Disease 0.83 (0.74 - 0.94) 
Hepatic Encephalopathy 1.42 (1.28 - 1.57) 
Home Medication Analgesics 0.85 (0.78 - 0.94) 
Admit Medication Albumin Infusion 1.40 (1.25 - 1.55) 
Admit Medication Non Opioid Analgesics 0.79 (0.70 - 0.89) 
Admit Procedure Paracentesis 1.36 (1.23 - 1.51) 
Intercept 0.43 
DISCUSSION 
In this study, we developed a risk model to diagnose HRS at the point of hospital admission to 
support clinical diagnosis and decision making during the critical 48 hour surveillance period. 
Our model achieved good discrimination (AUC of 0.84), with excellent calibration (Brier score 
of 0.053 and good O/E ratio), and consists of basic medical history, common laboratory values, 
and initial medical management that can be obtained quickly during the admission window.  This 
model includes modifiable risk factors, such as avoiding large volume paracentesis and use of 
non-opioid analgesics, and may support earlier initiation of treatment. Earlier treatment before 
kidney function worsens may improve survival.51–54 Furthermore, earlier decision making may 
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reduce costs, reduce length of stay, initiate transplant evaluation,262 and motivate referral to 
hospice.  
Using the risk model at hospital admission could impact the standard of care in diagnosing HRS, 
which involves withdrawal of diuretics, plasma expansion with albumin for 48 hours, and ruling 
out other causes of renal failure.  Other studies have attempted to use a variety of tests to 
diagnose HRS earlier. Investigations have either looked at imaging modalities or novel 
biomarkers. Promising imaging modalities include magnetic resonance imaging263 and 
ultrasound;264,265 whereas, biomarkers have looked at the predictive ability of arginine 
metabolism,266,267 neutrophil gelatinase-associated lipocalin,268 and cystatin C.269 Other research 
looking at long term risk of HRS include low serum sodium concentration, high plasma renin 
activity, absence of hepatomegaly, low cardiac output, and the MELD score.35,234,270,271  Though 
these studies are enticing, they were limited by small sample sizes, overly stringent exclusion 
criteria, or the need for specialized equipment or laboratory tests.  In contrast, our study uses 
common clinical variables obtainable at the point of care during the admission window.   
Our study corroborates known risk factors for HRS, but also highlights new ones.  Of all the 
other cirrhosis complications, a history of hepatic encephalopathy was the only one to achieve a 
statistically significant relationship with HRS. Interestingly, back in 1972 Fischer and James 
postulated a connection between hepatic encephalopathy and HRS due to amino acid precursors 
of false neurochemical transmitters, such as phenylalanine and tyrosine, and their derivatives 
produced by gut bacterial decarboxylases.272 Performing a paracentesis on admission, total 
number of paracenteses in the past 90 days, and SBP on admission were all highly predictive of 
HRS. Though we do not know if the paracenteses were diagnostic or therapeutic, since a 
diagnostic paracentesis’ association to HRS would likely be mediated through a diagnosis of 
SBP, it is likely that the additional risk of paracentesis is borne from large volume withdrawal. 
Paracentesis is known to cause significant hemodynamic changes and activation of the renin 
angiotensin aldosterone system,273,274 has been shown to precipitate AKI even with concomitant 
albumin expansion,275 and precipitate HRS if not accompanied by albumin infusion.276 A higher 
number of paracenteses in the past 90 days likely reflects patients with refractory ascites and is 
identifying patients with Type II HRS. Unsurprisingly, higher admission MELD score 
(indicating more advanced liver disease) and hyponatremia (which has already been shown to be 
predictive of future HRS)270 were both correlated with HRS.   
Counterintuitively, KDIGO Stage II renal failure was a significant predictor of HRS, but KDIGO 
Stage III was not. A greater percentage of patients with KDIGO Stage III went on to receive 
dialysis during their inpatient stay (2,642 out of 5,579 admissions, as opposed to 252 out of 
5,911 admissions for Stage III and Stage II, respectively, p < 0.0001). Dialysis is routinely 
reserved for HRS patients who are headed for transplant (only 57 of the KDIGO Stage III 
patients received one) suggesting that their renal failure was due to other causes. Furthermore, 
patients with KDIGO Stage III had higher levels of CKD Stage IV and IV (2,045 out of 5,579 
Stage III admissions versus 168 out of 5,911 Stage II admissions, p < 0.0001). For these KDIGO 
Stage III patients, a small amount of renal injury could have resulted in dialysis initiation. 
Looking at variables inversely correlated with HRS, patients with higher baseline creatinine were 
predisposed to other etiologies of renal failure include ATN, pre-renal causes, and medication 
induced kidney injury likely as a function of reduced renal reserve. Patients with existing kidney 
disease are more prone to community acquired AKI.277   
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There were several risk factors detected that have not previously been reported.  It is unclear why 
an elevated MCHC is correlated with a diagnosis of HRS. Patients with advanced liver disease 
often have abnormal red blood cells including acanthocytes, spur cells, echinocytes, and target 
cells.278  The reduced cell volume will lead to a higher MCHC calculation.  The increased 
MCHC may be an indicator of advanced liver disease; however, these cells are also prone to 
hemolysis further impairing oxygen transport that may further predispose to HRS. Interestingly, 
higher International Normalized Ratio (INR) values decreased the odds of HRS. Since the INR is 
part of the MELD score, it is possible that the MELD score already captured the patients with the 
higher INR values. Patients with higher INRs were also more likely to have a GI bleed in our 
cohort. When looking at admissions with INR > 3.0, 235 out of 1,280 (18.3%) had a GI Bleed 
versus 4361 out of 29417 (14.8%) (p = 0.0006). Although a GI bleed may precipitate HRS, it is 
more likely to cause prerenal renal failure. 
There are several limitations of this study that should be highlighted for further investigation. 
First, our cohort is largely male and may not generalize to female populations. However, 
biological sex has not played a role in prior research on HRS or AKI. Second, the administrative 
definition of the outcome showed limited sensitivity and good specificity.  This could impact the 
study by coding bias that neglects patients less likely to receive a HRS ICD-9 code, which are 
likely some of the borderline patients with a broader differential for their renal failure. 
Furthermore, we acknowledge that some patients in the “No HRS” group are likely false 
negatives; however, this would bias our study towards the null. Our validation of the ICD-9 code 
was based on older criteria for HRS (particularly a hard cutoff for creatinine) because chart 
review was conducted for patients treated prior to the 2015 criteria. We note, however, that the 
inclusion/exclusion criteria for this study did not use a minimum creatinine threshold, and used 
the KDIGO values for AKI consistent with the 2015 International Ascites Club guidelines. 
Third, we could not differentiate Type I from Type II HRS.  The average maximum creatinine 
during the inpatient stay for the HRS cohort was 4.22 +/- 2.18 (SD) mg/dL and 1767 out of the 
2258 patients had a maximum creatinine > 2.5 mg/dL. Therefore, our cohort likely 
overrepresented HRS Type I and may not work as well at detecting HRS Type II.  Fourth, ICD-9 
codes have limitations in identifying comorbidities.73 Fifth, we used an ICD-9 code for HRS at 
any point during hospitalization as the outcome measure whereas we limited our cohort to 
patients who presented with AKI. It is possible that some patients presented with non-HRS AKI 
and subsequently developed HRS during the hospitalization. 
In conclusion, this study constructed a probabilistic risk prediction model to diagnose HRS 
within 24 hours of hospital admission using routine clinical variables in the largest ever 
published HRS cohort. Separating HRS from other causes of kidney injury can be challenging, 
and our model showed good performance even for groups generally thought less likely to have 
HRS. This would provide clinical utility by allowing earlier treatment initiation.51–54   
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CHAPTER IV: INFORMATION VISUALIZATION FOR MODEL ANALYSIS 
 
CHAPTER OBJECTIVE 
Information Visualization can help make sense of complicated, high-dimensional data and 
complement insights obtained from traditional, numerical analyses. In this study, we sought first 
to identify the most salient clinical features of cirrhosis and HRS that hepatologists find 
important. We then constructed two visualizations to help clinical decision making. The first 
visualization was a per-patient visualization giving a temporal view/summary of a patient’s 
cirrhosis disease course, particularly as a means of helping to diagnose etiology of acute kidney 
injury. The second visualization uses a multiple coordinated views approach to assess the risk 
model performance presented in Chapter III. We report on a qualitative analysis of the 
visualizations.  
METHODS 
WORKFLOW OBSERVATION 
Forty consenting physicians were observed in inpatient and outpatient settings across two 
institutions as part of a larger study; refer to Miller et al.279 for details. In brief, observations 
were conducted using a human factors engineering approach including contextual interviews for 
data collection, interpretive debriefing sessions for data collation, data consolidation using 
thematic analysis, and additional data analysis using three work modeling approaches. The 
observations focused on “clinical decision making.”  
We paid special attention to the interaction between the clinician and the EHR. In particular, 
what information sources does a clinician use from the EHR when preparing for a patient 
encounter? Before most patient encounters, clinicians make an effort to obtain a quick overview 
of the patient’s clinical course. Although, the primary aim of the parent study was looking at 
clinicians interactions with cirrhosis patients in general, several key aspects were relevant to 
understanding cirrhotics who present with kidney injury. We asked clinicians what parts of the 
medical record should be abstracted and visualized for quickly summarizing the patient’s disease 
course. 
DESIGN RATIONALE AND TOOLS 
We constructed two visualizations. Broadly, both visualizations sought to improve early 
identification of HRS. The first visualization (TIMELINE) was a patient summary tool to help 
provide an overview of the patient’s medical history. The second (CLUSTERVIEW) was an 
interactive visualization aid to help the user utilize the risk prediction model presented in Chapter 
III. The second visualization’s goal was to use established paradigms for complex data and 
display a global view of this very complex model, yet allow the user to drill down and examine 
the relevant components. Doing so users are able to evaluate risk model performance in sub-
groups. In a secondary workflow, the user would be able to see the relationship between a 
hypothetical, new patient and the other patients within the training cohort.  
For TIMELINE we used D3.js, an interactive HTML based interface that allows for vector 
graphics and interactivity.280 The visualization layer communicated through standard hypertext 
protocols with Microsoft Internet Information Services. All data meant for visualization was 
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converted into JavaScript Object Notation (JSON) format. Radial coordinates were calculated 
with the standard d3 radial transform. Drawing was accomplished using the d3.js “arc” tool.  
We used the R programming interface and used Shiny for CLUSTERVIEW. Shiny is an interactive 
protocol that allows a web-like front end with the backend powered by R.281 Shiny Dashboards 
allow the user to streamline the process of data input, statistical analysis, and graphical 
exploration. The GUI is designed to streamline the process of model performance analysis. 
Distinct panels are used for various stages of the analysis, including data input and filtering, and 
outlier detection. 
DATA SETS 
For TIMELINE, we utilized the patient pool presented in Chapter II. In brief, it consisted of 504 
cirrhotic patients who were hospitalized with AKI from a variety of causes. Manual chart review 
adjudicated the cause of AKI. Though the dataset in Chapter II was primarily interested in the 
data surrounding the hospitalization of interest, for the visualization we expanded this dataset 
with time-series data of laboratory measurements, diagnoses, and procedure codes.  
For CLUSTERVIEW, we utilized the dataset presented in Chapter III. In brief, it consisted of 
35,412 patients with cirrhosis hospitalized with acute kidney injury from a variety of causes. The 
primary outcome of the model was development of HRS. The model was constructed with 287 
predictor variables. Refer to Chapter III for full details. 
METHODS ON USING CLUSTERING TO LOOK AT MODEL PERFORMANCE 
We also assessed sub-population calibration and discrimination using unsupervised clustering, 
which collates similar observations together without forehand knowledge of any group 
membership. We performed unsupervised clustering using Kohonen’s Self-Organizing Map 
(SOM),282 implemented by the kohonen R package,283 to divide our parent cohort into forty-nine 
subgroups based on the 286 variables. We used a SOM to perform the clustering because it also 
allows for abstraction and visualization. We utilized the Gower distance as the similarity 
measure, which handles both continuous and discrete variables.284 We used the cluster instability 
metric to choose a map size (i.e., the number of clusters).285 We tested the cluster instability 
metric for map sizes between 4x4 and 13x13 units and selected the size at which the instability 
metric displayed an “elbow point,” the point past which we have diminishing marginal return in 
cluster stability. 
The user can select to plot similar patients; each patient is represented by an asterixis on the plot. 
Patient similarity was defined in one of two ways: first, patients who all fall within a percentile 
range for HRS risk based on the model, e.g. top risk decile; second, all patients similar to a 
hypothetical, new patient. Unlike the clustering, however, when plotting similar patients to a new 
patient only the variables selected for plotting are used for computing similarity. The Gower 
distance was used for identifying patient similarity to a new patient. 
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Figure 12: Example clinical course visualization for a patient with alcoholic cirrhosis. 
Note: CREAT: creatinine; MELD: Model for End-Stage Liver Disease; ALB: Albumin; BILI: Total Bilirubin; PLT: 
Platelet; PT: Prothrombin Time 
  
Figure 13: Example comparison of two patients with different clinical trajectories as 
depicted by the clinical course visualization tool. 
The temporal axis is circular and moves clockwise, starting in the year 2005 (labeled on the outermost ring). The 
end of the ring represents the hospital encounter of interest; for example in patient A, the final hospitalization 
resulted in death. CREAT: creatinine; MELD: Model for End-Stage Liver Disease; ALB: Albumin; BILI: Total 
Bilirubin; PLT: Platelet; PT: Prothrombin Time 
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RESULTS 
TIMELINE VISUALIZATION 
Figure 12 demonstrates an example patient for the clinical course visualization. Six numerical 
parameters (five laboratory values and one risk score) are plotted within the rings using color 
coding for severity. The innermost ring-space identifies decompensating events such as 
complications of cirrhosis. Finally black triangles indicate inpatient admission. The example 
patient had a history of alcohol abuse and had a late diagnosis of cirrhosis around 2011. The 
patient had a rapidly decompensating course, particularly with the development of hepatocellular 
carcinoma in 2012 marked by multiple hospital admissions prior to his death. 
Figure 13 demonstrates a side-by-side comparison of two patients: Panel A demonstrates a 
patient admitted with HRS and Panel B demonstrates a patient admitted with AKI but not 
diagnosed with HRS. In order to facilitate comparison, both patient timelines are anchored on the 
last date visualized – the first day of index admission. Two trends are readily notable. The patient 
without HRS, has a relatively stable clinical course. His indices suggest moderate cirrhosis with 
recurring problems due to hepatic encephalopathy. He would be classified as Baveno stage I. The 
HRS patient, however, demonstrates a rapidly declining course. The patient’s timeline exhibits 
multiple paracenteses before admission—indicative of refractory ascites, a common precursor to 
HRS.  
CLUSTERING TO ANALYZE MODEL PERFORMANCE 
To look at population heterogeneity and assess model performance amongst subgroups of similar 
admissions, the total cohort was subdivided into 49 clusters using a 7x7 SOM.  There was a 
median of 622 observations per cluster with an interquartile range of 321 to 973 and a maximum 
of 2026 observations in one cluster. Excluding three clusters that had ≤ 2 observations, the 
minimum number of observations per cluster was 192. 
Table 14 reports the data as a table with point estimates and 95% confidence intervals around the 
estimates.   
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Table 14: Discrimination and calibration statistics for each cluster along with 95% confidence intervals obtained by bootstrap 
sampling.  
Clusters with “N/A” had ≤ 2 observations. When comparing the cluster number with the cluster map in Figure 3, cluster #1 starts in the bottom left corner and 
proceeds row-wise until cluster #49 in the top right corner. 
Cl. N Intercept Slope Brier AUC 
1 423 -0.374 (-0.707,-0.04) 0.612 (0.387,0.837) 0.17 (0.15,0.191) 0.665 (0.606,0.725) 
2 927 1.647 (-3.471,6.765) 1.555 (0.289,2.82) 0.008 (0.003,0.013) 0.803 (0.554,1.051) 
3 1535 0.686 (-0.552,1.923) 1.217 (0.883,1.551) 0.016 (0.01,0.022) 0.859 (0.784,0.934) 
4 2026 0.785 (-0.002,1.572) 1.214 (0.966,1.461) 0.027 (0.021,0.033) 0.821 (0.767,0.875) 
5 973 0.458 (-0.637,1.553) 1.075 (0.731,1.42) 0.033 (0.022,0.044) 0.762 (0.678,0.846) 
6 236 -0.166 (-0.644,0.312) 0.82 (0.507,1.132) 0.146 (0.116,0.176) 0.749 (0.672,0.826) 
7 266 -1.001 (-1.747,-0.255) 0.381 (-0.017,0.779) 0.139 (0.11,0.168) 0.617 (0.52,0.714) 
8 321 -0.615 (-1.144,-0.087) 0.682 (0.426,0.937) 0.124 (0.1,0.149) 0.757 (0.702,0.812) 
9 860 0.366 (-0.196,0.928) 1.037 (0.807,1.266) 0.08 (0.066,0.094) 0.792 (0.745,0.839) 
10 1332 2.172 (0.58,3.764) 1.665 (1.2,2.13) 0.02 (0.013,0.028) 0.865 (0.794,0.937) 
11 2006 0.104 (-0.523,0.73) 1.004 (0.81,1.197) 0.045 (0.036,0.053) 0.775 (0.733,0.817) 
12 1 N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) 
13 327 -0.262 (-1.273,0.749) 0.69 (0.281,1.1) 0.101 (0.071,0.13) 0.649 (0.555,0.743) 
14 0 N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) 
15 66 4.122 (-47.616,55.859) 4.391 (-14.986,23.769) 0.029 (-0.001,0.059) 0.515 (-0.17,1.2) 
16 425 -0.427 (-1.51,0.656) 0.865 (0.482,1.247) 0.05 (0.033,0.067) 0.819 (0.722,0.916) 
17 1117 0.757 (0.207,1.306) 1.315 (1.092,1.539) 0.053 (0.043,0.063) 0.868 (0.832,0.904) 
18 1223 0.053 (-0.327,0.433) 0.975 (0.807,1.144) 0.092 (0.08,0.104) 0.78 (0.743,0.817) 
19 378 0.176 (-0.421,0.773) 0.906 (0.656,1.157) 0.109 (0.083,0.134) 0.782 (0.727,0.838) 
20 457 -0.548 (-1.528,0.431) 0.963 (0.544,1.382) 0.035 (0.023,0.048) 0.801 (0.712,0.89) 
21 811 -1.029 (-1.621,-0.437) 0.541 (0.313,0.769) 0.077 (0.061,0.092) 0.665 (0.603,0.728) 
22 508 1.535 (-0.659,3.729) 1.55 (0.883,2.218) 0.02 (0.009,0.032) 0.835 (0.75,0.92) 
23 892 -0.312 (-2.116,1.492) 1.022 (0.544,1.5) 0.013 (0.007,0.02) 0.768 (0.665,0.871) 
24 788 -0.435 (-0.77,-0.1) 0.699 (0.496,0.901) 0.137 (0.122,0.152) 0.694 (0.649,0.739) 
25 831 -0.518 (-1.105,0.07) 0.888 (0.647,1.13) 0.055 (0.041,0.068) 0.783 (0.728,0.837) 
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Cl. N Intercept Slope Brier AUC 
26 819 0.148 (-1.106,1.402) 1.126 (0.642,1.61) 0.037 (0.027,0.047) 0.785 (0.687,0.882) 
27 121 7.581 (-13.038,28.201) 4.699 (-6.656,16.053) 0.034 (0.011,0.058) 0.969 (0.917,1.02) 
28 1092 0.956 (0.24,1.672) 1.209 (0.955,1.463) 0.054 (0.043,0.066) 0.807 (0.761,0.854) 
29 1256 1.191 (-1.188,3.571) 1.573 (0.826,2.321) 0.011 (0.006,0.016) 0.785 (0.661,0.908) 
30 907 0.137 (-0.709,0.983) 0.947 (0.636,1.259) 0.061 (0.048,0.075) 0.719 (0.652,0.785) 
31 261 -0.081 (-0.465,0.302) 1.02 (0.695,1.344) 0.16 (0.135,0.185) 0.761 (0.699,0.824) 
32 506 -0.316 (-0.544,-0.089) 0.584 (0.377,0.791) 0.206 (0.185,0.226) 0.667 (0.612,0.722) 
33 622 -0.043 (-0.981,0.894) 1.011 (0.669,1.353) 0.043 (0.03,0.056) 0.85 (0.778,0.923) 
34 1142 1.51 (-0.911,3.931) 1.631 (0.868,2.394) 0.012 (0.008,0.017) 0.871 (0.76,0.981) 
35 1493 -0.226 (-1.705,1.253) 1.128 (0.703,1.554) 0.012 (0.007,0.017) 0.83 (0.742,0.918) 
36 815 -0.211 (-1.09,0.668) 0.87 (0.557,1.183) 0.057 (0.043,0.07) 0.714 (0.644,0.785) 
37 449 -0.219 (-1.143,0.705) 1.029 (0.644,1.414) 0.039 (0.024,0.055) 0.829 (0.745,0.913) 
38 813 -0.019 (-0.633,0.595) 0.889 (0.631,1.146) 0.083 (0.068,0.098) 0.749 (0.685,0.813) 
39 253 -0.914 (-1.583,-0.246) 0.411 (0.162,0.66) 0.124 (0.091,0.156) 0.661 (0.575,0.748) 
40 192 0.566 (-1.037,2.169) 1.535 (0.664,2.407) 0.058 (0.036,0.08) 0.936 (0.886,0.986) 
41 562 0.275 (-3.947,4.496) 1.457 (0.262,2.653) 0.008 (0.001,0.014) 0.85 (0.636,1.064) 
42 604 -0.296 (-0.707,0.116) 0.821 (0.607,1.036) 0.115 (0.098,0.132) 0.782 (0.736,0.827) 
43 1456 0.756 (0.034,1.479) 1.23 (0.994,1.466) 0.036 (0.028,0.044) 0.819 (0.774,0.864) 
44 308 1.862 (-0.798,4.523) 1.7 (0.767,2.633) 0.023 (0.01,0.036) 0.874 (0.786,0.962) 
45 488 -0.619 (-1.257,0.018) 0.696 (0.378,1.014) 0.109 (0.086,0.133) 0.676 (0.602,0.749) 
46 2 N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) 
47 1537 0.181 (-0.325,0.687) 1.063 (0.841,1.285) 0.072 (0.062,0.082) 0.747 (0.706,0.788) 
48 131 -1.849 (-9.556,5.859) 1.985 (-5.986,9.957) 0.031 (0.012,0.05) 0.91 (0.805,1.015) 
49 854 -1.399 (-4.175,1.376) 1.168 (0.312,2.024) 0.006 (0.002,0.01) 0.908 (0.802,1.013) 
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There were twenty clusters with an AUC  0.8, seventeen with an AUC between 0.7 and 0.8, and 
nine with an AUC < 0.7. Clusters with AUC  0.8 demonstrated phenotypes of CKD, cardiac 
comorbidities with coronary artery disease, congestive heart failure (CHF), and atrial fibrillation, 
and higher serum sodium on admission. In addition, the group of well performing clusters in the 
bottom left quadrant showed a phenotype of alcohol abuse and higher serum sodium. Poorly 
performing clusters displayed a phenotype of patients with a history of decompensated cirrhosis 
(hepatic encephalopathy, spontaneous bacterial peritonitis, varices, and ascites) along with 
KDIGO Stage I kidney injury. When comparing the top versus bottom 5 performing clusters, in 
addition to the aforementioned phenotypic differences, there was a significant difference in 
degree of kidney injury (average admission creatinine of 6.2 ± 2.9 (SD) versus 2.1 ± 1.1 
(p<0.0001), respectively).  There was KDIGO Stage 3 kidney injury 1860 out of 1860 
hospitalizations in the top performing clusters versus 1 out of 1958 in the bottom performing 
clusters (1691 out of 1958 were KDIGO Stage 1). Finally, clusters where patients received a 
paracentesis on the day of admission also performed poorly. The clustering results were 
displayed using CLUSTERVIEW’s interface (Refer to Figure 16). 
CLUSTERVIEW  VISUALIZATION 
Layout 
The tool consists of three main areas (
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Figure 15): Panel A, control panel; Panel B, cluster visualization view; and Panel C, detail view. 
The control panel in the left area has multi-checkbox interface to choose options for the 
visualization: (1) selecting variables to display; (2) plotting observed outcomes; (3) plotting 
similar patients to an index patient; (4) plotting similar patients to the index patient in terms of 
clustering; and (5) exporting data. The cluster visualization view in the middle area visualizes 
multiple patient clusters using a glyph visualization. The detail view on the right allows a drill 
down of all the variables that make up the cluster. The user can retrieve summary statistics on a 
single cluster, or compare two clusters by selecting them in the middle panel. 
Each cluster represents a group of similar patients (Figure 14). The relative importance of 
features within each cluster is visualized using pie-piece glyphs. The larger the pie piece, the 
greater the feature’s importance to the respective cluster. The features of interest can be chosen 
from the left control panel.   
Figure 14: Visual representation of each patient cluster. 
Each cluster has an (optional) halo which color codes a user-selected outcome, e.g. probability of HRS (Arrow A). 
The user may (optionally) display up to fourteen variables within the visualization, symbolized by pie-pieces (Arrow 
B). The size of the pie-piece is proportional to the importance of that variable within the cluster. 
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Figure 15: Layout of statistics visualization tool. 
The layout includes three components: Panel A displays the control options including selection of variables and measures to display; 
Panel B contains the visualization; Panel C has drill-down information that dynamically responds to the visualized measure and 
chosen cluster. 
Figure 16: 7x7 Self Organizing Map with the 49 clusters of observations. Each cluster has an outer ring 
color coded to the risk model's performance (AUC) within that cluster. 
The slope and intercept of the risk model are color coded in the bottom semicircle and top semicircle, respectively, for each cluster. 
Each cluster’s affinity for 14 variables is represented by a color coded pie piece, with a larger pie piece showing greater affinity. (CR 
= Creatinine; NA = Sodium; AFIB = Atrial Fibrillation; CAD = Coronary Artery Disease; CHF = Congestive Heart Failure; CKD = 
Chronic Kidney Disease; HE = Hepatic Encephalopathy; SBP = Spontaneous Bacterial Peritonitis) 
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Figure 16 shows how the user can use CLUSTERVIEW to analyze overall model performance. The 
clustering along with the model’s AUC and model calibration using the slope and intercept of the 
regression line through O/E probability plot; additionally the visualization also shows each 
cluster’s affinity for fourteen key clinical variables.   
Figure 17: Statistics visualization user interface workflow. 
(A) The user utilizes the control panel to select desired outcome and predictors for plotting; (B) Plotting area 
displays clusters with the cluster measure displayed as a colored halo; (C) Patients similar in terms of risk percentile, 
chosen from the control panel, are plotted; (D) Patients with similar predictors are plotted; (E) Two clusters can be 
selected and compared using a drill-down table. 
Panel A 
 
Panel B 
 
Panel C 
 
Panel D 
 
Panel E 
 
User Interaction 
Refer to Figure 17 for the workflow. Using the left control panel users can select the predictors 
of interest to display within the cluster visualization from five domains: demographics, 
laboratory values, home medications, inpatient medications, and comorbidities. The user can also 
plot either the percentage of patients who have HRS within the cluster or the prediction model’s 
AUC for the respective cluster. This information is visualized as a color-coded halo. Using the 
selected features from the first step, users can visualize which features or combinations of 
features predispose patients to HRS. Figure 17 panels C and D demonstrate plotting similar 
patients via the two protocols discussed in the methods: similar patients based on predicted 
probability and patients similar to a new, hypothetical patient. Finally, the user may select a 
cluster (or select two clusters to compare) to obtain more information about the cluster. Cluster 
information is provided in tabular format in the right hand side of the interface. For example, one 
may see that patients in the first cluster, with a much higher prevalence of HRS, have a 
significantly higher history of cirrhosis complications.  
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DISCUSSION 
We constructed visualizations to better understand high dimensional data and represent complex 
information to help clinicians make healthcare decisions. Human cognition uses pre-attentive 
systems for significant parts of graphical data visual processing. To leverage the pre-attentive 
qualities of visual cognition, we used color and proximity in TIMELINE. For CLUSTERVIEW, we 
employed color, size, proximity, and similarity.  We leveraged design paradigms for high-
dimensional, temporal data including brushing within the timeline visualization, color mapping, 
and coordinated views within the clustering visualization.  
Radial graphs aren’t necessarily best for temporal tasks and can increase processing time.286 
Radial graphs are most useful for finding extreme values, particularly in relation to other 
dimensions.287,288 Radar graphs do have some shortcomings other than possibly increased 
processing time (depending on the task). They can be error prone because the individual needs to 
follow one of several concentric rings if the goal is to look up an individual value. However, for 
TIMELINE the goal is less to identify a particular value (e.g., what was the MELD score in 
January 1st, 2014) and more important to see the evolving pattern of values across multiple 
dimensions. 
Our clustering and visualization technique can be used at two stages of clinical care. During 
model formulation, it can be invoked to identify clusters with a different case mix and poor 
model performance. These outlier clusters may indicate the need to refit the model for these sub-
groups. Possible etiologies include not accounting for important risk variables or necessary 
interaction terms. Clustering to perform sub-group analysis also helps us perform assessment of 
strong calibration.289 Unlike measures such as Hosmer-Lemeshow or observed-to-expected 
probability plots which assess moderate calibration, strong calibration requires predicted risks to 
correspond to observed event rates for every covariate pattern. It is both computationally and 
cognitively infeasible to specify all possible covariate patterns. Clustering, however, provides an 
intuitive, parsimonious grouping of covariate patterns. 
Secondly, we can use CLUSTERVIEW at the point-of-care: when a new patient enters the 
emergency room they can be assigned to a cluster. Using this alternate clinical workflow, we 
obtain the model’s risk estimate and its performance for patients like the index case. Unlike the 
standard-of-care, if the algorithm indicates sufficient risk of HRS and the patient falls within a 
cluster where model performance is acceptable (i.e., AUC  0.8) we can initiate vasopressor 
therapy immediately. Though visualizing risk prediction and uncertainty has received some 
attention for patient-facing tools,168,204 physician-facing CDS has received sparse 
investigation.205  
In summary, we developed two cohesive information visualizations that combines model 
performance with identifying a patient’s phenotype. Next steps would be to have a formative and 
summative evaluation of these visualizations. Techniques could include semi-structured 
interviews and the use of eye-tracking to monitor areas of visualizations that users are spending 
more time on.290 This could help find pre-attentive errors that people are making because the 
visualization is poor. 
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CHAPTER V: CONCLUSIONS 
 
The widespread adoption of the electronic health record has created a new source of “Big Data.” 
As the cost of healthcare in the United States has significantly outpaced other countries,291 we 
have to turn to new technologies and exploit novel methods of analysis and decision making.  
Cirrhosis is one of the most expensive diseases in America, and is responsible for over $10 
billion dollars of spending annually.292 The majority of these costs accrue from frequent 
hospitalizations from cirrhosis-related complications.293 Hepatorenal Syndrome serves as one of 
the deadliest cirrhosis complications, with a median survival of weeks to months. Additionally, 
HRS doubles hospital length of stay and associated costs.294 
In order to improve the care of these high cost diseases, there is increasing emphasis on 
observational cohort trials and pragmatic clinical trials. These study designs require highly 
accurate methods to identify patient cases and controls. Traditional means of identifying cases, 
including chart review, are infeasible to provide sufficient cases for accurate model building. We 
have presented a highly accurate, and tunable algorithm to identify cases and controls using EHR 
phenotyping with an AUC of 0.93. Additionally, our phenotyping algorithm demonstrated the 
benefit of utilizing fixed vector representations of UMLS CUIs instead of free text. 
Predictive analytics plays an increasingly important part in delivering state of the art care and 
clinical decision support. Particularly in the era of big data we have the opportunity to improve 
the care of our sickest patients. The Veterans Health Administration has over three decades of 
experience collecting routine clinical information about the patients it serves. With the 
development of the VINCI infrastructure, the VA serves as one of the best resources for 
longitudinal observational cohort research. The VA’s decades of investment in its health IT 
infrastructure is starting to pay dividends.295 
This study showed that improved risk prediction modeling surrounding HRS patients can 
identify HRS patients at time of hospitalization. HRS is often difficult to diagnose as it mimics 
many other causes of kidney injury on presentation; moreover, cirrhotics are prone to kidney 
damage from many causes. The model helps identify those patients who are more likely to go on 
to develop acute kidney injury. We compiled a cohort of 2,435 inpatient hospitalizations with 
HRS, which is to our best knowledge the largest observational cohort for HRS ever assembled. 
Using this cohort we developed a model with an AUC of 0.84 for identifying patients at high risk 
for developing HRS with excellent calibration based on data in the peri-admission window. 
Clustering allowed us to analyze model performance within patient sub-cohorts. For example, 
patients with existing cardiac comorbidities or CKD did well. Given the recent evidence showing 
that insufficient cardiac output induces renal hypoperfusion in HRS,30,234 patients with heart 
failure comprise a demographic in need of more accurate prediction. Patients with CKD 
represent another subpopulation where diagnosing HRS can be difficult because of the increased 
variability in kidney function in patients with CKD.296 Subgroups where model performance is 
subpar show a higher proportion of cirrhosis complications and a lower level of kidney injury on 
presentation. However, in patients with Baveno stage III or IV decompensated cirrhosis297 and 
KDIGO stage III renal failure (3223 admissions), the model had an AUC of 0.81, suggesting that 
it was a combination of cirrhosis complications and low level kidney injury that comprised a 
challenging phenotype. 
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Despite aggressive promises of increasing health technology use and big data to affect 
healthcare, real world implementations of real-time predictive analytics still appear to be few and 
far between. One of the challenges faced in utilizing some of these new technologies lies in 
creating interpretable models.157 Information Visualization techniques have been employed to 
make previously ineluctable models such as neural networks more accessible.298,299 Information 
Visualization works best when it augments the human brain’s ability to find patterns in data. Our 
study created an interactive information visualization system to improve the care for patients 
with HRS. We first built a patient timeline viewer to help clinicians quickly understand the 
relevant history of a patient. During direct workflow observation we identified key attributes of a 
cirrhotic patient’s disease course that could help specialists (and non-specialists alike) 
understand how sick a patient was.  
Leveraged with this data we also constructed CLUSTERVIEW, our risk prediction model exploring 
and clustering visualization. Our clustering visualization allows rapid visualization of model 
performance within sub-groups of the cohort to assess for how case-mix may model 
performance. Additionally, we theorize an additional workflow where such a visualization will 
help providers provide tailored care for patients by identifying “Patients-like-me” cohorts.  
LIMITATIONS 
This work has some limitations that are worth noting. Most importantly, this work is based on 
retrospective observational cohort data from the Department of Veterans Affairs. The VA data 
may not be representative of other clinical environments due to the slightly older average age 
and predominance of men. We only performed internal validation; however, we aimed to 
increase generalizability by sampling across a broad range of kidney injury and liver disease. 
Moreover, all variables are common to other electronic health records, and the selected variables 
make pathophysiologic sense. Third, several significant predictors were ICD-9 codes, but with 
the transition to ICD-10 in the US, the algorithm’s performance cannot be assured. At the same 
time, it is worth noting that there are one-to-one mappings for two of the important ICD-9 codes 
(ATN and HRS) based on the General Equivalent Maps (GEMs) framework.252 The code sets 
defining other conditions would require validation. Though we included etiology of cirrhosis as a 
covariate in all of our models, it is possible that important interaction effects may go unnoticed.  
Our work showed that logistic regression was comparable, and at times superior, to certain 
machine learning methods. We did leverage penalized regression models to handle overfitting, 
however. Though this held true in this dataset, it is possible that in a dataset with significantly 
more observations, a machine learning model would offer superior performance. We did not 
perform formative or summative evaluation of our visualization for this study; however, we did 
discuss the evaluations with select domain experts for informal feedback.  
FUTURE DIRECTIONS 
The studies described in this thesis demonstrate that machine learning assisted models can 
improve and accelerate care of patients with Hepatorenal Syndrome. The validity of the 
phenotyping model will need to be assessed in an outside cohort. The phenotyping model may be 
improved by including temporal feature generation. There is exciting work using recurrent neural 
networks to capture temporal features within EHR models.300 Much of healthcare data is 
inherently temporal as the basic unit of measurement, the patient, is often reassessed multiple 
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times during their clinical course, e.g. repeat lab measurements for each day of their 
hospitalization.   
The risk prediction model only utilized structured data, and as discussed in the phenotyping 
model, the natural extension would be to utilize clinical text data within the algorithm in two 
phases. The first phase would be to implement the phenotyping model developed in Chapter II to 
identify HRS patients, thereby improving upon the sensitivity and specificity of the ICD code 
utilized as the gold standard. Secondly, elements in the free text could serve as important 
predictors of patients who would go on to develop, or have HRS. 
The question remains of the clinical utility, which can only be assessed in prospective clinical 
trial. The next step would be to implement a real-time system that would monitor cirrhotic 
patients admitted to the hospital with some level of renal failure. The system could not only 
highlight cases that are apparent based on the phenotyping model, but also cases that are likely to 
go onto develop HRS. The system would need to be integrated into routine clinical care. Future 
work would revolve around integrating these models into routine clinical care using technologies 
such as Fast Healthcare Interoperability Resources and CDS-Hooks301,302 
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APPENDIX A: DETAILS ON PHENOTYPING ALGORITHMS 
 
Appendix Table A.1: List of candidate predictor variables with their data domain (Class) 
and their timeframe (Preadmission or Home vs. Inpatient) along with summary measures, 
percent missing, and number of patients with a value > 0. 
Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Home Cond AAA Home Condition 12.00 (2.38) 0 12 
Home Cond AbdomSurg Home Condition 22.00 (4.37) 0 22 
Home Cond ACS Home Condition 39.00 (7.74) 0 39 
Home Cond AFIB Home Condition 65.00 (12.90) 0 65 
Home Cond ALD Home Condition 456.00 (90.48) 0 456 
Home Cond AnalFisFist Home Condition 2.00 (0.40) 0 2 
Home Cond Angina Home Condition 25.00 (4.96) 0 25 
Home Cond ANMA Home Condition 260.00 (51.59) 0 260 
Home Cond ARF Home Condition 232.00 (46.03) 0 232 
Home Cond ARRH Home Condition 141.00 (27.98) 0 141 
Home Cond Ascites Home Condition 254.00 (50.40) 0 254 
Home Cond ASP Home Condition 2.00 (0.40) 0 2 
Home Cond Asthma Home Condition 26.00 (5.16) 0 26 
Home Cond ATN Home Condition 18.00 (3.57) 0 18 
Home Cond 
AutoNeuropathy 
Home Condition 3.00 (0.60) 0 3 
Home Cond AZ Cancer Home Condition 126.00 (25.00) 0 126 
Home Cond BilCirrhosis Home Condition 3.00 (0.60) 0 3 
Home Cond BowelPerf Home Condition 3.00 (0.60) 0 3 
Home Cond BURN Home Condition 4.00 (0.79) 0 4 
Home Cond CABG Home Condition 25.00 (4.96) 0 25 
Home Cond CAD Home Condition 120.00 (23.81) 0 120 
Home Cond Cancer Home Condition 109.00 (21.63) 0 109 
Home Cond CANDI Home Condition 27.00 (5.36) 0 27 
Home Cond CardiacArrest Home Condition 5.00 (0.99) 0 5 
Home Cond CardSurg Home Condition 3.00 (0.60) 0 3 
Home Cond CarotidDis Home Condition 4.00 (0.79) 0 4 
Home Cond Cath Home Condition 23.00 (4.56) 0 23 
Home Cond CathPCIALL Home Condition 24.00 (4.76) 0 24 
Home Cond CathPCICont Home Condition 23.00 (4.56) 0 23 
Home Cond CathPCInoCont Home Condition 3.00 (0.60) 0 3 
Home Cond CathPCIwCont Home Condition 23.00 (4.56) 0 23 
Home Cond CDVD Home Condition 88.00 (17.46) 0 88 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Home Cond CHEMO Home Condition 17.00 (3.37) 0 17 
Home Cond CHF Home Condition 80.00 (15.87) 0 80 
Home Cond Cirrhosis Home Condition 444.00 (88.10) 0 444 
Home Cond Cirrhosis Risk 1 Home Condition 392.00 (77.78) 0 392 
Home Cond CKD Home Condition 74.00 (14.68) 0 74 
Home Cond Colitis Home Condition 4.00 (0.79) 0 4 
Home Cond Cons Condition Home Condition 98.00 (19.44) 0 98 
Home Cond COPDAsthma Home Condition 160.00 (31.75) 0 160 
Home Cond CS Home Condition 2.00 (0.40) 0 2 
Home Cond CVA Home Condition 48.00 (9.52) 0 48 
Home Cond DecALD Home Condition 467.00 (92.66) 0 467 
Home Cond Dementia Home Condition 5.00 (0.99) 0 5 
Home Cond DIAL Home Condition 12.00 (2.38) 0 12 
Home Cond DIAR Home Condition 73.00 (14.48) 0 73 
Home Cond DKA Home Condition 2.00 (0.40) 0 2 
Home Cond DM Home Condition 181.00 (35.91) 0 181 
Home Cond DMNeuropathy Home Condition 26.00 (5.16) 0 26 
Home Cond DMOsm Home Condition 4.00 (0.79) 0 4 
Home Cond DYS Home Condition 170.00 (33.73) 0 170 
Home Cond ETOH Home Condition 347.00 (68.85) 0 347 
Home Cond Etoh Abuse Home Condition 281.00 (55.75) 0 281 
Home Cond Fatigue Home Condition 1.00 (0.20) 0 1 
Home Cond Fibromyalgia Home Condition 11.00 (2.18) 0 11 
Home Cond Gastroparesis Home Condition 5.00 (0.99) 0 5 
Home Cond GI Home Condition 155.00 (30.75) 0 155 
Home Cond GIPerf Home Condition 3.00 (0.60) 0 3 
Home Cond GLOM Home Condition 2.00 (0.40) 0 2 
Home Cond GLOMNephEx Home Condition 2.00 (0.40) 0 2 
Home Cond HCC Home Condition 50.00 (9.92) 0 50 
Home Cond HE Home Condition 136.00 (26.98) 0 136 
Home Cond Headache Home Condition 36.00 (7.14) 0 36 
Home Cond Hemorrhoid Home Condition 95.00 (18.85) 0 95 
Home Cond HEP Home Condition 299.00 (59.33) 0 299 
Home Cond Hep B C Home Condition 242.00 (48.02) 0 242 
Home Cond HIV Home Condition 12.00 (2.38) 0 12 
Home Cond HOTN Home Condition 110.00 (21.83) 0 110 
Home Cond HRS Home Condition 113.00 (22.42) 0 113 
Home Cond HTN Home Condition 357.00 (70.83) 0 357 
Home Cond HTNEmer Home Condition 4.00 (0.79) 0 4 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Home Cond HYPC Home Condition 5.00 (0.99) 0 5 
Home Cond Hyperkalemia Home Condition 62.00 (12.30) 0 62 
Home Cond 
Hyperparathyroidism 
Home Condition 3.00 (0.60) 0 3 
Home Cond IBS Home Condition 5.00 (0.99) 0 5 
Home Cond IVD Home Condition 81.00 (16.07) 0 81 
Home Cond JAUD Home Condition 72.00 (14.29) 0 72 
Home Cond LIV Home Condition 462.00 (91.67) 0 462 
Home Cond LKM Home Condition 3.00 (0.60) 0 3 
Home Cond LUP Home Condition 7.00 (1.39) 0 7 
Home Cond MECHVENT Home Condition 20.00 (3.97) 0 20 
Home Cond Megacolon Home Condition 1.00 (0.20) 0 1 
Home Cond 
MetabolicSyndrome 
Home Condition 127.00 (25.20) 0 127 
Home Cond MI Home Condition 18.00 (3.57) 0 18 
Home Cond MVR Home Condition 14.00 (2.78) 0 14 
Home Cond Myopathies Home Condition 20.00 (3.97) 0 20 
Home Cond NAFLD Home Condition 72.00 (14.29) 0 72 
Home Cond NephGLOM Home Condition 9.00 (1.79) 0 9 
Home Cond Nephrtmy Home Condition 2.00 (0.40) 0 2 
Home Cond NFXss Home Condition 403.00 (79.96) 0 403 
Home Cond NSTEMI Home Condition 12.00 (2.38) 0 12 
Home Cond OA Home Condition 125.00 (24.80) 0 125 
Home Cond Obesity Home Condition 108.00 (21.43) 0 108 
Home Cond OFss Home Condition 367.00 (72.82) 0 367 
Home Cond OLG Home Condition 1.00 (0.20) 0 1 
Home Cond PALL Home Condition 47.00 (9.33) 0 47 
Home Cond Parkinsons Home Condition 3.00 (0.60) 0 3 
Home Cond PCI Home Condition 17.00 (3.37) 0 17 
Home Cond PCR Home Condition 50.00 (9.92) 0 50 
Home Cond PFT Home Condition 40.00 (7.94) 0 40 
Home Cond Plegia CC Home Condition 9.00 (1.79) 0 9 
Home Cond Porphyria Home Condition 2.00 (0.40) 0 2 
Home Cond PUD CC Home Condition 42.00 (8.33) 0 42 
Home Cond PVD Home Condition 28.00 (5.56) 0 28 
Home Cond RA Home Condition 4.00 (0.79) 0 4 
Home Cond RectalProlapse Home Condition 1.00 (0.20) 0 1 
Home Cond RHBD Home Condition 8.00 (1.59) 0 8 
Home Cond Rheum CC Home Condition 6.00 (1.19) 0 6 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Home Cond SBP Home Condition 49.00 (9.72) 0 49 
Home Cond Sickle Home Condition 1.00 (0.20) 0 1 
Home Cond SIRS Home Condition 51.00 (10.12) 0 51 
Home Cond SpinalCord Home Condition 4.00 (0.79) 0 4 
Home Cond SPS Home Condition 33.00 (6.55) 0 33 
Home Cond StableAngina Home Condition 21.00 (4.17) 0 21 
Home Cond STEMI Home Condition 13.00 (2.58) 0 13 
Home Cond STROKE Home Condition 30.00 (5.95) 0 30 
Home Cond TB Home Condition 3.00 (0.60) 0 3 
Home Cond TIA Home Condition 13.00 (2.58) 0 13 
Home Cond TIPS Home Condition 13.00 (2.58) 0 13 
Home Cond TOBC Home Condition 234.00 (46.43) 0 234 
Home Cond TRAU Home Condition 30.00 (5.95) 0 30 
Home Cond UNAN Home Condition 34.00 (6.75) 0 34 
Home Cond UrinaryObst Home Condition 46.00 (9.13) 0 46 
Home Cond Varices Home Condition 124.00 (24.60) 0 124 
Home Cond VascProc Home Condition 73.00 (14.48) 0 73 
Home Cond VascSurg Home Condition 58.00 (11.51) 0 58 
Home Cond VHD Home Condition 25.00 (4.96) 0 25 
Home Cond VLP Home Condition 58.00 (11.51) 0 58 
Home Cond VMT Home Condition 22.00 (4.37) 0 22 
Inpt Cond AA, Elixhauser Inpatie
nt 
Condition 1.16 (2.01) 0 276 
Inpt Cond AAA Inpatie
nt 
Condition 0.04 (0.73) 0 5 
Inpt Cond AbdomSurg Inpatie
nt 
Condition 0.08 (0.44) 0 18 
Inpt Cond ACS Inpatie
nt 
Condition 0.05 (0.33) 0 14 
Inpt Cond aDIAL Inpatie
nt 
Condition 0.33 (1.68) 0 39 
Inpt Cond AFIB Inpatie
nt 
Condition 0.20 (0.90) 0 50 
Inpt Cond AFL Inpatie
nt 
Condition 0.27 (1.16) 0 68 
Inpt Cond AIDS/HIV, 
Elixhauser 
Inpatie
nt 
Condition 0.04 (0.41) 0 8 
Inpt Cond ALD Inpatie
nt 
Condition 2.89 (3.49) 0 445 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Cond Angina Inpatie
nt 
Condition 0.02 (0.19) 0 7 
Inpt Cond ANMA Inpatie
nt 
Condition 0.67 (1.62) 0 185 
Inpt Cond ARF Inpatie
nt 
Condition 1.54 (2.77) 0 346 
Inpt Cond ARRH Inpatie
nt 
Condition 0.38 (1.04) 0 102 
Inpt Cond Arrhythmias, 
Elixhauser 
Inpatie
nt 
Condition 0.09 (0.37) 0 30 
Inpt Cond Ascites Inpatie
nt 
Condition 1.06 (1.69) 0 256 
Inpt Cond Asthma Inpatie
nt 
Condition 0.06 (0.54) 0 16 
Inpt Cond ATN Inpatie
nt 
Condition 0.11 (0.74) 0 35 
Inpt Cond AutoNeuropathy Inpatie
nt 
Condition 1.00 (0.20) 0 1 
Inpt Cond AZ Cancer Inpatie
nt 
Condition 0.51 (1.84) 0 94 
Inpt Cond BilCirrhosis Inpatie
nt 
Condition 0.00 (0.09) 0 1 
Inpt Cond BLA, Elixhauser Inpatie
nt 
Condition 6.00 (1.19) 0 6 
Inpt Cond BowelPerf Inpatie
nt 
Condition 0.01 (0.10) 0 2 
Inpt Cond CABG Inpatie
nt 
Condition 0.04 (0.44) 0 10 
Inpt Cond CAD Inpatie
nt 
Condition 0.23 (0.73) 0 75 
Inpt Cond Cancer Inpatie
nt 
Condition 0.48 (1.82) 0 87 
Inpt Cond CANDI Inpatie
nt 
Condition 0.05 (0.24) 0 21 
Inpt Cond CardiacArrest Inpatie
nt 
Condition 8.00 (1.59) 0 8 
Inpt Cond CardSurg Inpatie
nt 
Condition 0.01 (0.14) 0 4 
Inpt Cond Cath Inpatie
nt 
Condition 0.02 (0.16) 0 7 
Inpt Cond CathPCIALL Inpatie
nt 
Condition 0.02 (0.16) 0 7 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Cond CathPCICont Inpatie
nt 
Condition 0.02 (0.15) 0 6 
Inpt Cond CathPCInoCont Inpatie
nt 
Condition 4.00 (0.79) 0 4 
Inpt Cond CathPCIwCont Inpatie
nt 
Condition 0.02 (0.15) 0 6 
Inpt Cond CDVD Inpatie
nt 
Condition 0.15 (0.85) 0 39 
Inpt Cond CGP, Elixhauser Inpatie
nt 
Condition 0.38 (1.06) 0 134 
Inpt Cond CHF Inpatie
nt 
Condition 0.41 (1.78) 0 79 
Inpt Cond CHF bansal Inpatie
nt 
Condition 0.41 (1.78) 0 79 
Inpt Cond CHF, Elixhauser Inpatie
nt 
Condition 0.40 (1.78) 0 78 
Inpt Cond Cirrhosis Inpatie
nt 
Condition 2.01 (2.53) 0 420 
Inpt Cond Cirrhosis Risk 1 Inpatie
nt 
Condition 1.73 (3.09) 0 344 
Inpt Cond CKD Inpatie
nt 
Condition 0.36 (1.22) 0 98 
Inpt Cond Cons Condition Inpatie
nt 
Condition 0.09 (0.60) 0 24 
Inpt Cond Cons Proc Inpatie
nt 
Condition 1.00 (0.20) 0 1 
Inpt Cond COPD Inpatie
nt 
Condition 0.57 (1.98) 0 114 
Inpt Cond COPDAsthma Inpatie
nt 
Condition 0.61 (2.04) 0 121 
Inpt Cond CPD, Elixhauser Inpatie
nt 
Condition 0.63 (2.04) 0 130 
Inpt Cond CS Inpatie
nt 
Condition 0.01 (0.11) 0 3 
Inpt Cond CVA Inpatie
nt 
Condition 0.10 (0.86) 0 23 
Inpt Cond DA, Elixhauser Inpatie
nt 
Condition 0.08 (0.32) 0 34 
Inpt Cond DecALD Inpatie
nt 
Condition 3.09 (3.60) 0 451 
Inpt Cond Deyo's CHF Inpatie
nt 
Condition 0.39 (1.77) 0 73 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Cond Deyo's CPD Inpatie
nt 
Condition 0.57 (1.98) 0 115 
Inpt Cond Deyo's CVD Inpatie
nt 
Condition 0.11 (0.87) 0 26 
Inpt Cond Deyo's DM w/ 
chronic comp 
Inpatie
nt 
Condition 0.06 (0.38) 0 20 
Inpt Cond Deyo's DM w/o 
chronic comp 
Inpatie
nt 
Condition 0.47 (1.16) 0 135 
Inpt Cond Deyo's 
Hemiplegia or Paraplegia 
Inpatie
nt 
Condition 0.01 (0.10) 0 2 
Inpt Cond Deyo's HIV Inpatie
nt 
Condition 0.04 (0.41) 0 8 
Inpt Cond Deyo's 
Malignancy 
Inpatie
nt 
Condition 0.48 (1.82) 0 87 
Inpt Cond Deyo's MI Inpatie
nt 
Condition 0.04 (0.29) 0 15 
Inpt Cond Deyo's Mild Liver 
Disease 
Inpatie
nt 
Condition 2.03 (2.54) 0 420 
Inpt Cond Deyo's Moderate 
to Severe Liver Disease 
Inpatie
nt 
Condition 1.44 (2.12) 0 337 
Inpt Cond Deyo's PUD Inpatie
nt 
Condition 0.06 (0.32) 0 18 
Inpt Cond Deyo's PVD Inpatie
nt 
Condition 0.14 (0.91) 0 25 
Inpt Cond Deyo's Renal Inpatie
nt 
Condition 0.45 (1.33) 0 120 
Inpt Cond Deyo's Rheumatic Inpatie
nt 
Condition 0.01 (0.11) 0 3 
Inpt Cond Deyo's Tumor Inpatie
nt 
Condition 0.05 (0.25) 0 20 
Inpt Cond DiabetesC, 
Elixhauser 
Inpatie
nt 
Condition 0.14 (0.86) 0 31 
Inpt Cond DiabetesU, 
Elixhauser 
Inpatie
nt 
Condition 0.44 (1.07) 0 134 
Inpt Cond DIAL Inpatie
nt 
Condition 0.48 (2.49) 0 44 
Inpt Cond DIAR Inpatie
nt 
Condition 0.07 (0.33) 0 26 
Inpt Cond DKA Inpatie
nt 
Condition 1.00 (0.20) 0 1 
Inpt Cond DM Inpatie
nt 
Condition 0.57 (1.49) 0 149 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Cond DMNeuropathy Inpatie
nt 
Condition 8.00 (1.59) 0 8 
Inpt Cond DMOsm Inpatie
nt 
Condition 0.03 (0.42) 0 4 
Inpt Cond DP, Elixhauser Inpatie
nt 
Condition 0.13 (0.56) 0 42 
Inpt Cond Drug Abuse, 
Elixhauser 
Inpatie
nt 
Condition 0.11 (0.89) 0 24 
Inpt Cond DYS Inpatie
nt 
Condition 0.13 (0.41) 0 53 
Inpt Cond ETOH Inpatie
nt 
Condition 1.64 (3.13) 0 301 
Inpt Cond Etoh Abuse Inpatie
nt 
Condition 0.73 (2.23) 0 178 
Inpt Cond FED, Elixhauser Inpatie
nt 
Condition 0.88 (1.95) 0 249 
Inpt Cond Gastroparesis Inpatie
nt 
Condition 1.00 (0.20) 0 1 
Inpt Cond GI Inpatie
nt 
Condition 0.31 (1.14) 0 69 
Inpt Cond GIPerf Inpatie
nt 
Condition 0.01 (0.10) 0 2 
Inpt Cond GLOM Inpatie
nt 
Condition 3.00 (0.60) 0 3 
Inpt Cond GLOMNephEx Inpatie
nt 
Condition 3.00 (0.60) 0 3 
Inpt Cond HBC Inpatie
nt 
Condition 0.91 (1.99) 0 215 
Inpt Cond HCC Inpatie
nt 
Condition 0.23 (1.19) 0 44 
Inpt Cond HE Inpatie
nt 
Condition 0.50 (1.46) 0 137 
Inpt Cond Headache Inpatie
nt 
Condition 0.01 (0.11) 0 3 
Inpt Cond HEMOCH Inpatie
nt 
Condition 0.03 (0.63) 0 2 
Inpt Cond Hemorrhoid Inpatie
nt 
Condition 0.03 (0.20) 0 12 
Inpt Cond HEP Inpatie
nt 
Condition 1.15 (2.20) 0 261 
Inpt Cond Hep B C Inpatie
nt 
Condition 0.91 (1.99) 0 215 
 80 
Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Cond HF, Elixhauser Inpatie
nt 
Condition 0.53 (1.02) 0 178 
Inpt Cond HFC, Elixhauser Inpatie
nt 
Condition 0.14 (0.56) 0 56 
Inpt Cond HIV Inpatie
nt 
Condition 0.06 (0.48) 0 11 
Inpt Cond HOSP Inpatie
nt 
Condition 1.00 (0.20) 0 1 
Inpt Cond HOTN Inpatie
nt 
Condition 0.22 (0.62) 0 77 
Inpt Cond HRS Inpatie
nt 
Condition 0.69 (1.37) 0 233 
Inpt Cond HTD, Elixhauser Inpatie
nt 
Condition 0.08 (0.31) 0 37 
Inpt Cond HTN Inpatie
nt 
Condition 0.67 (1.14) 0 221 
Inpt Cond Hydronephrosis Inpatie
nt 
Condition 4.00 (0.79) 0 4 
Inpt Cond HYPC Inpatie
nt 
Condition 0.02 (0.24) 0 6 
Inpt Cond Hyperkalemia Inpatie
nt 
Condition 0.17 (0.79) 0 59 
Inpt Cond 
Hyperparathyroidism 
Inpatie
nt 
Condition 1.00 (0.20) 0 1 
Inpt Cond IABP Inpatie
nt 
Condition 1.00 (0.20) 0 1 
Inpt Cond IBS Inpatie
nt 
Condition 1.00 (0.20) 0 1 
Inpt Cond iDIAL Inpatie
nt 
Condition 0.15 (0.72) 0 38 
Inpt Cond IVD Inpatie
nt 
Condition 0.14 (0.43) 0 59 
Inpt Cond JAUD Inpatie
nt 
Condition 0.19 (0.77) 0 56 
Inpt Cond LD, Elixhauser Inpatie
nt 
Condition 3.40 (4.03) 0 458 
Inpt Cond LIV Inpatie
nt 
Condition 2.60 (3.08) 0 446 
Inpt Cond LKM Inpatie
nt 
Condition 0.01 (0.17) 0 3 
Inpt Cond LM, Elixhauser Inpatie
nt 
Condition 0.01 (0.20) 0 2 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Cond LUP Inpatie
nt 
Condition 0.01 (0.15) 0 5 
Inpt Cond LvrTx Inpatie
nt 
Condition 0.02 (0.40) 0 2 
Inpt Cond MC, Elixhauser Inpatie
nt 
Condition 0.05 (0.25) 0 20 
Inpt Cond MECHVENT Inpatie
nt 
Condition 0.17 (0.49) 0 65 
Inpt Cond MI Inpatie
nt 
Condition 0.03 (0.25) 0 9 
Inpt Cond MVR Inpatie
nt 
Condition 0.01 (0.13) 0 5 
Inpt Cond Myopathies Inpatie
nt 
Condition 9.00 (1.79) 0 9 
Inpt Cond NAFLD Inpatie
nt 
Condition 0.10 (0.42) 0 37 
Inpt Cond NAS Inpatie
nt 
Condition 0.06 (0.40) 0 20 
Inpt Cond NephGLOM Inpatie
nt 
Condition 0.01 (0.14) 0 2 
Inpt Cond Nephrtmy Inpatie
nt 
Condition 0.02 (0.17) 0 5 
Inpt Cond NFXss Inpatie
nt 
Condition 1.46 (2.91) 0 298 
Inpt Cond NSTEMI Inpatie
nt 
Condition 0.01 (0.13) 0 6 
Inpt Cond OA Inpatie
nt 
Condition 0.03 (0.28) 0 10 
Inpt Cond Obesity Inpatie
nt 
Condition 0.04 (0.26) 0 13 
Inpt Cond OFss Inpatie
nt 
Condition 2.33 (3.62) 0 416 
Inpt Cond OLG Inpatie
nt 
Condition 0.01 (0.19) 0 4 
Inpt Cond OND, Elixhauser Inpatie
nt 
Condition 0.04 (0.46) 0 10 
Inpt Cond OrganTrans Inpatie
nt 
Condition 0.02 (0.36) 0 2 
Inpt Cond PALL Inpatie
nt 
Condition 0.59 (1.88) 0 117 
Inpt Cond Paracentesis Inpatie
nt 
Condition 0.76 (1.17) 0 215 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Cond Paralysis, 
Elixhauser 
Inpatie
nt 
Condition 0.01 (0.10) 0 2 
Inpt Cond Parkinsons Inpatie
nt 
Condition 0.02 (0.40) 0 1 
Inpt Cond PCD, Elixhauser Inpatie
nt 
Condition 0.05 (0.27) 0 19 
Inpt Cond PCI Inpatie
nt 
Condition 3.00 (0.60) 0 3 
Inpt Cond PCR Inpatie
nt 
Condition 0.08 (0.55) 0 22 
Inpt Cond PFT Inpatie
nt 
Condition 0.04 (0.22) 0 15 
Inpt Cond Plegia CC Inpatie
nt 
Condition 0.01 (0.10) 0 2 
Inpt Cond PUD CC Inpatie
nt 
Condition 0.06 (0.32) 0 18 
Inpt Cond PVD Inpatie
nt 
Condition 0.10 (0.86) 0 18 
Inpt Cond PVD, Elixhauser Inpatie
nt 
Condition 0.16 (1.06) 0 31 
Inpt Cond PY, Elixhauser Inpatie
nt 
Condition 0.24 (2.79) 0 25 
Inpt Cond RA Inpatie
nt 
Condition 0.01 (0.11) 0 3 
Inpt Cond RA, Elixhauser Inpatie
nt 
Condition 0.01 (0.17) 0 3 
Inpt Cond RenalTrans Inpatie
nt 
Condition 1.00 (0.20) 0 1 
Inpt Cond RF, Elixhauser Inpatie
nt 
Condition 0.52 (1.53) 0 129 
Inpt Cond RHBD Inpatie
nt 
Condition 0.01 (0.11) 0 3 
Inpt Cond Rheum CC Inpatie
nt 
Condition 0.01 (0.17) 0 3 
Inpt Cond RUD, Elixhauser Inpatie
nt 
Condition 0.04 (0.26) 0 12 
Inpt Cond SBP Inpatie
nt 
Condition 0.17 (0.63) 0 56 
Inpt Cond SIRS Inpatie
nt 
Condition 0.17 (0.61) 0 77 
Inpt Cond SPS Inpatie
nt 
Condition 0.19 (1.26) 0 53 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Cond ST, Elixhauser Inpatie
nt 
Condition 0.45 (1.81) 0 82 
Inpt Cond StableAngina Inpatie
nt 
Condition 0.01 (0.17) 0 3 
Inpt Cond STEMI Inpatie
nt 
Condition 0.02 (0.19) 0 5 
Inpt Cond STROKE Inpatie
nt 
Condition 0.07 (0.75) 0 13 
Inpt Cond TB Inpatie
nt 
Condition 1.00 (0.20) 0 1 
Inpt Cond TIA Inpatie
nt 
Condition 1.00 (0.20) 0 1 
Inpt Cond TIPS Inpatie
nt 
Condition 0.02 (0.15) 0 6 
Inpt Cond TOBC Inpatie
nt 
Condition 0.23 (0.87) 0 81 
Inpt Cond TRAU Inpatie
nt 
Condition 0.02 (0.24) 0 4 
Inpt Cond UNAN Inpatie
nt 
Condition 0.02 (0.19) 0 7 
Inpt Cond UrinaryObst Inpatie
nt 
Condition 0.02 (0.16) 0 7 
Inpt Cond Valvular, 
Elixhauser 
Inpatie
nt 
Condition 0.10 (0.46) 0 31 
Inpt Cond Varices Inpatie
nt 
Condition 0.23 (0.71) 0 73 
Inpt Cond VascProc Inpatie
nt 
Condition 0.37 (0.71) 0 136 
Inpt Cond VascSurg Inpatie
nt 
Condition 0.34 (0.67) 0 129 
Inpt Cond VHD Inpatie
nt 
Condition 0.05 (0.29) 0 16 
Inpt Cond VLP Inpatie
nt 
Condition 0.13 (0.52) 0 39 
Inpt Cond VMT Inpatie
nt 
Condition 0.04 (0.23) 0 19 
Inpt Cond WL, Elixhauser Inpatie
nt 
Condition 0.09 (0.30) 0 45 
X3DPreAdmitProc_Paracent
esis 
Inpatie
nt 
Condition 8.00 (1.59) 0 8 
Race: 0 UNKNOWN Inpatie
nt 
Demographic 38.00 (7.54) 0 NA 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Race: 1 WHITE Inpatie
nt 
Demographic 355.00 (70.44) 0 NA 
Race: 2 BLACK Inpatie
nt 
Demographic 93.00 (18.45) 0 NA 
Race: 3 ASIAN-HAWAIIAN-
PACIFIC ISLANDER 
Inpatie
nt 
Demographic 9.00 (1.79) 0 NA 
Race: 4 AMERICAN INDIAN-
ALASKAN NATIVE 
Inpatie
nt 
Demographic 9.00 (1.79) 0 NA 
Age Inpatie
nt 
Demographic 61.55 (9.35) 0 504 
Gender Inpatie
nt 
Demographic 500.00 (99.21) 0 NA 
AdmissionToPostAdmDiffer
ence 
Inpatie
nt 
Laboratory -0.73 (1.79) 7.94 187 
Inpt Lab Avg Alb Inpatie
nt 
Laboratory 2.55 (0.68) 2.98 504 
Inpt Lab Avg AlkPhos Inpatie
nt 
Laboratory 147.90 (107.48) 3.97 504 
Inpt Lab Avg ALT Inpatie
nt 
Laboratory 80.10 (153.46) 3.77 504 
Inpt Lab Avg AST Inpatie
nt 
Laboratory 153.80 (304.61) 5.56 504 
Inpt Lab Avg BilirubinD Inpatie
nt 
Laboratory 3.56 (6.26) 38.1 411 
Inpt Lab Avg BilirubinT Inpatie
nt 
Laboratory 7.86 (9.67) 3.77 504 
Inpt Lab Avg BNP Inpatie
nt 
Laboratory 6040000000.00 
(96949181037.19
) 
68.06 504 
Inpt Lab Avg BS Inpatie
nt 
Laboratory 132.10 (47.11) 0.4 504 
Inpt Lab Avg BUN Inpatie
nt 
Laboratory 41.20 (20.96) 6.15 504 
Inpt Lab Avg CA Inpatie
nt 
Laboratory 8.27 (0.94) 1.59 504 
Inpt Lab Avg CK Inpatie
nt 
Laboratory 27560.00 
(581533.94) 
58.33 504 
Inpt Lab Avg CL Inpatie
nt 
Laboratory 102.60 (6.49) 0 504 
Inpt Lab Avg FeNa Inpatie
nt 
Laboratory 2.80 (26.09) 40.08 504 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Lab Avg HCO3 Inpatie
nt 
Laboratory 22.51 (4.20) 0 504 
Inpt Lab Avg HCT Inpatie
nt 
Laboratory 31.55 (5.47) 0 504 
Inpt Lab Avg HGB Inpatie
nt 
Laboratory 10.80 (2.16) 3.57 504 
Inpt Lab Avg INR Inpatie
nt 
Laboratory 1.83 (0.69) 8.33 504 
Inpt Lab Avg MCH Inpatie
nt 
Laboratory 32.85 (3.39) 0.4 504 
Inpt Lab Avg MCHC Inpatie
nt 
Laboratory 34.08 (1.16) 0.2 504 
Inpt Lab Avg MCV Inpatie
nt 
Laboratory 96.31 (8.45) 0.2 504 
Inpt Lab Avg NA Inpatie
nt 
Laboratory 134.50 (5.58) 0.6 504 
Inpt Lab Avg PLT Inpatie
nt 
Laboratory 121.00 (75.28) 0.2 504 
Inpt Lab Avg PT Inpatie
nt 
Laboratory 20.53 (7.56) 11.31 504 
Inpt Lab Avg PTT Inpatie
nt 
Laboratory 42.18 (13.46) 20.04 504 
Inpt Lab Avg TropI Inpatie
nt 
Laboratory 0.44 (3.18) 57.54 400 
Inpt Lab Avg UrineNa Inpatie
nt 
Laboratory 28.86 (26.68) 32.94 504 
Inpt Lab Avg WBC Inpatie
nt 
Laboratory 10.14 (7.04) 0.2 504 
Inpt Lab Max Alb Inpatie
nt 
Laboratory 3.01 (0.85) 2.98 504 
Inpt Lab Max AlkPhos Inpatie
nt 
Laboratory 188.20 (139.48) 3.97 504 
Inpt Lab Max ALT Inpatie
nt 
Laboratory 146.70 (389.40) 3.77 504 
Inpt Lab Max AST Inpatie
nt 
Laboratory 334.90 (1078.05) 5.56 504 
Inpt Lab Max BilirubinD Inpatie
nt 
Laboratory 4.30 (7.48) 38.1 410 
Inpt Lab Max BilirubinT Inpatie
nt 
Laboratory 10.21 (12.10) 3.77 504 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Lab Max BNP Inpatie
nt 
Laboratory 5017000000.00 
(84550541645.45
) 
68.06 504 
Inpt Lab Max BS Inpatie
nt 
Laboratory 225.30 (144.24) 0.4 504 
Inpt Lab Max BUN Inpatie
nt 
Laboratory 61.69 (39.84) 6.15 504 
Inpt Lab Max CA Inpatie
nt 
Laboratory 8.96 (0.91) 1.59 504 
Inpt Lab Max CK Inpatie
nt 
Laboratory 50190.00 
(515634.62) 
58.33 504 
Inpt Lab Max CL Inpatie
nt 
Laboratory 108.00 (7.94) 0 504 
Inpt Lab Max FeNa Inpatie
nt 
Laboratory 3.45 (24.64) 40.08 504 
Inpt Lab Max HCO3 Inpatie
nt 
Laboratory 26.45 (4.98) 0 504 
Inpt Lab Max HCT Inpatie
nt 
Laboratory 36.29 (5.70) 0 504 
Inpt Lab Max HGB Inpatie
nt 
Laboratory 12.53 (4.19) 3.57 504 
Inpt Lab Max INR Inpatie
nt 
Laboratory 2.36 (1.70) 8.33 504 
Inpt Lab Max MCH Inpatie
nt 
Laboratory 33.74 (3.59) 0.4 504 
Inpt Lab Max MCHC Inpatie
nt 
Laboratory 34.90 (1.23) 0.2 504 
Inpt Lab Max MCV Inpatie
nt 
Laboratory 98.71 (9.02) 0.2 504 
Inpt Lab Max NA Inpatie
nt 
Laboratory 139.40 (6.53) 0.6 504 
Inpt Lab Max PLT Inpatie
nt 
Laboratory 171.00 (97.60) 0.2 504 
Inpt Lab Max PT Inpatie
nt 
Laboratory 25.91 (18.83) 11.31 504 
Inpt Lab Max PTT Inpatie
nt 
Laboratory 54.83 (37.02) 20.04 504 
Inpt Lab Max TropI Inpatie
nt 
Laboratory 0.82 (6.75) 57.54 396 
Inpt Lab Max UrineNa Inpatie
nt 
Laboratory 38.25 (40.16) 32.94 504 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Lab Max WBC Inpatie
nt 
Laboratory 15.08 (10.52) 0.2 504 
Inpt Lab Min Alb Inpatie
nt 
Laboratory 2.17 (0.69) 2.98 504 
Inpt Lab Min AlkPhos Inpatie
nt 
Laboratory 120.40 (90.32) 3.97 504 
Inpt Lab Min ALT Inpatie
nt 
Laboratory 47.70 (76.25) 3.77 504 
Inpt Lab Min AST Inpatie
nt 
Laboratory 83.30 (114.25) 5.56 504 
Inpt Lab Min BilirubinD Inpatie
nt 
Laboratory 2.90 (5.52) 38.1 409 
Inpt Lab Min BilirubinT Inpatie
nt 
Laboratory 5.89 (7.93) 3.77 504 
Inpt Lab Min BNP Inpatie
nt 
Laboratory 399900000000.0
0 
(8803822474195.
57) 
68.06 504 
Inpt Lab Min BS Inpatie
nt 
Laboratory 79.34 (30.20) 0.4 504 
Inpt Lab Min BUN Inpatie
nt 
Laboratory 26.37 (18.74) 6.15 504 
Inpt Lab Min CA Inpatie
nt 
Laboratory 7.64 (1.28) 1.59 504 
Inpt Lab Min CK Inpatie
nt 
Laboratory 2578000.00 
(52985939.99) 
58.33 504 
Inpt Lab Min CL Inpatie
nt 
Laboratory 96.58 (7.04) 0 504 
Inpt Lab Min FeNa Inpatie
nt 
Laboratory 1.47 (21.43) 40.08 452 
Inpt Lab Min HCO3 Inpatie
nt 
Laboratory 18.45 (5.10) 0 504 
Inpt Lab Min HCT Inpatie
nt 
Laboratory 27.31 (6.72) 0 504 
Inpt Lab Min HGB Inpatie
nt 
Laboratory 9.31 (2.30) 3.57 504 
Inpt Lab Min INR Inpatie
nt 
Laboratory 1.54 (0.44) 8.33 504 
Inpt Lab Min MCH Inpatie
nt 
Laboratory 32.05 (3.39) 0.4 504 
Inpt Lab Min MCHC Inpatie
nt 
Laboratory 33.24 (1.32) 0.2 504 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Lab Min MCV Inpatie
nt 
Laboratory 94.25 (8.32) 0.2 504 
Inpt Lab Min NA Inpatie
nt 
Laboratory 129.40 (6.36) 0.6 504 
Inpt Lab Min PLT Inpatie
nt 
Laboratory 93.29 (67.59) 0.2 502 
Inpt Lab Min PT Inpatie
nt 
Laboratory 17.54 (4.63) 11.31 504 
Inpt Lab Min PTT Inpatie
nt 
Laboratory 36.05 (8.77) 20.04 504 
Inpt Lab Min TropI Inpatie
nt 
Laboratory 1667.00 
(37272.08) 
57.54 405 
Inpt Lab Min UrineNa Inpatie
nt 
Laboratory 26.40 (49.23) 32.94 504 
Inpt Lab Min WBC Inpatie
nt 
Laboratory 6.82 (5.12) 0.2 504 
Inpt Lab ProteinStick High Inpatie
nt 
Laboratory 1.91 (7.21) 13.69 366 
Inpt Lab ProteinStick 
Median 
Inpatie
nt 
Laboratory 1.18 (2.04) 13.69 350 
MaxAdmissionCreatinine Inpatie
nt 
Laboratory 2.36 (1.55) 0.2 504 
MaxCreatinineChange Inpatie
nt 
Laboratory 2.23 (1.92) 0 504 
MaxInpatientCreatinine Inpatie
nt 
Laboratory 3.34 (1.90) 0 504 
MeanInpatientCreatinine Inpatie
nt 
Laboratory 2.24 (1.37) 0 504 
PeakPostAdmToDisCreatini
ne 
Inpatie
nt 
Laboratory 3.07 (2.06) 7.74 504 
PreAdmitLab_ProteinStick_
High 
Inpatie
nt 
Laboratory 1.20 (1.11) 21.83 351 
PreAdmitLab_ProteinStick_
Median 
Inpatie
nt 
Laboratory 0.68 (1.07) 21.83 196 
PreAdmMeanCreatinine Inpatie
nt 
Laboratory 1.10 (0.47) 0 504 
Home Med Lactulose Home Medication 91.00 (18.06) 0 91 
Home Med Rifaximin Home Medication 21.00 (4.17) 0 21 
Inpt Med Cyclosporine Inpatie
nt 
Medication 1.00 (0.20) 0 1 
Inpt Med Dobutamine Inpatie
nt 
Medication 8.00 (1.59) 0 8 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Med Dopamine Inpatie
nt 
Medication 33.00 (6.55) 0 33 
Inpt Med Human Albumin Inpatie
nt 
Medication 246.00 (48.81) 0 246 
Inpt Med Lactulose Inpatie
nt 
Medication 299.00 (59.33) 0 299 
Inpt Med Midodrine Inpatie
nt 
Medication 127.00 (25.20) 0 127 
Inpt Med Nacetylcysteine Inpatie
nt 
Medication 40.00 (7.94) 0 40 
Inpt Med Norepinephrine Inpatie
nt 
Medication 66.00 (13.10) 0 66 
Inpt Med Octreotide Inpatie
nt 
Medication 164.00 (32.54) 0 164 
Inpt Med Phenylephrine Inpatie
nt 
Medication 20.00 (3.97) 0 20 
Inpt Med Rifaximin Inpatie
nt 
Medication 71.00 (14.09) 0 71 
Inpt Med Septra Inpatie
nt 
Medication 20.00 (3.97) 0 20 
Inpt Med Trimethoprim Inpatie
nt 
Medication 16.00 (3.17) 0 16 
Inpt Med Vancomycin Inpatie
nt 
Medication 205.00 (40.67) 0 205 
Inpt Med Vasopressin Inpatie
nt 
Medication 33.00 (6.55) 0 33 
Octreotide_and_Midodrine Inpatie
nt 
Medication 119.00 (23.61) 0 119 
Octreotide_and_Norepineph
rine 
Inpatie
nt 
Medication 31.00 (6.15) 0 31 
Octreotide_and_Vasopressin Inpatie
nt 
Medication 15.00 (2.98) 0 15 
Any_IV_Vasopressor Inpatie
nt 
Medication 
Class 
86.00 (17.06) 0 86 
Home Med Ace Inhibitors Home Medication 
Class 
96.00 (19.05) 0 96 
Home Med Alcohol 
Deterrents 
Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Alpha Blockers 
Related 
Home Medication 
Class 
45.00 (8.93) 0 45 
Home Med Aminoglycosides Home Medication 
Class 
4.00 (0.79) 0 4 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Home Med Amphetamine 
Like Stimulants 
Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Analgesics Home Medication 
Class 
155.00 (30.75) 0 155 
Home Med Analgesics 
Topical 
Home Medication 
Class 
9.00 (1.79) 0 9 
Home Med Angiotensin Ii 
Inhibitor 
Home Medication 
Class 
21.00 (4.17) 0 21 
Home Med Anti Infective 
Topical 
Home Medication 
Class 
27.00 (5.36) 0 27 
Home Med Anti Infective 
Topical Other 
Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med Anti Infectives 
Other 
Home Medication 
Class 
30.00 (5.95) 0 30 
Home Med Anti 
Inflammatory Topical 
Home Medication 
Class 
23.00 (4.56) 0 23 
Home Med Antiacne Agents Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med Antiacne Agents 
Topical 
Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med Antianginals Home Medication 
Class 
17.00 (3.37) 0 17 
Home Med Antiarrhythmics Home Medication 
Class 
4.00 (0.79) 0 4 
Home Med Antibacterial 
Topical 
Home Medication 
Class 
9.00 (1.79) 0 9 
Home Med Anticoagulants Home Medication 
Class 
16.00 (3.17) 0 16 
Home Med Anticonvulsants Home Medication 
Class 
44.00 (8.73) 0 44 
Home Med Antidepressants Home Medication 
Class 
119.00 (23.61) 0 119 
Home Med Antidepressants 
Other 
Home Medication 
Class 
114.00 (22.62) 0 114 
Home Med Antidotes 
Deterrents And Poison 
Control 
Home Medication 
Class 
11.00 (2.18) 0 11 
Home Med Antidotes 
Deterrents And Poison 
Control Exchange Resins 
Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med Antidotes 
Deterrents Other 
Home Medication 
Class 
7.00 (1.39) 0 7 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Home Med Antifungal 
Topical 
Home Medication 
Class 
18.00 (3.57) 0 18 
Home Med Antifungals Home Medication 
Class 
4.00 (0.79) 0 4 
Home Med Antihistamines Home Medication 
Class 
51.00 (10.12) 0 51 
Home Med Antihistamines 
Alkylamine 
Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med Antihistamines 
Ethanolamine 
Home Medication 
Class 
7.00 (1.39) 0 7 
Home Med Antihistamines 
Other 
Home Medication 
Class 
21.00 (4.17) 0 21 
Home Med Antihistamines 
Phenothiazine 
Home Medication 
Class 
9.00 (1.79) 0 9 
Home Med Antihistamines 
Piperazine 
Home Medication 
Class 
14.00 (2.78) 0 14 
Home Med Antihistamines 
Piperidine 
Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med 
Antihypertensive 
Combinations 
Home Medication 
Class 
13.00 (2.58) 0 13 
Home Med 
Antihypertensives Other 
Home Medication 
Class 
11.00 (2.18) 0 11 
Home Med Antilipemic 
Agents 
Home Medication 
Class 
58.00 (11.51) 0 58 
Home Med Antimalarials Home Medication 
Class 
4.00 (0.79) 0 4 
Home Med Antimicrobials Home Medication 
Class 
97.00 (19.25) 0 97 
Home Med Antimigraine 
Agents 
Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med Antineoplastic 
Hormones 
Home Medication 
Class 
3.00 (0.60) 0 3 
Home Med Antineoplastic 
Other 
Home Medication 
Class 
7.00 (1.39) 0 7 
Home Med Antineoplastics Home Medication 
Class 
11.00 (2.18) 0 11 
Home Med Antineoplastics 
Antimetabolites 
Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Antiparasitics Home Medication 
Class 
4.00 (0.79) 0 4 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Home Med Antiparkinson 
Agents 
Home Medication 
Class 
3.00 (0.60) 0 3 
Home Med Antiprotozoals Home Medication 
Class 
4.00 (0.79) 0 4 
Home Med Antipsoriatic Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med Antipsoriatics 
Topical 
Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med Antipsychotics Home Medication 
Class 
28.00 (5.56) 0 28 
Home Med Antipsychotics 
Other 
Home Medication 
Class 
27.00 (5.36) 0 27 
Home Med Antituberculars Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Antivirals Home Medication 
Class 
16.00 (3.17) 0 16 
Home Med Autonomic 
Medications 
Home Medication 
Class 
7.00 (1.39) 0 7 
Home Med Benzodiazepine 
Derivative Sedatives 
Hypnotics 
Home Medication 
Class 
40.00 (7.94) 0 40 
Home Med Beta Blockers 
Related 
Home Medication 
Class 
189.00 (37.50) 0 189 
Home Med Blood Formation 
Products 
Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med Blood Products 
Modifiers Volume 
Expanders 
Home Medication 
Class 
30.00 (5.95) 0 30 
Home Med Calcium Channel 
Blockers 
Home Medication 
Class 
59.00 (11.71) 0 59 
Home Med Carbonic 
Anhydrase Inhibitor 
Diuretics 
Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Cardiovascular 
Agents Other 
Home Medication 
Class 
7.00 (1.39) 0 7 
Home Med Cardiovascular 
Medications 
Home Medication 
Class 
352.00 (69.84) 0 352 
Home Med Central Nervous 
System Medications 
Home Medication 
Class 
232.00 (46.03) 0 232 
Home Med Cephalosporin 
1st Generation 
Home Medication 
Class 
1.00 (0.20) 0 1 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Home Med Cephalosporin 
3rd Generation 
Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Cns Medications 
Other 
Home Medication 
Class 
6.00 (1.19) 0 6 
Home Med Cns Stimulants Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Dermatological 
Agents 
Home Medication 
Class 
67.00 (13.29) 0 67 
Home Med Dermatologicals 
Topical Other 
Home Medication 
Class 
7.00 (1.39) 0 7 
Home Med Digitalis 
Glycosides 
Home Medication 
Class 
10.00 (1.98) 0 10 
Home Med Diuretics Home Medication 
Class 
257.00 (50.99) 0 257 
Home Med Emollients Home Medication 
Class 
16.00 (3.17) 0 16 
Home Med Erythromycins 
Macrolides 
Home Medication 
Class 
6.00 (1.19) 0 6 
Home Med Heavy Metal 
Antagonists 
Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Keratolytics 
Caustics Topical 
Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med Lithium Salts Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Local 
Anesthetics Topical 
Home Medication 
Class 
3.00 (0.60) 0 3 
Home Med Loop Diuretics Home Medication 
Class 
202.00 (40.08) 0 202 
Home Med Nitrofurans 
Antimicrobials 
Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Non Opioid 
Analgesics 
Home Medication 
Class 
66.00 (13.10) 0 66 
Home Med Opioid 
Analgesics 
Home Medication 
Class 
112.00 (22.22) 0 112 
Home Med Opioid 
Antagonist Analgesics 
Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med 
Parasympatholytics 
Home Medication 
Class 
4.00 (0.79) 0 4 
Home Med 
Parasympathomimetics 
Cholinergics 
Home Medication 
Class 
3.00 (0.60) 0 3 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Home Med Penicillinase 
Resistant Penicillins 
Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Penicillins 
Amino Derivatives 
Home Medication 
Class 
11.00 (2.18) 0 11 
Home Med Penicillins And 
Beta Lactam Antimicrobials 
Home Medication 
Class 
13.00 (2.58) 0 13 
Home Med Phenothiazine 
Related Antipsychotics 
Home Medication 
Class 
1.00 (0.20) 0 1 
Home Med Platelet 
Aggregation Inhibitors 
Home Medication 
Class 
13.00 (2.58) 0 13 
Home Med Potassium 
Sparing Combinations 
Diuretics 
Home Medication 
Class 
184.00 (36.51) 0 184 
Home Med Quinolones Home Medication 
Class 
46.00 (9.13) 0 46 
Home Med Sedatives 
Hypnotics Other 
Home Medication 
Class 
21.00 (4.17) 0 21 
Home Med Sedatives 
Hypontics 
Home Medication 
Class 
58.00 (11.51) 0 58 
Home Med Sulfonamide 
Related Antimicrobials 
Home Medication 
Class 
7.00 (1.39) 0 7 
Home Med Sun Protectants 
Screens Topical 
Home Medication 
Class 
2.00 (0.40) 0 2 
Home Med Tetracyclines Home Medication 
Class 
4.00 (0.79) 0 4 
Home Med Thiazides 
Related Diuretics 
Home Medication 
Class 
33.00 (6.55) 0 33 
Home Med Tricyclic 
Antidepressants 
Home Medication 
Class 
9.00 (1.79) 0 9 
Inpt Med Class Ace Inpatie
nt 
Medication 
Class 
81.00 (16.07) 0 81 
Inpt Med Class 
Aminoglycosides 
Inpatie
nt 
Medication 
Class 
29.00 (5.75) 0 29 
Inpt Med Class Arb Inpatie
nt 
Medication 
Class 
10.00 (1.98) 0 10 
Inpt Med Class 
Benzodiazepines 
Inpatie
nt 
Medication 
Class 
205.00 (40.67) 0 205 
Inpt Med Class Betablockers Inpatie
nt 
Medication 
Class 
301.00 (59.72) 0 301 
Inpt Med Class 
Fluoroquinolones 
Inpatie
nt 
Medication 
Class 
141.00 (27.98) 0 141 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Med Class 
Glucocorticoids 
Inpatie
nt 
Medication 
Class 
100.00 (19.84) 0 100 
Inpt Med Class Insulin Inpatie
nt 
Medication 
Class 
216.00 (42.86) 0 216 
Inpt Med Class 
Ksparingdiuretic 
Inpatie
nt 
Medication 
Class 
191.00 (37.90) 0 191 
Inpt Med Class Nsaids Inpatie
nt 
Medication 
Class 
43.00 (8.53) 0 43 
Inpt Med Class Opioids Inpatie
nt 
Medication 
Class 
418.00 (82.94) 0 418 
Inpt Med Class Statins Inpatie
nt 
Medication 
Class 
57.00 (11.31) 0 57 
Inpt Med Va Class Ace 
Inhibitors 
Inpatie
nt 
Medication 
Class 
81.00 (16.07) 0 81 
Inpt Med Va Class Alcohol 
Deterrents 
Inpatie
nt 
Medication 
Class 
3.00 (0.60) 0 3 
Inpt Med Va Class Alpha 
Blockers Related 
Inpatie
nt 
Medication 
Class 
66.00 (13.10) 0 66 
Inpt Med Va Class 
Aminoglycosides 
Inpatie
nt 
Medication 
Class 
26.00 (5.16) 0 26 
Inpt Med Va Class 
Amphetamine Like 
Stimulants 
Inpatie
nt 
Medication 
Class 
2.00 (0.40) 0 2 
Inpt Med Va Class 
Analgesics Topical 
Inpatie
nt 
Medication 
Class 
9.00 (1.79) 0 9 
Inpt Med Va Class 
Angiotensin Ii Inhibitor 
Inpatie
nt 
Medication 
Class 
10.00 (1.98) 0 10 
Inpt Med Va Class Anti 
Infective Anti Inflammatory 
Combinations Topical 
Inpatie
nt 
Medication 
Class 
1.00 (0.20) 0 1 
Inpt Med Va Class Anti 
Infective Topical Other 
Inpatie
nt 
Medication 
Class 
8.00 (1.59) 0 8 
Inpt Med Va Class Anti 
Infectives Other 
Inpatie
nt 
Medication 
Class 
274.00 (54.37) 0 274 
Inpt Med Va Class Anti 
Inflammatory Topical 
Inpatie
nt 
Medication 
Class 
28.00 (5.56) 0 28 
Inpt Med Va Class Antiacne 
Agents Topical 
Inpatie
nt 
Medication 
Class 
2.00 (0.40) 0 2 
Inpt Med Va Class 
Antianginals 
Inpatie
nt 
Medication 
Class 
26.00 (5.16) 0 26 
Inpt Med Va Class 
Antiarrhythmics 
Inpatie
nt 
Medication 
Class 
19.00 (3.77) 0 19 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Med Va Class 
Antibacterial Topical 
Inpatie
nt 
Medication 
Class 
28.00 (5.56) 0 28 
Inpt Med Va Class 
Anticoagulants 
Inpatie
nt 
Medication 
Class 
233.00 (46.23) 0 233 
Inpt Med Va Class 
Anticonvulsants 
Inpatie
nt 
Medication 
Class 
76.00 (15.08) 0 76 
Inpt Med Va Class 
Antidepressants Other 
Inpatie
nt 
Medication 
Class 
151.00 (29.96) 0 151 
Inpt Med Va Class Antidotes 
Deterrents And Poison 
Control Exchange Resins 
Inpatie
nt 
Medication 
Class 
110.00 (21.83) 0 110 
Inpt Med Va Class Antidotes 
Deterrents Other 
Inpatie
nt 
Medication 
Class 
17.00 (3.37) 0 17 
Inpt Med Va Class 
Antifungal Topical 
Inpatie
nt 
Medication 
Class 
64.00 (12.70) 0 64 
Inpt Med Va Class 
Antifungals 
Inpatie
nt 
Medication 
Class 
69.00 (13.69) 0 69 
Inpt Med Va Class 
Antihemorrhagics 
Inpatie
nt 
Medication 
Class 
4.00 (0.79) 0 4 
Inpt Med Va Class 
Antihistamines 
Ethanolamine 
Inpatie
nt 
Medication 
Class 
86.00 (17.06) 0 86 
Inpt Med Va Class 
Antihistamines Other 
Inpatie
nt 
Medication 
Class 
12.00 (2.38) 0 12 
Inpt Med Va Class 
Antihistamines 
Phenothiazine 
Inpatie
nt 
Medication 
Class 
43.00 (8.53) 0 43 
Inpt Med Va Class 
Antihistamines Piperazine 
Inpatie
nt 
Medication 
Class 
28.00 (5.56) 0 28 
Inpt Med Va Class 
Antihistamines Piperidine 
Inpatie
nt 
Medication 
Class 
1.00 (0.20) 0 1 
Inpt Med Va Class 
Antihypertensive 
Combinations 
Inpatie
nt 
Medication 
Class 
8.00 (1.59) 0 8 
Inpt Med Va Class 
Antihypertensives Other 
Inpatie
nt 
Medication 
Class 
45.00 (8.93) 0 45 
Inpt Med Va Class 
Antilipemic Agents 
Inpatie
nt 
Medication 
Class 
67.00 (13.29) 0 67 
Inpt Med Va Class 
Antimalarials 
Inpatie
nt 
Medication 
Class 
4.00 (0.79) 0 4 
Inpt Med Va Class 
Antineoplastic Other 
Inpatie
nt 
Medication 
Class 
4.00 (0.79) 0 4 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Med Va Class 
Antiparkinson Agents 
Inpatie
nt 
Medication 
Class 
3.00 (0.60) 0 3 
Inpt Med Va Class 
Antiprotozoals Other 
Inpatie
nt 
Medication 
Class 
1.00 (0.20) 0 1 
Inpt Med Va Class 
Antipsoriatics Topical 
Inpatie
nt 
Medication 
Class 
1.00 (0.20) 0 1 
Inpt Med Va Class 
Antipsychotics Other 
Inpatie
nt 
Medication 
Class 
84.00 (16.67) 0 84 
Inpt Med Va Class 
Antituberculars 
Inpatie
nt 
Medication 
Class 
2.00 (0.40) 0 2 
Inpt Med Va Class 
Antivertigo Agents 
Inpatie
nt 
Medication 
Class 
9.00 (1.79) 0 9 
Inpt Med Va Class Antivirals Inpatie
nt 
Medication 
Class 
15.00 (2.98) 0 15 
Inpt Med Va Class Barbituric 
Acid Derivative Sedatives 
Hypnotics 
Inpatie
nt 
Medication 
Class 
1.00 (0.20) 0 1 
Inpt Med Va Class 
Benzodiazepine Derivative 
Sedatives Hypnotics 
Inpatie
nt 
Medication 
Class 
205.00 (40.67) 0 205 
Inpt Med Va Class Beta 
Blockers Related 
Inpatie
nt 
Medication 
Class 
301.00 (59.72) 0 301 
Inpt Med Va Class Blood 
Derivatives 
Inpatie
nt 
Medication 
Class 
247.00 (49.01) 0 247 
Inpt Med Va Class Blood 
Formation Products 
Inpatie
nt 
Medication 
Class 
19.00 (3.77) 0 19 
Inpt Med Va Class Calcium 
Channel Blockers 
Inpatie
nt 
Medication 
Class 
81.00 (16.07) 0 81 
Inpt Med Va Class Carbonic 
Anhydrase Inhibitor 
Diuretics 
Inpatie
nt 
Medication 
Class 
4.00 (0.79) 0 4 
Inpt Med Va Class 
Cardiovascular Agents 
Other 
Inpatie
nt 
Medication 
Class 
139.00 (27.58) 0 139 
Inpt Med Va Class 
Cephalosporin 1st 
Generation 
Inpatie
nt 
Medication 
Class 
31.00 (6.15) 0 31 
Inpt Med Va Class 
Cephalosporin 2nd 
Generation 
Inpatie
nt 
Medication 
Class 
6.00 (1.19) 0 6 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Med Va Class 
Cephalosporin 3rd 
Generation 
Inpatie
nt 
Medication 
Class 
171.00 (33.93) 0 171 
Inpt Med Va Class Cns 
Medications Other 
Inpatie
nt 
Medication 
Class 
7.00 (1.39) 0 7 
Inpt Med Va Class 
Dermatologicals Topical 
Other 
Inpatie
nt 
Medication 
Class 
46.00 (9.13) 0 46 
Inpt Med Va Class Digitalis 
Glycosides 
Inpatie
nt 
Medication 
Class 
25.00 (4.96) 0 25 
Inpt Med Va Class 
Emollients 
Inpatie
nt 
Medication 
Class 
37.00 (7.34) 0 37 
Inpt Med Va Class 
Erythromycins Macrolides 
Inpatie
nt 
Medication 
Class 
45.00 (8.93) 0 45 
Inpt Med Va Class Extended 
Spectrum Penicillins 
Inpatie
nt 
Medication 
Class 
171.00 (33.93) 0 171 
Inpt Med Va Class Heavy 
Metal Antagonists 
Inpatie
nt 
Medication 
Class 
1.00 (0.20) 0 1 
Inpt Med Va Class 
Lincomycins 
Inpatie
nt 
Medication 
Class 
21.00 (4.17) 0 21 
Inpt Med Va Class Lithium 
Salts 
Inpatie
nt 
Medication 
Class 
1.00 (0.20) 0 1 
Inpt Med Va Class Local 
Anesthetics Injection 
Inpatie
nt 
Medication 
Class 
22.00 (4.37) 0 22 
Inpt Med Va Class Local 
Anesthetics Topical 
Inpatie
nt 
Medication 
Class 
13.00 (2.58) 0 13 
Inpt Med Va Class Loop 
Diuretics 
Inpatie
nt 
Medication 
Class 
305.00 (60.52) 0 305 
Inpt Med Va Class 
Nitrofurans Antimicrobials 
Inpatie
nt 
Medication 
Class 
1.00 (0.20) 0 1 
Inpt Med Va Class Non 
Opioid Analgesics 
Inpatie
nt 
Medication 
Class 
218.00 (43.25) 0 218 
Inpt Med Va Class Opioid 
Analgesics 
Inpatie
nt 
Medication 
Class 
370.00 (73.41) 0 370 
Inpt Med Va Class Opioid 
Antagonist Analgesics 
Inpatie
nt 
Medication 
Class 
13.00 (2.58) 0 13 
Inpt Med Va Class 
Parasympatholytics 
Inpatie
nt 
Medication 
Class 
16.00 (3.17) 0 16 
Inpt Med Va Class 
Parasympathomimetics 
Cholinergics 
Inpatie
nt 
Medication 
Class 
49.00 (9.72) 0 49 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Inpt Med Va Class Penicillin 
G Related Penicillins 
Inpatie
nt 
Medication 
Class 
1.00 (0.20) 0 1 
Inpt Med Va Class 
Penicillinase Resistant 
Penicillins 
Inpatie
nt 
Medication 
Class 
11.00 (2.18) 0 11 
Inpt Med Va Class 
Penicillins Amino 
Derivatives 
Inpatie
nt 
Medication 
Class 
47.00 (9.33) 0 47 
Inpt Med Va Class 
Phenothiazine Related 
Antipsychotics 
Inpatie
nt 
Medication 
Class 
6.00 (1.19) 0 6 
Inpt Med Va Class Platelet 
Aggregation Inhibitors 
Inpatie
nt 
Medication 
Class 
16.00 (3.17) 0 16 
Inpt Med Va Class 
Potassium Sparing 
Combinations Diuretics 
Inpatie
nt 
Medication 
Class 
191.00 (37.90) 0 191 
Inpt Med Va Class 
Quinolones 
Inpatie
nt 
Medication 
Class 
201.00 (39.88) 0 201 
Inpt Med Va Class Sedatives 
Hypnotics Other 
Inpatie
nt 
Medication 
Class 
42.00 (8.33) 0 42 
Inpt Med Va Class Sedatives 
Hypontics 
Inpatie
nt 
Medication 
Class 
1.00 (0.20) 0 1 
Inpt Med Va Class Soaps 
Shampoos Soap Free 
Cleansers 
Inpatie
nt 
Medication 
Class 
6.00 (1.19) 0 6 
Inpt Med Va Class 
Sulfonamide Related 
Antimicrobials 
Inpatie
nt 
Medication 
Class 
20.00 (3.97) 0 20 
Inpt Med Va Class Sun 
Protectants Screens Topical 
Inpatie
nt 
Medication 
Class 
1.00 (0.20) 0 1 
Inpt Med Va Class 
Tetracyclines 
Inpatie
nt 
Medication 
Class 
7.00 (1.39) 0 7 
Inpt Med Va Class Thiazides 
Related Diuretics 
Inpatie
nt 
Medication 
Class 
38.00 (7.54) 0 38 
Inpt Med Va Class Tricyclic 
Antidepressants 
Inpatie
nt 
Medication 
Class 
7.00 (1.39) 0 7 
Inpt Med Va Class Volume 
Expanders 
Inpatie
nt 
Medication 
Class 
9.00 (1.79) 0 9 
LOSHours Inpatie
nt 
Misc 311.10 (736.92) 0 504 
MELD Inpatie
nt 
Misc 22.98 (8.16) 19.05 504 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
Num_paracentesis_90D Inpatie
nt 
Misc 1.17 (0.76) 0 504 
PalliativeConsult Inpatie
nt 
Misc 181.00 (35.91) 0 181 
n_Anuria Inpatie
nt 
NLP 0.02 (0.19) 2.38 7 
n_ARDS Inpatie
nt 
NLP 0.04 (0.38) 2.38 7 
n_Ascites Inpatie
nt 
NLP 3.03 (5.00) 2.38 335 
n_ATN Inpatie
nt 
NLP 0.02 (0.45) 2.38 1 
n_Casts Inpatie
nt 
NLP 0.05 (0.41) 2.38 13 
n_Dehydration Inpatie
nt 
NLP 0.04 (0.30) 2.38 16 
n_Edema Inpatie
nt 
NLP 7.05 (6.90) 2.38 460 
n_Glomerulonephritis Inpatie
nt 
NLP 1.00 (0.20) 2.38 1 
n_HE Inpatie
nt 
NLP 0.35 (1.28) 2.38 78 
n_Hematemesis Inpatie
nt 
NLP 0.69 (1.69) 2.38 169 
n_HRS Inpatie
nt 
NLP 1.19 (2.61) 2.38 203 
n_Hydronephrosis Inpatie
nt 
NLP 0.98 (2.61) 2.38 144 
n_Hypotension Inpatie
nt 
NLP 0.31 (1.03) 2.38 76 
n_Nephritis Inpatie
nt 
NLP 0.11 (0.69) 2.38 18 
n_Nephrotoxic Inpatie
nt 
NLP 0.25 (1.24) 2.38 45 
n_NSAIDS Inpatie
nt 
NLP 0.44 (1.51) 2.38 99 
n_NVD Inpatie
nt 
NLP 6.02 (6.85) 2.38 417 
n_Paracentesis Inpatie
nt 
NLP 1.95 (3.87) 2.38 237 
n_Peritonitis Inpatie
nt 
NLP 0.26 (1.19) 2.38 50 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
n_Prerenal Inpatie
nt 
NLP 0.00 (0.00) 2.38 0 
n_RBCs Inpatie
nt 
NLP 1.59 (4.21) 2.38 211 
n_sepsis Inpatie
nt 
NLP 0.95 (2.96) 2.38 119 
n_Shock Inpatie
nt 
NLP 0.30 (1.29) 2.38 50 
n_SIRS Inpatie
nt 
NLP 0.06 (0.38) 2.38 20 
n_TubularCells Inpatie
nt 
NLP 0.02 (0.26) 2.38 3 
n_UrineSediment Inpatie
nt 
NLP 0.05 (0.43) 2.38 9 
p_Anuria Inpatie
nt 
NLP 0.15 (0.77) 1.98 32 
p_ARDS Inpatie
nt 
NLP 0.57 (3.65) 1.98 26 
p_Ascites Inpatie
nt 
NLP 26.25 (36.76) 1.98 406 
p_ATN Inpatie
nt 
NLP 0.07 (0.53) 1.98 14 
p_Casts Inpatie
nt 
NLP 0.25 (1.07) 1.98 54 
p_Dehydration Inpatie
nt 
NLP 1.16 (3.91) 1.98 149 
p_Edema Inpatie
nt 
NLP 16.42 (20.32) 1.98 438 
p_Glomerulonephritis Inpatie
nt 
NLP 0.15 (1.38) 1.98 17 
p_HE Inpatie
nt 
NLP 5.34 (11.36) 1.98 245 
p_Hematemesis Inpatie
nt 
NLP 0.70 (3.20) 1.98 68 
p_HRS Inpatie
nt 
NLP 10.71 (16.78) 1.98 368 
p_Hydronephrosis Inpatie
nt 
NLP 0.19 (1.75) 1.98 30 
p_Hypotension Inpatie
nt 
NLP 5.43 (11.63) 1.98 304 
p_Nephritis Inpatie
nt 
NLP 1.01 (6.72) 1.98 55 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
p_Nephrotoxic Inpatie
nt 
NLP 0.51 (1.81) 1.98 79 
p_NSAIDS Inpatie
nt 
NLP 0.66 (2.27) 1.98 97 
p_NVD Inpatie
nt 
NLP 15.56 (28.71) 1.98 398 
p_Paracentesis Inpatie
nt 
NLP 14.93 (22.78) 1.98 353 
p_Peritonitis Inpatie
nt 
NLP 1.24 (6.23) 1.98 104 
p_Prerenal Inpatie
nt 
NLP 0.00 (0.00) 1.98 0 
p_RBCs Inpatie
nt 
NLP 11.18 (14.12) 1.98 453 
p_sepsis Inpatie
nt 
NLP 3.68 (10.76) 1.98 172 
p_Shock Inpatie
nt 
NLP 3.18 (13.91) 1.98 91 
p_SIRS Inpatie
nt 
NLP 0.26 (1.33) 1.98 37 
p_TubularCells Inpatie
nt 
NLP 0.12 (0.75) 1.98 23 
p_UrineSediment Inpatie
nt 
NLP 0.31 (1.93) 1.98 43 
FluidResponsive Inpatie
nt 
Temporal 91.00 (18.06) 0 91 
MaxInptToDisCreatDifferen
ce 
Inpatie
nt 
Temporal 0.71 (1.66) 0 331 
PostAlbuminSlope Inpatie
nt 
Temporal 0.10 (0.24) 66.07 434 
PostContrastSlope Inpatie
nt 
Temporal 0.05 (0.19) 81.35 463 
PostAnyFluidSlope Inpatie
nt 
Temporal 0.01 (0.33) 0 129 
PostHypotensionSlope Inpatie
nt 
Temporal 0.01 (0.14) 89.48 18 
PostInsultSlope Inpatie
nt 
Temporal 0.08 (0.25) 0 441 
PostIVFSlope Inpatie
nt 
Temporal 0.01 (0.33) 48.21 102 
PostVasopressorSlope Inpatie
nt 
Temporal 0.16 (0.09) 93.65 497 
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Varname Time Class Summary, n(%) 
or mean (SD) 
% 
missin
g 
N > 0 
AvgInptDiastolic Inpatie
nt 
Vitals 65.69 (9.52) 0.6 504 
AvgInptMAP Inpatie
nt 
Vitals 82.12 (10.65) 0.6 504 
AvgInptPulse Inpatie
nt 
Vitals 81.23 (13.04) 0.4 504 
AvgInptResp Inpatie
nt 
Vitals 19.37 (2.09) 0.6 504 
AvgInptSystolic Inpatie
nt 
Vitals 116.30 (16.69) 0.6 504 
AvgInptTemp Inpatie
nt 
Vitals 97.71 (0.77) 0.6 504 
AvgInptWeight Inpatie
nt 
Vitals 203.00 (49.40) 7.54 504 
MaxInptDiastolic Inpatie
nt 
Vitals 86.10 (14.14) 0.6 504 
MaxInptMAP Inpatie
nt 
Vitals 94.79 (13.35) 0.6 504 
MaxInptPulse Inpatie
nt 
Vitals 104.70 (21.75) 0.4 504 
MaxInptResp Inpatie
nt 
Vitals 26.80 (12.32) 0.6 504 
MaxInptSystolic Inpatie
nt 
Vitals 148.00 (25.10) 0.6 504 
MaxInptTemp Inpatie
nt 
Vitals 99.46 (1.31) 0.6 504 
MaxInptWeight Inpatie
nt 
Vitals 211.80 (51.43) 7.54 504 
MinInptDiastolic Inpatie
nt 
Vitals 47.10 (12.14) 0.6 501 
MinInptMAP Inpatie
nt 
Vitals 69.89 (12.02) 0.6 504 
MinInptPulse Inpatie
nt 
Vitals 60.81 (16.12) 0.4 499 
MinInptResp Inpatie
nt 
Vitals 14.73 (3.14) 0.6 502 
MinInptSystolic Inpatie
nt 
Vitals 89.17 (18.77) 0.6 501 
MinInptTemp Inpatie
nt 
Vitals 95.95 (1.49) 0.6 504 
MinInptWeight Inpatie
nt 
Vitals 192.60 (53.09) 7.54 503 
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Appendix Table A.2: Code definitions for co-morbid conditions and procedures used in the 
model based on International Classification of Diseases-Version 9, Current Procedural 
Terminology, and ICD Procedure Code. 
Condition Abbreviation Description Codes 
AA, Elixhauser Alcohol Abuse 265.2, 291.[12356789], 
303.[09], 305.0, 357.5, 
425.5, 535.3, 571.[0123], 
980.*, V11.3 
AAA Abdominal Aortic Aneurysm, 
Procedure 
3480[02-5], 3482[56], 
3483[012], 350[89][12], 
3510[23], 33877, 441.4, 
39.71 
AbdomSurg Abdominal Surgery, Procedure 3810[012], 38115, 
3812[09], 4310[78], 
4311[23678], 4312[1-4], 
4330[05], 4331[02], 
43320, 4334[01], 
4335[012], 4336[01], 
4350[012], 43510, 
4362[012], 4363[1-489], 
43659, 4384[023678], 
4385[05], 4386[05], 
43870, 43880, 43999, 
44010, 4402[015], 
4405[05], 4411[01], 
4412[015], 44130, 
4414[013-7], 4415[0-
356], 44160, 4420[1-8], 
4421[012], 4423[89], 
44300, 4431[0246], 
4432[02], 4434[056], 
4460[2-5], 4462[056], 
44640, 44650, 4466[01], 
44680, 44799, 44820, 
44850, 44900, 4495[05], 
44960, 44899, 4511[0-
469], 4512[0136], 45805, 
45825, 4712[025], 47130, 
47350, 4736[012], 47399, 
4760[05], 4761[02], 
47620, 47701, 4772[01], 
4774[01], 4776[05], 
4778[05], 47800, 48005, 
4814[056], 4815[02-5], 
48180, 48520, 48540, 
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4854[57], 48556, 48999, 
4900[02], 49010, 49020, 
49062, 49040, 49060, 
49085, 4920[01], 49220, 
49999, 41.4[123], 41.5, 
41.9[59], 42.1[0129], 
42.4[012], 42.5[1-689], 
42.6[1-689], 43.0, 43.5, 
43.6, 43.7, 43.8[129], 
43.9[19], 44.3[189], 
44.4[012], 44.5, 
44.6[123589], 44.99, 
45.0[123], 45.6[123], 
45.7[1-69], 45.8[123], 
45.9[0-5], 46.0[1-4], 
46.1[0134], 46.2[0-4], 
46.3[19], 46.4[0-3], 
46.5[012], 46.6[0-4], 
46.7[1-69], 46.8[012], 
46.9[349], 48.4[239], 
48.5[0129], 48.6[1-59], 
50.0, 50.2[2-69], 50.3, 
50.4, 50.6[19], 51.0[34], 
51.2[1-4], 52.22, 
52.5[1239], 52.6, 52.7, 
52.9[59], 54.1[129], 54.99 
ACS Acute Coronary 
Syndrome,Condition 
410*, 411* 
aDIAL Acute Dialysis,Procedure 90935, 90937, 90945, 
90947, 90999, V45.1, 
V56.0, V56.1, 39.95 
AFIB Atrial Fibrillation, Condition 427.3[12] 
AFL Alcoholic Fatty Liver 571.[013] 
AIDS/HIV, Elixhauser AIDS/HIV 04[234].* 
ALD Advanced Liver 
Disease,Condition 
070.22, 070.23, 070.44, 
456.0, 456.1, 456.20, 
456.21, 571.2, 571.3, 
571.5, 571.6, 572.[2348] 
Amyloidosis Amyloidosis, Diagnosis 277.3, 277.3[019] 
AnalFisFist Anal Fissures or Fistula, 
Diagnosis 
565.1 
Angina Angina, Condition 413*, 411.1 
ANMA Anemia,Condition 280*, 281*, 282.01, 
282.2*, 282.3*, 282.4*, 
282.71, 282.8, 282.9, 
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283.[019]*, 284*, 285*, 
648.2*, 776.5* 
ARF Acute Renal Failure, Condition 584.[5-9], 669.3[0124] 
ARRH Arrhythmia,Condition 427*, 785.0, 785.1, 
779.81, 426*, V45.0*, 
V53.3*, 746.86 
Arrhythmias, Elixhauser Cardiac Arrhythmias, Diagnosis 426.[079], 426.[1][023], 
427.[012346789], 785.0, 
996.0[14], V45.0, V53.3 
Ascites Ascites, Condition or Procedure 
(paracentesis) 
4908[0-3], 789.5*, 54.91 
ASP Aspergillosis,Condition 117.3, 484.6, 518.6 
Asthma Asthma, Condition 493.* 
ATN Acute Tubular Necrosis, 
Condition 
584.5 
AUTOHEP Autoimmune Hepatitis 571.42 
AutoNeuropathy Autonomic Neuropathy, 
Diagnosis 
337.9 
AZ_Cancer Cancer,Condition 1[4-9][0-9]*, 20[0-8]*, 
209.[0-3]*, 23[0-3]* 
BilCirrhosis Biliary Cirrhosis 571.6 
BLA, Elixhauser Blood Loss Anemia 280 
BmTx Bone Marrow Transplant, 
Procedure 
3824[012], 996.8[58], 
V42.8[12], 41.0* 
BowelPerf BowelPerforation, Diagnosis 569.83 
BURN Burns,Condition 906.5, 906.6, 906.7, 906.8, 
906.9, 906.9, 940*, 941*, 
942*, 943*, 944*, 945*, 
946*, 947*, 948.1*, 
948.2*, 948.3*, 948.4*, 
948.5*, 948.6*, 948.7*, 
948.8*, 948.9*, 949* 
CABG CABG,Procedure 3351[012346789], 
3352[123], 3353[3-6], 
V45.81, 414.04, 36.1*, 
36.2* 
CAD Coronary Artery 
Disease,Condition 
410.*, 411.*, 412.*, 413.*, 
414.[02-9]*, V45.81, 
V45.82 
Cancer Cancer,Condition 1[4568]_.*, 
17[012456789].*, 
19[0124].*, 
195.[012345678]*, 
20[012345678].*, 238.6* 
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CANDI Candidiasis,Condition 112* 
CardiacArrest Cardiac Arrest, Diagnosis 427.4[12], 427.5 
CardSurg Cardiac Surgery, Procedure 33020, 33120, 33130, 
3314[01], 3323[678], 
33243, 3325[13], 33261, 
3330[05], 3331[05], 
3332[012], 3333[025], 
33404, 3341[4-7], 
3347[68], 33496, 
3340[01356], 3341[0-3], 
3342[02567], 33430, 
3346[03458], 
3347[012579], 3350[0-
6], 3351[0-46-9], 3352[1-
3], 3353[03-6], 3354[25], 
33572, 3360[0268], 
3361[012579], 
3364[157], 3368[148], 
3369[0247], 3386[013], 
3387[057], 3391[0567], 
3366[05], 33670, 33702, 
33710, 3372[02], 
3373[02567], 3375[05], 
3376[2467], 3377[014-
9], 3378[0168], 
3380[023], 3381[34], 
33824, 3384[05], 
3385[123], 3391[89], 
3392[02], 33999, 35.*, 
35.1[0-4], 35.2[0-8], 
35.3[1-59], 35.5[134], 
35.[67][0-3], 35.8[1-4], 
35.9*, 36.03, 36.1[0-79], 
36.2, 36.3[129], 36.9[19], 
37.1[01], 37.3[12356], 
37.49, 39.6[1-46] 
CarotidDis Carotid Disease, Condition 433.1, 38.12 
Cath Cardiac Catheterization, 
Procedure 
9350[138], 9351[014], 
9352[46789], 
9353[01239], 
9354[0235], 9355[56], 
9356[12], 37.2[1-3], 
88.5[2-7] 
CathPCIALL Cath/PCI ALL, Procedure 9350[138], 9351[014], 
9352[46789], 
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9353[01239], 
9354[0235], 9355[56], 
9356[12], 9297[34], 
9298[0124], 9299[56], 
G029[01], 37.2[123], 
88.5[2-7], 00.66, 
36.0[125679] 
CathPCICont Cath/PCI w Contrast,Procedure 93508, 9351[014], 
9352[46789], 
9353[1239], 9354[035], 
9355[56], 9297[34], 
9298[0124], 9299[56], 
G029[01], 37.2[23], 
88.5[2-7], 00.66, 
36.0[125679] 
CathPCInoCont Cath/PCI NO Contrast, 
Procedure 
9350[13], 93530, 93542, 
9356[12], 37.21 
CDVD Cardiovascular 
Disease,Condition 
3353[03456]*, 
3351[0123456789]*, 
3352[012358]*, 
3353[03456]*, 
9298[0124]*, 
9299[5678]*, 
3480[023456]*, 3525*, 
3528*, 3530*, 3535[15]*, 
3537[12]*, 35381, 
354[5789]*, 355[468]*, 
3555[168]*, 3557[01]*, 
356[4567]*, 410.*, 411.*, 
412.*, 413.*, 429.7*, 430.*, 
431.*, 433._1, 435.*, 436.*, 
434.0, 434.01, 434.1, 
434.11, 434.9, 434.91 
CGP, Elixhauser Coagulopathy 286.*, 287.[1345] 
CHEMO Chemotherapy, Procedure 4180F, 9640[01289], 
9641[0-7], 
9650[012589], 
9651[012], 99555, 
C895[345], G0292, 
G035[59], 99.25, 00.10 
CHF Congestive Heart 
Failure,Condition 
398.91, 402.11, 404.01, 
404.11, 404.91, 428*, 
402.01, 402.91, 404.03, 
404.13, 404.93, 
425.[145789]* 
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CHF, Elixhauser Congestive Heart Failure, 
Diagnosis 
398.91, 402.[019]1, 
404.[019][13], 
425.[456789], 428.* 
CHF  CHF, Condition 398.91, 402.11, 404.01, 
404.11, 404.91, 428*, 
402.01, 402.91, 404.13, 
404.93, 425.[145789]* 
Cirrhosis Cirrhosis,Condition 571.2, 571.5 
Cirrhosis_Risk_1 Combination of Cirrhosis Risk 
Factors 
291.[0123589], 303.*, 
305.0*, 571.[013], 
070.[23][0-3], V02.6[12], 
070.[45][14], 070.7[01], 
275.0[1-3], 571.42, 571.6 
CKD Chronic Kidney 
Disease,Condition 
585*, 403*, 404* 
Colitis Colitis, Diagnosis 555.[0129], 556., 556.[0-
6] 
Cons_Condition Constipation, Condition 564.0*, 560.3[029], 
560.89, 560.9*, 564.7*, 
787.99 
Cons_Proc Constipation, Procedure 45915, E035[02], A4458, 
E0740, 96.3[789], 96.09 
COPD COPD, Condition 49[126]*, 493.2* 
COPDAsthma COPD/Asthma,Condition 491.*, 492.*, 493.*, 496.*, 
V17.5*, V81.3* 
CPD, Elixhauser Chronic Pulmonary Disease 416.[89], 
49[0123456789].*, 
50[012345].*, 506.4, 
508.[18] 
CS Cardiogenic Shock,Condition 785.51 
CVA Cerebrovascular 
Disease,Condition 
43[0-8]*, 362.34 
DA, Elixhauser Deficiency Anemia 280.[123456789], 281.* 
DecALD Decompensated Cirrhosis, 
Condition 
456.[012], 571.*, 572.[1-
8], 789.5 
Dementia Dementia w/o Delirium, 
Condition 
290.*, 294.[1]*, 
331.[012]* 
Dermatomyositis Dermatomyositis, Diagnosis 710.3 
Deyo's CHF Congestive Heart Failure, 
Diagnosis 
428* 
Deyo's CPD Chronic Pulmonary Disease, 
Diagnosis 
49[0-24-9]*, 493.[2-8]*, 
50[0-5]*, 506.4* 
Deyo's CVD Cerebrovascular Disease, 
Diagnosis 
43[0-8]* 
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Deyo's Dementia Dementia, Diagnosis 290* 
Deyo's DM w/ chronic 
comp 
Diabetes with chronic 
complication, Diagnosis 
250.[4-6]* 
Deyo's DM w/o chronic 
comp 
Diabetes without chronic 
complication, Diagnosis 
250.[0-37]* 
Deyo's Hemiplegia or 
Paraplegia 
Hemiplegia or Paraplegia, 
Diagnosis 
344.1*, 342* 
Deyo's HIV AIDS/HIV, Diagnosis 04[2-4]* 
Deyo's Malignancy Any Malignancy (except of 
skin), Lymphoma, or Leukemia 
1[4-6][0-9]*, 17[0-24-9]*, 
18[0-9]*, 19[0-5]*, 20[0-
8]* 
Deyo's MI Myocardial Infarction, 
Diagnosis 
410*, 412* 
Deyo's Mild Liver Disease Mild Liver Disease, Diagnosis 571.[24-6]* 
Deyo's Moderate to 
Severe Liver Disease 
Moderate or Severe Liver 
Disease, Diagnosis 
456.[01]*, 456.2[01], 
572.[2-8]* 
Deyo's PUD Peptic Ulcer Disease, Diagnosis 53[1-4]* 
Deyo's PVD Peripheral Vascular Disease 443.9*, 441*, 785.4*, 
V43.4*, 38.48 
Deyo's Renal Renal Disease, Diagnosis 58[2568]*, 583.[0-7]* 
Deyo's Rheumatic Rheumatic Disease, Diagnosis 710.[014]*, 714.[0-2]*, 
714.81, 725* 
Deyo's Tumor Metastatic Solid Tumor, 
Diagnosis 
19[6-9]* 
DiabetesC, Elixhauser Diabetes, Complicated 250.[456789]* 
DiabetesU, Elixhauser Diabetes, uncomplicated 250.[0123]* 
DIAL Dialysis,Procedure 90921, 90925, 90935, 
90937, 90945, 
9096[0126], G8956, 
90947, 90989, 9099[39], 
585.6, V39.27, V39.42, 
V39.43, V45.1, V56.0, 
V56.2, V56.31, V56.32, 
V56.8, 39.9[35], 54.98 
DIAR Diarrhea,Condition 009.2, 009.3, 564.5, 
787.91 
DKA Diabetic Ketoacidosis, 
Condition 
249.1*, 250.1* 
DM Diabetes,Condition 249*, 250*, 357.2*, 
362.0*, 366.41, V45.85, 
V53.91 
DMNeuropathy Diabetic Neuropathy, Diagnosis 357.2 
DMOsm Diabetic w/ Hyperosmolarity, 
Condition 
249.2*, 250.2* 
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DP, Elixhauser Depression 296.[235], 300.4, 309.*, 
311 
Drug Abuse, Elixhauser Drug Abuse 292.*, 304.*, 
305.[23456789], V65.42 
DYS Dyslipidemia,Condition 272.* 
ECMO ECMO, Procedure 3396[01], 37.62 
ETOH Alcohol Use,Condition 291.*, 303.*, 305.0*, 
535.3*, 292.21, 357.5, 
425.5, 571.0, 571.1, 571.2, 
571.3, 760.71, 790.3, 
977.3, 980.[012456789]*, 
E947.3, 
E860.[012356789]*, 
V11.3 
Etoh_Abuse Alcohol Abuse 291.[0123589], 303.*, 
305.0* 
Fatigue Chronic Fatigue, Diagnosis 780.71 
FED, Elixhauser Fluid and Electrolyte Disorder 253.6, 276.* 
Fibromyalgia Fibromyalgia, Diagnosis 729.1 
Gastroparesis Gastroparesis, Diagnosis 536.3 
GI GI Bleeding,Condition 530.82, 53[1-4].[0246]0, 
535.[045]1, 578.* 
GIPerf GI Perforation, Diagnosis 569.83 
GLOM Acute GLOMERULONEPHRITIS, 
Condition 
580.* 
GLOMNephEx Glomerular Nephritis 
(Exclusion), Condition 
580.[049], 580.8[19], 
581.[0123], 582.[01249], 
582.8[19], 583.[0124], 
581.89 
HBC Cirrhosis Risk Cohort without 
NAFLD 
070.[23][0-3], V02.6[12], 
070.[45][14], 070.7[01] 
HCC Hepatocellular Carcinoma, 
Condition 
155 
HE Hepatic Encephalopathy, 
Condition 
572.2*, 070.00, 070.2*, 
070.40, 070.41, 070.44, 
070.49, 070.60 
Headache Migraine & Headache, Diagnosis 784.0, 339.0[0123459], 
339.[12][0-2], 339.3, 
339.4[1-4], 
339.8[123459], 346.[0-
5][0-3], 346.[0-2], 346.[7-
9][0-3], 346.[89] 
HEMOCH Cirrhosis Risk Cohort without 
NAFLD 
275.0[1-3] 
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Hemorrhoid Hemorrhoids, Diagnosis 455.[0-9] 
HEP Hepatitis,Condition 070.*, 072.71, 091.62, 
130.5, 571.1, 571.4*, 
573.1, 573.2, 573.3, 
V02.6*, V05.3 
Hep_B_C Hepatitis B and C, acute and 
chronic 
070.[23][0-3], V02.6[12], 
070.[45][14], 070.7[01] 
HF, Elixhauser Hypertension, uncomplicated, 
Diagnosis 
401.* 
HFC, Elixhauser Hypertension, complicated, 
Diagnosis 
40[2345].* 
HIV HIV,Condition 04[234]*, 079.53, 795.71, 
V08* 
HOSP Hospice,Condition 99377, 99378 
HOTN Hypotension,Condition 458.* 
HRS Hepatorenal Syndrome 572.4 
HrtTx Heart Transplant,Procedure V42.1, 37.5[1-5] 
HSVNeuralgia Post Herpetic Neuralgia, 
Diagnosis 
53.19 
HTD, Elixhauser Hypothyroidism 240.9, 24[34].*, 246.[18] 
HTN Hypertension,Condition 401*, 402*, 403*, 404*, 
405*, 437.2* 
HTNEmer Hypertension Emergency, 
Condition 
40[1-5].0, 40[2-5].01, 
404.0[23], 405.0[19] 
Hydronephrosis Hydronephrosis 591* 
HYPC Hypercalcemia,Condition 275.42 
Hyperkalemia Hyperkalemia, Diagnosis 276.7 
Hyperparathyroidism Hyperparathyroidism, 
Diagnosis 
252.0* 
IABP Intra-Aortic Balloon Pump, 
Procedure 
3396[78], 3397[0134], 
37.61 
IBS Irritable Bowel Syndrome, 
Diagnosis 
564.1 
iDIAL Dialysis Inpatient v45.1, v56.0, v56.1, 39.95 
Impaction Impaction, Diagnosis 560.32 
IVD Intravascular Volume 
Disease,Condition 
276.5, 276.5[01] 
JAUD Jaundice,Condition 282.00, 774.[0123567]*, 
782.4, , ,  
LD, Elixhauser Liver Disease 070.[23][23], 070.[45]4, 
070.[69], 456.[012], 
57[01].*, 572.[2345678], 
573.[3489], V42.7 
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LIV Liver,Condition 070.22, 070.23, 070.33, 
070.44, 070.54, 456.0, 
456.1, 456.20, 456.21, 
571.0, 571.2, 571.3, 
571.40, 571.41, 571.42, 
571.49, 571.5, 571.6, 
571.8, 571.9, 572.3, 572.8, 
573.5, V42.7 
LKM Leukemia,Condition 202.4*, 203.1*, 20[4-8].*, 
V10.6* 
LM, Elixhauser Lymphoma 20[012].*, 203.0, 238.6 
LngTx Lung Transplant,Procedure V42.6, 33.5* 
LUP Systemic Lupus 
Erythematosus,Condition 
286.5, 323.81, 517.8, 
58[023].81, 695.4, 710.0 
LvrTx Liver Transplant,Procedure 4713[56], V42.7, 50.5[19] 
MC, Elixhauser Metastatic Cancer 19[6789].* 
MECHVENT Mechanical Ventilation, 
Procedure 
93.92, 96.0[45], 96.7[012] 
Megacolon Megacolon, Diagnosis 564.7 
MEN Multiple Endocrine Neoplasia, 
Diagnosis 
258.0* 
MetabolicSyndrome Metabolic Syndrome using sub-
conditions 
usp_Build_Metabolic_Syn
drome 
MI Myocardial Infarction,Condition 410* 
MM Multiple Myeloma,Condition 203.0* 
MultScler Multiple Sclerosis, Diagnosis 340 
MVR Mitral Regurgitation,Procedure 396.3, 424.0, 746.6 
Myopathies Myopathies, Diagnosis 359.8, 359.89, 425.4 
NAFLD Non-alcoholic fatty liver disease 571.8, 571.9 
NAS Nausea,Condition 787.0, 787.01, 787.02 
NephGLOM Nephritis Glomerular Not 
Specified,Condition 
580.81, 58[03].9, 
583.8[19] 
Nephrtmy Nephrectomy, Procedure 5022[05], 5023[046], 
50240, 50300, 50320, 
50340, 50370, 5054[35-
8], 55.4, 55.5[1-4] 
NFXss Infection (sepsis sup),Condition 00[1-589]*, 01[0-8]*, 
02[0-7]*, 03*, 04[01]*, 
09[0-8]*, 10[0-4]*, 11[0-
24-8]*, 32[0245]*, 
42[01]*, 451*, 46[1-5]*, 
48[1256]*, 491.21, 494*, 
51[03]*, 54[012]*, 
562.[01][13], 56[67]*, 
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569.5*, 569.83, 572.[01]*, 
575.0*, 59[07]*, 599.0*, 
601*, 61[456]*, 
68[1236]*, 711.0*, 730*, 
790.7*, 996.6*, 998.5*, 
999.3* 
NSTEMI NSTEMI, Condition 410.7* 
OA Osteoarthritis, Diagnosis 715.0[049], 715.1[0-8], 
715.2[0-8], 715.3[0-8], 
715.8[09], 715.9[0-8], 
V13.4 
Obesity Obesity 278.0, 278.0[01], 649.1, 
278.03 
Obesity, Elixhauser Obesity 278 
OFss Organ Failure (sepsis 
sup),Condition 
785.5*, 458*, 348.3*, 
293*, 348.1*, 286.[69]*, 
287.[45]*, 570*, 573.4*, 
584*, 96.7* 
OLG Oliguria,Condition 788.5 
OND, Elixhauser Other Neurological Disorders 331.9, 332.[01], 333.[45], 
333.92, 33[45].*, 336.2, 
34[015].*, 348.[13], 
78[04].3 
OrganTrans Organ Transplant,Procedure 50320, 50360, 50365, 
50370, 50380, 33935, 
33940, 33945, 32851, 
32852, 32853, 32854, 
47135, 47136, 38240, 
38241, 48554, 48556, 
V42.0*, V42.1*, V42.6*, 
V42.7*, V42.81*, V42.83* 
PALL Pallative Care,Condition V66.7* 
PANTx Pancreas Transplant,Procedure 48554, 99686, V42.83, 
52.8[0-3] 
Paracentesis Paracentesis, procedure 4908[0-3], 54.91 
Paralysis, Elixhauser Paralysis, Diagnosis 334.1, 34[23].*, 
344.[01234569] 
Parkinsons Parkinson’s Disease, Diagnosis 332 
PCD, Elixhauser Pulmonary Circulation 
Disorders, Diagnosis 
415.[01], 416.*, 417.[089] 
PCI PCI, Procedure 9297[34], 9298[0124], 
9299[56], G029[01], 
V45.82, 00.66, 
36.0[125679], 92.27 
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PCR Pancreatitis,Condition 577.[01]* 
PFT Spirometry,Procedure 94010, 94060, 94375, 
94150, 94200, 93720, 
93721, 93722, 94726, 
94727, 94728, 94729, 
94240, 94260, 94350, 
94360, 94370, 94720, 
94725 
Plegia_CC Hemiplegia or Paraplegia 
(Charlson Comorbidity 
Definition) 
334.1*, 342.*, 343.*, 
344.[01234569]* 
Porphyria Porphyria, Diagnosis 277.1 
PREG Pregnancy,Condition V22.*, 6[3-7]* 
ProctFugax Proctalgia Fugax, Diagnosis 564.6 
PUD_CC Peptic Ulcer Disease (Charlson 
Comorbidity Definition) 
531.*, 532.*, 533.*, 534.* 
PVD Peripheral Vascular 
Disease,Condition 
440*, 441*, 442*, 444.2*, 
V43.4 
PVD, Elixhauser Peripheral Vascular Disorders, 
Diagnosis 
093.0, 437.3, 44[01].*, 
443.[123456789], 447.1, 
557.[19], V43.4 
PY, Elixhauser Psychoses 293.8, 295.*, 296.[0145]4, 
29[78].* 
RA Rheumatoid Arthritis, Diagnosis 714 
RA, Elixhauser Rheumatoid Arthritis, Collagen 
vascular diseases 
446.*, 701.0, 
710.[0123489], 711.2, 
714.*, 719.3, 72[05].*, 
728.5, 728.89, 729.30 
RectalProlapse Rectal prolapse, Diagnosis 569.1 
Rectocele Rectocele, Diagnosis 618.04 
RenalTrans Renal Transplant,Procedure 50365, 50360, 996.81, 
V42.0, 55.69*, 00.9[123] 
RF, Elixhauser Renal Failure 403.[019]1, 404.0[23], 
404.[19][23], 58[56].*, 
588.0, V42.0, V45.1, V56.* 
RHBD Rhabdomyolysis,Condition 728.88 
Rheum_CC Rheumatic Disease (Charlson 
Comorbidity Definition) 
446.5*, 710.[01234]*, 
714.[0128]*, 725.* 
PUD, Elixhauser Peptic Ulcer Disease, excluding 
bleeding 
53[1234].[79]* 
SBP Spontaneous Bacterial 
Peritonitis - extra general, 
Condition 
567.23, 567.[0289]0, 
567.2[19], 567.89, 
567.[0289] 
Scleroderma Scleroderma, Diagnosis 701 
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Sickle Sickle Cell Disease, Condition 282.4[1-4]*, 282.6* 
SIRS SIRS,Condition 995.9* 
SpinalCord Spinal Cord Injury / Tumors, 
Diagnosis 
349.39, 806.[0-3][0-9], 
806.[4589], 
806.[67][0129], 907.2, 
952.[01][0-9], 
952.[23489] 
SPS Sepsis,Condition 785.52, 995.92 
SSTS Schistosomiasis,Condition 120* 
ST, Elixhauser Solid Tumor without Metastasis 1[456][0123456789].*, 
17[012].*, 17[456789].*, 
18[0123456789].*, 
19[012345].* 
StableAngina Stable Angina, Diagnosis 413.[019] 
STEMI STEMI, Condition 410.[012345689]* 
STROKE Stroke, Condition 43[01]*, 434.[019], 
434.[019]1, 436*, 997.02 
TB Tuburculosis,Condition 01[0-8].*, 137.*, V12.01 
TIA TIA, Condition 435.[89] 
TIPS Transjugular Intrahepatic 
Portosystemic Shunt 
3718[23], 39.1 
TOBC Tobacco Use,Condition 305.1*, V15.82 
TRAU Injury-Trauma,Condition 349.39, 716.1*, 717.*, 
718.0*, 718.3*, 806.*, 
80[0134].[12346789]*, 
83_.*, 85[01234].*, 86_.*, 
90[012347].*, 905.6, 
906.4, 908.[01234]*, 
92[56789].*, 952.*, 
V15.52 
UNAN Unstable Angina, Condition 411.1*, 413* 
UrinaryObst Urinary Obstruction, Condition 592.1, 593.4, 594.[29], 
596.0, 598.[1289], 599.6, 
599.69, 599.82, 
600.[0129]1, 753.[26], 
753.2[129], 788.2, 
788.29, V44.6, V55.6 
VAD Ventricular Assist Device, 
Procedure 
3397[5-9], 33980, 37.41, 
37.5[2-5], 37.6[0356] 
Valvular, Elixhauser Valvular Disease, Diagnosis 093.2, 39[4567].*, 424.*, 
746.[3456], V42.2, V43.3 
Varices Varices, Condition or Procedure 4324[34], 4320[45], 
456.[012][01], 456.[012], 
42.33 
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VascProc All Vascular Procedures 3332[012], 3333[025], 
3386[013], 3387[057], 
3388[01], 34001, 34051, 
34101, 34111, 34151, 
3420[13], 34401, 34421, 
34451, 34471, 34490, 
3480[02-5], 3482[56], 
3483[0-2], 34900, 
3500[12], 3501[13], 
3502[12], 35045, 
3508[12], 3509[12], 
3510[23], 3511[12], 
3512[12], 3513[12], 
3514[12], 3515[12], 
3516[12], 3521[16], 
3522[16], 3523[16], 
3524[16], 3525[16], 
3526[16], 3527[16], 
3528[16], 3530[1-6], 
35311, 35321, 35331, 
35341, 3535[15], 
3536[13], 3537[12], 
35381, 35390, 
3545[024689], 3547[0-
5], 3548[0-5], 3549[0-5], 
3550[16-9], 3551[1568], 
3552[16], 3553[135-9], 
3554[01689], 3555[168], 
3556[0356], 3557[01], 
3558[2357], 3560[16], 
3561[26], 3562[136], 
3563[12678], 
3564[12567], 
3565[0146], 3566[1356], 
35671, 3569[45], 35700, 
35820, 35840, 35860, 
3587[0569], 35881, 
3590[1357], 37799, 
38.0[0-9], 38.1[0-68], 
38.2[1-69], 38.3[0-9], 
38.4[0-9], 38.5[0-3579], 
38.6[0-9], 38.7, 38.8[0-9], 
38.9[1-5789], 39.0, 39.1, 
39.2[1-9], 39.3[012], 
39.4[1239], 39.5[1-9], 
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39.7[1-9], 39.8[1-9], 
39.9[0-46-9] 
VascSurg Major Vascular Surgery, 
Procedure 
3332[012], 3333[025], 
3386[013], 3387[057], 
3388[01], 34151, 34201, 
3480[02-5], 3482[56], 
3483[0-2], 3508[12], 
3509[12], 3510[23], 
3511[12], 3512[12], 
3521[16], 35221, 
3524[16], 35251, 
3527[16], 35281, 35331, 
35341, 3536[13], 
3545[02], 3547[12], 
3548[01], 3549[01], 
3553[15-9], 
3554[01689], 35551, 
35560, 35582, 
3563[12678], 3564[167], 
35651, 35820, 35840, 
35870, 3590[57], 
38.0[456], 38.1[4568], 
38.2[123], 
38.[3468][456], 38.9[1-
5789], 39.0, 39.2[13-6], 
39.5[45], 39.7[138] 
VHD Valvular Heart Disease, 
Condition 
424.[0-3] 
VLP Valvulopathy,Condition 39[4567].*, 424.*, 745.*, 
746.[0-7]*, 746.8[134], 
747.3, 785.[23]*, V42.2, 
V43.3 
VMT Vomiting,Condition 078.82, 307.54, 536.2, 
564.3, 569.87, 578.0, 
643*, 787.0, 787.00, 
787.01 
WL, Elixhauser Weight Loss 26[0123].*, 783.2, 799.4 
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Appendix Table A.3: Variables used in the multiple imputation of laboratory values. 
Multiple imputation was carried out by the mi package for the R statistical programming 
software. Imputation was carried out for 30 iterations using 4 separate chains. Imputations 
were carried out to convergence. Values from the four separate chains were averaged 
together for the final imputed values used in the dataset. 
Domain TimePeriod Variable 
Condition Home Atrial Fibrillation 
Condition Home Anemia 
Condition Home Ascites 
Condition Home AZ_Cancer 
Condition Home Biliary Cirrhosis 
Condition Home Coronary Artery Disease 
Condition Home Congestive Heart Failure 
Condition Home Chronic Kidney Disease 
Condition Home Dialysis 
Condition Home Diabetes Mellitus 
Condition Home Etoh Abuse 
Condition Home GI Bleed 
Condition Home Hepatocellular Carcinoma 
Condition Home Hepatic Encephalopathy 
Condition Home Viral Hepatitis 
Condition Home HIV 
Condition Home HTN 
Condition Home Nonalcoholic Fatty Liver Disease 
Condition Home Spontaneous Bacterial Peritonitis 
Condition Home Transjugular Intrahepatic Portosystemic Shunt 
Condition Home Varices 
Medication Home Rifaxmin 
Medication Home Lactulose 
MedClass Home Quinolones 
MedClass Home Anticoagulants 
MedClass Home Platelet Aggregation Inhibitors 
MedClass Home Opioids 
MedClass Home Sedative Hypnotics 
MedClass Home Anticonvulsants 
MedClass Home Antidepressants 
MedClass Home Digitalis glycosides 
MedClass Home Beta Blockers 
MedClass Home Alpha Blockers 
MedClass Home Calcium Channel Blockers 
MedClass Home Antiarrhythmics 
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MedClass Home Antilipemic Agents 
MedClass Home Thiazides 
MedClass Home Loop Diuretics 
MedClass Home Potassium Sparing Combination Diuretics 
MedClass Home ACE Inhibitors 
MedClass Home Angiotensin II Inhibitors 
Procedure Home Paracentesis 
Medication Inpt Trimethoprim 
Medication Inpt Vancomycin 
Medication Inpt Lactulose 
Medication Inpt Octreotide 
Medication Inpt Midodrine 
Medication Inpt Human Albumin 
Medication Inpt Norepinephrine 
Medication Inpt Vasopressin 
Medication Inpt Rifaximin 
Medication Inpt Septra 
Medication Inpt Dobutamine 
Medication Inpt Phenylephrine 
Medication Inpt Octreotide and Midodrine 
Medication Inpt Octreotide and Norepinephrine 
Medication Inpt Octreotide and Vasopressin 
Medication Inpt Any IV Vasopressor 
MedClass Inpt NSAIDs 
MedClass Inpt Aminoglycosides 
MedClass Inpt Beta Blockers 
MedClass Inpt ACE Inhibitors 
MedClass Inpt Angiotensin Receptor Blockers 
MedClass Inpt Glucocorticoids 
MedClass Inpt Potassium Sparing Diuretics 
MedClass Inpt Statins 
MedClass Inpt Insulin 
MedClass Inpt Extended Spectrum Penicillins 
MedClass Inpt 3rd Generation Cephalosporins 
MedClass Inpt Anticoagulants 
MedClass Inpt Platelet Aggregation Inhibitors 
Condition Inpt Dialysis 
Condition Inpt Chronic Kidney Disease 
Condition Inpt Diabetes Mellitus 
Condition Inpt Coronary Artery Disease 
Condition Inpt Hypertension 
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Condition Inpt Hospice 
Condition Inpt Congestive Heart Failure 
Condition Inpt Cancer 
Condition Inpt Sepsis 
Condition Inpt Diarrhea 
Condition Inpt SIRS 
Condition Inpt Hepatitis 
Condition Inpt Vomiting 
Condition Inpt Alcohol Use 
Condition Inpt Anemia 
Condition Inpt GI Bleed 
Condition Inpt Cardiovascular Disease 
Condition Inpt COPDAsthma 
Condition Inpt Glomerulonephritis 
Condition Inpt Acute Tubular Necrosis 
Condition Inpt Decompensated Liver Disease 
Condition Inpt Urinary Obstruction 
Condition Inpt Glomerularnephritis NOS 
Condition Inpt Atrial Fibrillation 
Condition Inpt Acute Renal Failure 
Condition Inpt Nephrectomy 
Condition Inpt Palliative Care 
Condition Inpt Hydronephrosis 
Condition Inpt Etoh Abuse 
Condition Inpt Ascites 
Condition Inpt Hepatorenal Syndrome 
Condition Inpt Transjugular Intrahepatic Portosystemic Shunt 
Condition Inpt Varices 
Condition Inpt Hepatic Encephalopathy 
Condition Inpt Spontaneous Bacterial Peritonitis 
Condition Inpt Hepatocellular Carcinoma 
Condition Inpt Nonalcoholic Fatty Liver Disease 
Condition Inpt Elixhauser: CHF 
Condition Inpt Elixhauser: Arrhythmias 
Condition Inpt Elixhauser: Valvular Heart Disease 
Condition Inpt Elixhauser: Pulmonary Circulation d/o 
Condition Inpt Elixhauser: Peripheral Vascular Dz 
Condition Inpt Elixhauser: HTN uncomplicated 
Condition Inpt Elixhauser: HTN complicated 
Condition Inpt Elixhauser: Paralysis 
Condition Inpt Elixhauser: Other Neurological d/o 
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Condition Inpt Elixhauser: Pulmonary Disease 
Condition Inpt Elixhauser: Diabetes uncomplicated 
Condition Inpt Elixhauser: Diabetes Complicated 
Condition Inpt Elixhauser: Hypothyroidism 
Condition Inpt Elixhauser: Renal Failure 
Condition Inpt Elixhauser: Liver Disease 
Condition Inpt Elixhauser: Peptic Ulcer Disease 
Condition Inpt Elixhauser: AIDS/HIV 
Condition Inpt Elixhauser: Lymphoma 
Condition Inpt Elixhauser: Metastatic Cancer 
Condition Inpt Elixhauser: Solid Tumor without mets 
Condition Inpt Elixhauser: Collagen vascular diseases 
Condition Inpt Elixhauser: Coagulopathy 
Condition Inpt Elixhauser: Weight Loss 
Condition Inpt Elixhauser: Fluid and Electrolyte Disorder 
Condition Inpt Elixhauser: Blood Loss Anemia 
Condition Inpt Elixhauser: Deficiency Anemia 
Condition Inpt Elixhauser: Alcohol Abuse 
Condition Inpt Elixhauser: Drug Abuse 
Condition Inpt Elixhauser: Psychoses 
Condition Inpt Elixhauser: Depression 
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Appendix Table A.4: List of semantic types used to filter variables for semantic  
Semantic Type Identifier Description 
T020  acquired abnormality 
T190  anatomical abnormality 
T053  behavior 
T031  body substance 
T201  clinical attribute 
T060  diagnostic procedure 
T047  disease or syndrome 
T033  Finding 
T131  Hazardous or Poisonous Substance 
T058  Health Care Activity 
T129  Immunologic Factor 
T037  Injury or Poisoning 
T048  mental or behavioral dysfunction 
T191  neoplastic process 
T046  pathologic function 
T184  sign or symptom 
T061  therapeutic or preventive procedure 
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Appendix Table A.5: List of a-priori CUIs 
CUI STR Assigned Variable 
Category 
C0035222 Acquired respiratory distress syndrome Acquired respiratory 
distress syndrome 
C0003460 ANURIA Anuria 
C0000731 abdomen distended Ascites 
C0003962 abdominal dropsy Ascites 
C0426682 fluid wave Ascites 
C0741244 Tense ascites Ascites 
C0333501 Acute necrosis Acute Tubular Necrosis 
C0344391 granular cast Casts 
C0011175 body water dehydration Dehydration 
C0013604 dropsies Edema 
C0017658 Glomerulonephritis NOS Glomerulonephritis 
C0017662 GLOMERULONEPHRITIS, 
MEMBRANOPROLIFERATIVE 
Glomerulonephritis 
C0156221 acute glomerulonephritis Glomerulonephritis 
C0017665 glomerulonephritis membranous Glomerulopnephritis 
C0018926 Hematemeses Hematemesis 
C0019151 coma hepaticum Hepatic Encephalopathy 
C0019212 Hepatorenal syndrome Hepatorenal Syndrome 
C1708271 HRS Hepatorenal Syndrome 
C0020295 Hydronephrosis Hydronephrosis 
C0020649 hypotension Hypotension 
C0027707 Interstitial Nephritis Nephritis 
C0041349 Tubulo-interstitial nephritis Nephritis 
C0149937 acute interstitial nephritis Nephritis 
C0347129 AIN Nephritis 
C1514118 nephrotoxic Nephrotoxic 
C0003211 Agents, Nonsteroidal Antiinflammatory NSAIDs 
C0011991 bowel loose movements Nausea/Vomiting/Diarrhea 
(NVD) 
C0027497 nausea Nausea/Vomiting/Diarrhea 
(NVD) 
C0027498 N&V - Nausea and vomiting Nausea/Vomiting/Diarrhea 
(NVD) 
C0042963 Emesis Nausea/Vomiting/Diarrhea 
(NVD) 
C0034115 paracentesis Paracentesis 
C0031154 Peritonitis Peritonitis 
C0014772 blood cell count red RBCs 
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C0014772 Red Cell Count RBCs 
C0036690 SEPSIS Sepsis 
C0243026 SEPSIS Sepsis 
C0036974 Shock Shock 
C0036982 Haemorrhagic shock Shock 
C0036983 SHOCK SEPTIC Shock 
C0242966 SIRS Systemic Inflammatory 
Response Syndrome (SIRS) 
C0552639 tubular cell Tubular Cells 
C0553257 Epithelial cell of renal tubule Tubular Cells 
C1261248 urinary sediment Urine Sediment 
XXXXXXX XXXXXXX Prerenal 
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Appendix Table A.6: Evaluation of model performance after exclude “Maybe HRS” cases 
from model building and evaluation using the a priori CUIs. 
 
AUC (95% 
CI) 
Slope 
(95% CI) 
Intercept 
(95% CI) 
Brier Score 
(95% CI) 
Logistic 
Regression 
0.94 (0.93, 
0.94) 
0.36 (0.31, 
0.40) 
-0.24 (-0.32, -
0.16) 
0.08 (0.08, 
0.09) 
Gradient 
Boosting 
0.94 (0.93, 
0.94) 
1.70 (1.64, 
1.75) 
0.16 (0.08, 
0.24) 
0.10 (0.09, 
0.10) 
Naïve Bayes 0.77 (0.74, 
0.79) 
0.20 (0.19, 
0.22) 
-3.84 (-4.28, -
3.40) 
0.44 (0.40, 
0.47) 
Random 
Forest 
0.94 (0.94, 
0.94) 
2.54 (2.44, 
2.65) 
0.45 (0.36, 
0.54) 
0.10 (0.10, 
0.11) 
Support 
Vector 
Machine 
0.94 (0.93, 
0.94) 
0.86 (0.82, 
0.89) 
-0.06 (-0.14, 
0.02) 
0.09 (0.09, 
0.10) 
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Appendix Table A.7. Discrimination and calibration performance of the five models to 
phenotype Hepatorenal Syndrome using the SAFE concept unique identifiers.  
(Note: Slope and Intercept refer to the parameters of the best-fit line through the observed-to-
predicted probability plot; AUC: Area Under the Curve) 
 
AUC (95% 
CI) 
Slope (95% 
CI) 
Intercept 
(95% CI) 
Brier Score 
(95% CI) 
Logistic 
Regression 
0.93 (0.92, 
0.93) 
0.47 (0.43, 
0.50) 
-0.16 (-0.22, -
0.11) 
0.11 (0.11, 
0.11) 
Gradient 
Boosting 
0.91 (0.91, 
0.92) 
1.60 (1.54, 
1.65) 
0.09 (0.04, 
0.14) 
0.12 (0.12, 
0.13) 
Naïve Bayes 0.70 (0.68, 
0.73) 
0.14 (0.12, 
0.15) 
-2.60 (-2.91, -
2.29) 
0.42 (0.40, 
0.45) 
Random 
Forest 
0.91 (0.91, 
0.92) 
1.97 (1.92, 
2.02) 
0.32 (0.27, 
0.37) 
0.13 (0.13, 
0.13) 
Support 
Vector 
Machine 
0.91 (0.90, 
0.91) 
0.85 (0.82, 
0.87) 
-0.01 (-0.06, 
0.04) 
0.12 (0.12, 
0.13) 
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Appendix A.8: CUIs selected based on the Automated Feature Extraction for Phenotyping 
(AFEP) and the Surrogate-Assisted Feature Extraction (SAFE) method. 
Candidate CUIs for consideration in the AFEP algorithm 93 were extracted from Medscape and 
Wikipedia articles on HRS.  The SAFE algorithm 92 also considered CUIs extracted from the 
HRS entries in Merck Manuals and Medline Plus Medical Encyclopedia. Mayo Clinic Disease 
and Conditions did not include relevant content on HRS to allow inclusion in the SAFE 
approach.  We limit candidate CUIs lists for both methods based on semantic type and grouped 
drug concepts by generic names and drug classes. Brand name concept to generic concept 
mapping was performed using the “has_tradename” and “tradename_of” relationships in the 
UMLS hierarchy, similar to the AFEP paper. Drug class identification was performed using the 
RxNorm hierarchy and the RxNorm WebAPI.303 The remaining candidates were filtered for 
rarity and commonality as recommended. A list of filtered candidate CUIs based on the public 
knowledge sources is available in the Online Appendix.  We adjusted the SAFE silver standard 
thresholds to ensure reasonable sample sizes in the extreme subsets (LICD=0, LNLP=0, UICD=1, 
and UNLP=3). We implemented 50 iterations of the elastic net models for each of the three silver 
standards in the SAFE approach, selecting CUIs included in 50% of the models overall. The final 
list of CUIs selected by AFEP and SAFE are listed in Appendix Table A.8. 
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Appendix Table A.8: List of Concept Unique Identifiers (CUI) used in the automated 
feature extraction for phenotyping (AFEP) and surrogate-assisted feature extraction 
(SAFE) methods.  
The sources are: Wikipedia, Medscape, Merck Manual, MedlinePlus, and MayoClinic. 
 
Included in public knowledge source AFEP SAFE 
CUI Wiki. Med. Merck Medline Mayo Candidate Selected Candidate Selected 
C0000731       X           
C0000970   X       X       
C0001047 X X       X       
C0001128   X       X X     
C0001306 X X   X   X   X   
C0001443   X       X       
C0001648   X       X       
C0001924 X X X X   X X X   
C0002006 X         X       
C0002170   X       X       
C0002210   X       X       
C0002556   X       X       
C0002772   X       X       
C0002792   X       X       
C0003009   X       X       
C0003018 X X       X       
C0003211       X           
C0003232 X X   X   X   X   
C0003402   X       X       
C0003448 X         X       
C0003779   X       X       
C0003962 X X X X   X X X   
C0004610   X       X       
C0004623 X X       X       
C0005771   X       X       
C0005779   X       X X     
C0006318   X       X       
C0007430   X       X       
C0007554   X       X       
C0007584   X       X       
C0007955   X       X       
C0008370   X       X       
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Included in public knowledge source AFEP SAFE 
C0008679   X   X   X       
C0008809   X       X       
C0009319   X       X       
C0009421       X           
C0009429     X             
C0009450 X X   X   X   X   
C0009555   X       X       
C0009566 X X   X   X   X   
C0009676       X           
C0009905       X           
C0009924 X X       X       
C0010403   X       X       
C0010404   X       X       
C0010592 X         X       
C0010957 X   X X   X   X   
C0011276   X       X       
C0011710   X       X       
C0011744   X       X       
C0011923   X       X       
C0011946 X X   X   X X X   
C0011947   X       X       
C0012169   X       X       
C0012237   X       X       
C0012299   X       X       
C0012359 X         X       
C0012582   X       X       
C0012772   X       X       
C0012798 X X   X   X X X   
C0012854   X       X       
C0013030   X       X       
C0013103   X       X       
C0013221 X         X       
C0013378   X       X       
C0013516   X       X       
C0013604   X       X X     
C0013819       X           
C0013862       X           
C0013983   X       X       
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Included in public knowledge source AFEP SAFE 
C0014245 X         X       
C0014264 X         X       
C0014442   X       X       
C0014745   X       X       
C0014772   X       X X     
C0014867 X X       X       
C0015672   X       X       
C0015950   X       X       
C0016059 X         X       
C0016107 X X X     X   X   
C0017181 X X   X   X   X   
C0017654 X X X     X   X   
C0017658   X       X       
C0017662   X       X       
C0017665   X       X       
C0017675   X       X       
C0017817   X       X       
C0018418   X   X   X       
C0018801       X           
C0018935   X       X       
C0018941   X       X       
C0018965 X X       X       
C0019004 X X       X       
C0019014   X       X       
C0019080 X X   X   X   X   
C0019151 X     X   X X     
C0019158 X X X X   X X X   
C0019163 X X       X       
C0019187 X X   X   X   X   
C0019214   X       X       
C0019270   X       X       
C0019311   X       X       
C0019868   X       X       
C0019932 X X       X       
C0020295   X       X       
C0020488   X       X       
C0020538 X X       X       
C0020541 X X       X       
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Included in public knowledge source AFEP SAFE 
C0020625   X       X X     
C0020649 X X   X   X X X   
C0020651       X           
C0020683   X       X       
C0020740       X           
C0021081 X X       X       
C0021368 X         X       
C0021440 X         X       
C0021936   X       X       
C0021968   X       X       
C0022116 X X       X       
C0022346 X X   X   X X X   
C0022658 X X   X   X   X   
C0022660 X X       X X     
C0022671 X         X       
C0022672   X       X       
C0023175 X         X       
C0023518   X       X       
C0023545   X       X       
C0023890 X X X X   X   X   
C0023891 X         X X     
C0023895 X X   X   X X X   
C0023899   X       X       
C0023901   X       X       
C0023911 X X X     X   X   
C0024337   X       X       
C0025424   X       X       
C0026018 X         X       
C0026078 X X X     X X X X 
C0026160 X X       X       
C0026846   X       X       
C0027310   X       X       
C0027479 X         X       
C0027481 X         X       
C0027497       X           
C0027769   X       X       
C0028128 X X       X       
C0028158       X           
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Included in public knowledge source AFEP SAFE 
C0028259 X         X       
C0028351   X       X       
C0028365   X       X       
C0028778   X       X       
C0028833 X X X     X X X   
C0028961 X X X     X   X   
C0029276 X X       X       
C0029944   X       X       
C0030125 X         X       
C0030899 X X       X       
C0030946   X       X       
C0031001   X       X       
C0031154 X X       X       
C0031448   X       X       
C0032017 X X       X       
C0032042   X       X       
C0032181   X       X       
C0033085   X       X       
C0033095 X X       X       
C0033554 X         X       
C0033567 X         X       
C0033684 X         X X     
C0033687 X X       X       
C0033707   X   X   X       
C0034783   X       X       
C0034933       X           
C0035078 X X X X   X X X   
C0035139 X X       X       
C0036140   X       X       
C0036193   X       X       
C0036974 X X       X       
C0037473 X X       X       
C0037494   X       X       
C0037659 X X       X       
C0038257 X         X       
C0038689   X       X       
C0038999       X           
C0039052   X       X       
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Included in public knowledge source AFEP SAFE 
C0039082 X X X X   X X X X 
C0039796   X       X       
C0040057 X         X       
C0040061 X         X       
C0040125   X       X       
C0040549 X         X       
C0040732 X X X     X X X   
C0040808 X X       X       
C0040958 X         X       
C0041041   X       X       
C0041044   X       X       
C0041834   X       X       
C0041942   X       X       
C0042029   X       X       
C0042345 X X       X X     
C0042373   X       X       
C0042397 X X X     X   X   
C0042402   X       X       
C0042769 X         X       
C0042963       X           
C0043047   X   X   X       
C0043094       X           
C0066480   X       X       
C0066563 X         X       
C0072471   X       X       
C0078077   X       X       
C0079284   X       X       
C0079595 X         X       
C0080059   X       X       
C0080274   X       X       
C0082420   X   X   X       
C0085128   X       X       
C0085149 X         X       
C0085174 X X       X       
C0085584 X X   X   X X X   
C0085590 X X       X       
C0085605 X X   X   X X X   
C0085649   X       X       
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Included in public knowledge source AFEP SAFE 
C0086761   X       X       
C0087111 X X X X   X   X   
C0105421 X X   X   X   X   
C0125644   X       X       
C0127400 X         X       
C0145185 X X X     X   X   
C0149651   X       X       
C0150041   X       X       
C0150077   X       X       
C0151578   X       X       
C0152451   X       X       
C0155210   X       X       
C0155789 X         X       
C0156221   X       X       
C0156246   X       X       
C0156247   X       X       
C0161959   X       X       
C0162529   X       X       
C0162557 X         X       
C0175661   X       X       
C0179802   X       X       
C0181074   X       X       
C0181805 X         X       
C0184486 X         X       
C0194133   X       X       
C0198497       X           
C0199176 X X       X       
C0200396   X   X   X       
C0200679 X         X       
C0200949   X       X       
C0201803 X X       X       
C0201838 X X       X X     
C0201849 X         X       
C0201879       X           
C0201888   X       X       
C0201913   X       X X     
C0201975 X X       X       
C0201976 X X       X       
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Included in public knowledge source AFEP SAFE 
C0201989   X       X       
C0202145   X       X       
C0202195   X       X       
C0217843   X       X       
C0221135   X       X       
C0221198       X           
C0221226   X       X       
C0221239   X       X       
C0221423 X         X       
C0221752 X         X       
C0231176   X   X   X       
C0231187   X       X       
C0231218 X X       X       
C0232342 X         X       
C0232766   X       X       
C0232831       X           
C0233494 X         X       
C0235395 X X       X       
C0235618   X       X       
C0239571   X       X       
C0240182   X       X       
C0240962   X       X X     
C0242528   X X X   X   X   
C0242656 X         X       
C0242889   X       X       
C0242903       X           
C0242937   X       X       
C0243026   X       X       
C0243071 X X       X       
C0262926 X X       X       
C0266258   X       X       
C0275551 X X       X       
C0277787   X       X       
C0278252   X       X X     
C0279033 X         X       
C0282090   X       X       
C0282151   X       X       
C0282638   X       X       
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Included in public knowledge source AFEP SAFE 
C0302353   X       X       
C0302809   X X     X       
C0303753 X X       X       
C0304550   X       X       
C0304551   X       X       
C0304925   X       X       
C0309872   X       X       
C0311392 X X   X   X   X   
C0333121 X         X       
C0333501 X X       X       
C0337443 X X X X   X X X   
C0338237   X       X       
C0339897 X X X     X   X   
C0341503 X X       X       
C0344441 X         X       
C0348042   X   X   X       
C0350056 X         X       
C0353714   X       X       
C0355614   X       X       
C0368721   X       X       
C0373535 X X       X       
C0373595 X X       X       
C0373719 X X       X       
C0392148 X X       X       
C0403416   X       X       
C0418967 X         X       
C0422768   X       X       
C0426396       X           
C0427944   X       X       
C0428279 X X       X       
C0428283 X         X       
C0428437       X           
C0428601   X       X       
C0428642   X       X       
C0428886   X       X       
C0429119   X       X       
C0430397 X         X       
C0439775 X         X       
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Included in public knowledge source AFEP SAFE 
C0440102 X X       X       
C0441513 X         X       
C0441610   X       X       
C0442811 X     X   X       
C0442856   X       X       
C0442886       X           
C0445115 X         X       
C0449970   X       X       
C0450442 X X       X       
C0450458   X       X       
C0456378 X X       X       
C0457422   X       X       
C0460139 X X   X   X   X   
C0472683   X       X       
C0475371 X     X   X       
C0475806   X       X       
C0487602 X         X       
C0520819 X         X       
C0520890   X       X       
C0520891 X         X       
C0521302   X       X       
C0523444 X X       X       
C0523891 X X       X       
C0542331 X X       X       
C0545131   X       X       
C0546817       X           
C0546866 X         X       
C0546884   X       X       
C0554309   X X     X       
C0554756   X       X       
C0558148       X           
C0559546   X       X       
C0572025   X       X       
C0574032 X     X   X       
C0577060       X           
C0577118   X       X       
C0580859       X           
C0581142   X       X       
 140 
 
Included in public knowledge source AFEP SAFE 
C0585109   X       X       
C0587081   X       X       
C0587355   X       X       
C0587362   X       X       
C0591050   X       X       
C0596170   X       X       
C0597198   X       X       
C0597357 X X       X       
C0600061 X X       X       
C0600688 X         X       
C0677039 X         X       
C0677582   X       X       
C0679861 X         X       
C0681827   X       X       
C0684336 X X       X       
C0700308   X       X       
C0700445   X       X       
C0724649   X       X       
C0728940 X         X       
C0732165   X       X       
C0740085 X X       X       
C0740469       X           
C0741244 X X       X       
C0742724   X       X       
C0859036   X       X       
C0868945 X X       X       
C0949378   X       X       
C1137947 X X       X       
C1140999 X         X       
C1145640   X       X       
C1171398   X       X       
C1256585 X X   X   X X X X 
C1261287 X         X       
C1261720   X       X       
C1263666     X             
C1266240   X       X       
C1268852   X       X       
C1271104 X     X   X       
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Included in public knowledge source AFEP SAFE 
C1272641   X       X       
C1272919   X       X       
C1278293 X X       X       
C1287298 X X   X   X X X   
C1292856   X       X       
C1293861 X X       X       
C1299583 X         X       
C1302112 X         X       
C1318478 X         X       
C1366678   X       X       
C1396851 X         X       
C1442858 X X X X   X   X   
C1443036 X         X       
C1444662   X       X       
C1511237   X       X       
C1522240   X       X       
C1533693   X       X       
C1533734 X X       X       
C1536696   X       X       
C1559265 X X   X   X   X   
C1705480 X X       X       
C1710425 X X X X   X   X   
C1718097   X       X       
C1832073   X       X       
C1874188   X       X       
C1874190   X       X       
C1874191   X       X       
C1874271 X X       X       
C1874288   X       X       
C1874289   X       X       
C1874292   X       X       
C1874295   X       X       
C1874882   X       X       
C1874911   X       X       
C1874953   X       X       
C1874955   X       X       
C1874970   X       X       
C1875099   X       X       
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Included in public knowledge source AFEP SAFE 
C1875100   X       X       
C1875146   X   X   X       
C1875186   X       X       
C1875409   X       X       
C1875410   X       X       
C1875417   X       X       
C1875522   X       X       
C1875542       X           
C1875577   X       X       
C1875579   X       X       
C1875643   X   X   X       
C1875728   X   X   X       
C1875761 X         X       
C1875865   X X     X       
C1881049   X       X       
C1882365 X         X       
C1882443 X X       X       
C1962945 X         X       
C1970989   X       X       
C2239176   X       X       
C2242979   X       X       
C2266920 X         X       
C2266943 X         X       
C2266959   X       X X     
C2266960   X       X       
C2266971   X       X       
C2266972   X       X       
C2347023 X         X       
C2347080 X         X       
C2348813 X         X       
C2746010   X   X   X       
C2825032   X       X       
C2825050 X         X       
C2825091 X X       X       
C2826616   X       X       
C2917331   X       X       
C2917342 X X       X       
C2917344   X       X       
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Included in public knowledge source AFEP SAFE 
C2917403 X X       X       
C2917419   X       X X     
C2919641   X       X       
C2986592 X         X       
C2986642 X X       X       
C2987634 X X       X       
C3263722   X       X       
C3275118   X       X       
C3514012 X         X       
C3532188   X       X       
C3536742   X       X       
C3536752   X       X       
C3536808 X X       X       
C3536825 X X X     X X X   
C3536828 X X X     X X X   
C3536840       X           
C3536843 X X       X       
C3536888   X       X       
C3537198   X       X       
C3537226   X       X       
C3537240 X X       X       
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APPENDIX B: DETAILS ON RISK PREDICTION ALGORITHMS 
 
Appendix Table 1: List of initial candidate predictor variables and ultimate variables 
chosen for the LASSO model after elimination of low prevalence and collinear variables. 
Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Gender 34785 (98.23%) 0 (0%) X 
Race 
 
950 
(2.68%) 
 
0 UNKNOWN 2037 (5.75%) 
 
X 
1 WHITE 25168 (71.07%) 
 
X 
2 BLACK 7191 (20.31%) 
 
X 
3 ASIAN-HAWAIIAN-PACIFIC 
ISLANDER 
538 (1.52%) 
 
X 
4 AMERICAN INDIAN-ALASKAN 
NATIVE 
478 (1.35%) 
 
X 
Age 61 (57.%) 0 (0%) X 
KDIGO Renal Failure Stage 
   
   1 23920 (67.55%) 0 (0%) X 
   2 5913 (16.7%) 0 (0%) X 
   3 5579 (15.75%) 0 (0%) X 
Admit MELD 19.28 (15.13,23.67) 5313 
(15.%) 
X 
Baseline Creatinine 1.13 (0.9,1.59) 0 (0%) X 
Admit Avg Creatinine 1.86 (1.39,2.8) 29 (0.08%) X 
Admit Avg Sodium 135. (131.,138.) 162 
(0.46%) 
X 
Admit Avg Chloride 102. (97.5,106.5) 60 (0.17%) X 
Admit Avg Bicarbonate 23. (20.,26.) 59 (0.17%) X 
Admit Avg Calcium 8.45 (8.,8.88) 1467 
(4.14%) 
X 
Admit Avg Blood Urea Nitrogen 34. (22.,52.) 2193 
(6.19%) 
X 
Admit Avg Glucose 121.6 (101.7,157.) 138 
(0.39%) 
X 
Admit Avg Hemoglobin 10.6 (9.2,12.15) 1153 
(3.26%) 
X 
Admit Avg Hematocrit 31.35 (27.2,35.8) 189 
(0.53%) 
X 
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Admit Avg White Blood Cell 7.7 (5.5,10.9) 202 
(0.57%) 
X 
Admit Avg Platelet 116.3 (73.5,176.) 312 
(0.88%) 
X 
Admit Avg Mean Corpuscular Volume 94.1 (88.75,99.7) 217 
(0.61%) 
X 
Admit Avg Mean Corpuscular 
Hemoglobin Conc. 
33.93 (33.1,34.65) 215 
(0.61%) 
X 
Admit Avg Mean Corpuscular 
Hemoglobin 
31.9 (29.7,34.15) 348 
(0.98%) 
X 
Admit Avg Albumin 2.5 (2.,3.05) 3309 
(9.34%) 
X 
Admit Avg Aspartate 
Aminotransferase 
54.5 (34.,92.) 3490 
(9.86%) 
X 
Admit Avg Alanine Aminotransferase 30. (18.,50.27) 2991 
(8.45%) 
X 
Admit Avg Direct Bilirubin 0.42 (0.11,1.3) 21438 
(60.54%) 
X 
Admit Avg Total Bilirubin 1.6 (0.8,3.4) 2751 
(7.77%) 
X 
Admit Avg Alkaline Phosphatase 118. (82.,173.) 2716 
(7.67%) 
X 
Admit Avg Prothrombin Time 16.55 (14.5,19.5) 5907 
(16.68%) 
X 
Admit Avg Partial Thromboplastin 
Time 
34.7 (31.3,39.1) 10577 
(29.87%) 
X 
Admit Avg International Normalized 
Ratio 
1.4 (1.22,1.7) 4706 
(13.29%) 
X 
Admit Systolic Blood Pressure 116. (104.,129.) 613 
(1.73%) 
X 
Admit Diastolic Blood Pressure 66. (59.,73.) 617 
(1.74%) 
X 
Admit Mean Arterial Pressure 99. (90.,110.) 617 
(1.74%) 
X 
Admit Temperature 97.72 (97.22,98.16) 692 
(1.95%) 
X 
Admit Pulse 81.4 (71.33,92.) 598 
(1.69%) 
X 
Admit Respirations 19. (18.,20.) 662 
(1.87%) 
X 
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Admit Weight 193.6 (167.,209.9) 7707 
(21.76%) 
X 
Admit Min Systolic Blood Pressure 100. (90.,113.) 613 
(1.73%) 
X 
Admit Max Temperature 98.6 (98.,99.1) 692 
(1.95%) 
X 
Admit Max Pulse 93. (81.,106.) 598 
(1.69%) 
X 
Admit Max Resp 20. (20.,24.) 662 
(1.87%) 
X 
Admit Weight Change -2.44 (-9.28,4.52) 7885 
(22.27%) 
X 
# Paracentesis in last 90 days 1. (1.,1.) 0 (0%) X 
Atrial Fibrillation 6233 (17.6%) 0 (0%) X 
Amyloidosis 84 (0.24%) 0 (0%) X 
Angina 3235 (9.14%) 0 (0%) X 
Anemia 24253 (68.49%) 0 (0%) X 
Arrhythmia 12836 (36.25%) 0 (0%) X 
Ascites 27836 (78.6%) 0 (0%) 
 
Asthma 2022 (5.71%) 0 (0%) X 
Autonomic Neuropathy 62 (0.18%) 0 (0%)   
Cancer 10729 (30.3%) 0 (0%) X 
Biliary Cirrhosis 181 (0.51%) 0 (0%) X 
Bone Marrow Transplant 9 (0.03%) 0 (0%)   
CABG 3083 (8.71%) 0 (0%) X 
Coronary Artery Disease 12410 (35.04%) 0 (0%) X 
Carotid Disease 133 (0.38%) 0 (0%) X 
Congestive Heart Failure 10172 (28.72%) 0 (0%) X 
Chronic Kidney Disease 13585 (38.36%) 0 (0%) X 
Colitis 300 (0.85%) 0 (0%) X 
Chronic Obstructive Pulmonary 
Disease 
12683 (35.82%) 0 (0%) X 
Cerebrovascular Accident 4159 (11.74%) 0 (0%) X 
Dementia 1025 (2.89%) 0 (0%) X 
Dermatomyositis 9 (0.03%) 0 (0%)   
Dialysis 4191 (11.83%) 0 (0%) X 
Diabetes Mellitus 17980 (50.77%) 0 (0%) X 
Diabetic Neuropathy 4225 (11.93%) 0 (0%) X 
Dyslipidemia 14992 (42.34%) 0 (0%) X 
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Etoh Abuse 19001 (53.66%) 0 (0%) X 
Gastrointestinal Bleed 12073 (34.09%) 0 (0%) X 
Acute Glomerulonephritis 330 (0.93%) 0 (0%) X 
Glomerular Nephritis 911 (2.57%) 0 (0%) X 
Hepatocellular Carcinoma 4134 (11.67%) 0 (0%) X 
Hepatic Encephalopathy 11646 (32.89%) 0 (0%) X 
Viral Hepatitis 18548 (52.38%) 0 (0%) X 
HIV 722 (2.04%) 0 (0%) X 
Hospice 27 (0.08%) 0 (0%)   
Heart Transplant 63 (0.18%) 0 (0%)   
Hypertension 28271 (79.83%) 0 (0%) X 
Hyperparathyroidism 433 (1.22%) 0 (0%) X 
Leukemia 307 (0.87%) 0 (0%) X 
Lung Transplant 28 (0.08%) 0 (0%)   
Lupus 2122 (5.99%) 0 (0%) X 
Multiple Endocrine Neoplasia 4 (0.01%) 0 (0%)   
Myocardial Infarction 2674 (7.55%) 0 (0%) X 
Multiple Myeloma 202 (0.57%) 0 (0%) X 
Multiple Sclerosis 47 (0.13%) 0 (0%)   
Myopathies 3248 (9.17%) 0 (0%) X 
NAFLD 5390 (15.22%) 0 (0%) X 
Glomerular Nephritis, NOS 2800 (7.91%) 0 (0%) X 
Nephrectomy 165 (0.47%) 0 (0%) X 
Osteoarthritis 8919 (25.19%) 0 (0%) X 
Obesity 7607 (21.48%) 0 (0%) X 
Palliative Care 4159 (11.74%) 0 (0%) X 
Parkinsons 273 (0.77%) 0 (0%) X 
Pancreatitis 3964 (11.19%) 0 (0%) X 
Hemi- or Paraplegia 882 (2.49%) 0 (0%) X 
Porphyria 104 (0.29%) 0 (0%) X 
Peptic Ulcer Disease 3879 (10.95%) 0 (0%) X 
Peripheral Vascular Disease 3621 (10.23%) 0 (0%) X 
Rheumatoid Arthritis 461 (1.3%) 0 (0%) X 
Renal Transplant 169 (0.48%) 0 (0%) X 
Rheumatic Disease (Charlson 
Comorbidity Index Definition) 
715 (2.02%) 0 (0%) X 
Spontaneous Bacterial Peritonitis 4691 (13.25%) 0 (0%) X 
Scleroderma 28 (0.08%) 0 (0%)   
 148 
Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Sickle Cell Anemia 48 (0.14%) 0 (0%)   
Spinal Cord Injury 247 (0.7%) 0 (0%) X 
STEMI 1783 (5.04%) 0 (0%) X 
Stroke 2657 (7.5%) 0 (0%) X 
Tuberculosis 416 (1.17%) 0 (0%) X 
Transient Ischemic Attack 902 (2.55%) 0 (0%) X 
TIPS 599 (1.69%) 0 (0%) X 
Tobacco Use 16956 (47.88%) 0 (0%) X 
Urinary Obstruction 4598 (12.98%) 0 (0%) X 
Varices 9129 (25.78%) 0 (0%) X 
Valvular Heart Disease 3736 (10.55%) 0 (0%) X 
Home Med Rifaximin 2166 (6.12%) 0 (0%) X 
Home Med Lactulose 8439 (23.83%) 0 (0%) X 
Home Med Antidotes Deterrents And 
Poison Control 
995 (2.81%) 0 (0%) X 
Home Med Alcohol Deterrents 48 (0.14%) 0 (0%)   
Home Med Heavy Metal Antagonists 15 (0.04%) 0 (0%)   
Home Med Antidotes Deterrents And 
Poison Control Exchange Resins 
276 (0.78%) 0 (0%) X 
Home Med Antidotes Deterrents Other 664 (1.88%) 0 (0%) X 
Home Med Antihistamines 4730 (13.36%) 0 (0%) X 
Home Med Antihistamines 
Phenothiazine 
806 (2.28%) 0 (0%) X 
Home Med Antihistamines 
Ethanolamine 
961 (2.71%) 0 (0%) X 
Home Med Antihistamines Alkylamine 49 (0.14%) 0 (0%)   
Home Med Antihistamines Piperazine 1876 (5.3%) 0 (0%) X 
Home Med Antihistamines 
Butyrophenone 
49 (0.14%) 0 (0%)   
Home Med Antihistamines Piperidine 104 (0.29%) 0 (0%) X 
Home Med Antihistamines Other 1461 (4.13%) 0 (0%) X 
Home Med Antimicrobials 9133 (25.79%) 0 (0%) X 
Home Med Penicillin G Related 
Penicillins 
40 (0.11%) 0 (0%)   
Home Med Penicillins Amino 
Derivatives 
858 (2.42%) 0 (0%) X 
Home Med Penicillinase Resistant 
Penicillins 
47 (0.13%) 0 (0%)   
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Home Med Extended Spectrum 
Penicillins 
10 (0.03%) 0 (0%)   
Home Med Penicillins And Beta Lactam 
Antimicrobials 
1553 (4.39%) 0 (0%) X 
Home Med Cephalosporin 1st 
Generation 
449 (1.27%) 0 (0%) X 
Home Med Cephalosporin 2nd 
Generation 
62 (0.18%) 0 (0%)   
Home Med Cephalosporin 3rd 
Generation 
122 (0.34%) 0 (0%) X 
Home Med Cephalosporin 4th 
Generation 
2 (0.01%) 0 (0%)   
Home Med Beta Lactams 
Antimicrobials Other 
2 (0.01%) 0 (0%)   
Home Med Erythromycins Macrolides 382 (1.08%) 0 (0%) X 
Home Med Tetracyclines 370 (1.04%) 0 (0%) X 
Home Med Aminoglycosides 398 (1.12%) 0 (0%) X 
Home Med Lincomycins 249 (0.7%) 0 (0%) X 
Home Med Quinolones 4125 (11.65%) 0 (0%) X 
Home Med Antituberculars 93 (0.26%) 0 (0%) X 
Home Med Methenamine Salts 
Antimicrobials 
9 (0.03%) 0 (0%)   
Home Med Nitrofurans Antimicrobials 85 (0.24%) 0 (0%) X 
Home Med Sulfonamide Related 
Antimicrobials 
1123 (3.17%) 0 (0%) X 
Home Med Antifungals 490 (1.38%) 0 (0%) X 
Home Med Antivirals 774 (2.19%) 0 (0%) X 
Home Med Anti Infectives Other 3051 (8.62%) 0 (0%) X 
Home Med Antineoplastics 690 (1.95%) 0 (0%) X 
Home Med Antineoplastics Alkylating 
Agents 
10 (0.03%) 0 (0%)   
Home Med Antineoplastic Antibiotics 0 (0.%) 0 (0%)   
Home Med Antineoplastics 
Antimetabolites 
98 (0.28%) 0 (0%) X 
Home Med Antineoplastic Hormones 121 (0.34%) 0 (0%) X 
Home Med Protective Agents 0 (0.%) 0 (0%)   
Home Med Antineoplastic Other 502 (1.42%) 0 (0%) X 
Home Med Antiparasitics 284 (0.8%) 0 (0%) X 
Home Med Antiprotozoals 255 (0.72%) 0 (0%) X 
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Home Med Antimalarials 234 (0.66%) 0 (0%) X 
Home Med Antiprotozoals Other 21 (0.06%) 0 (0%)   
Home Med Anthelmintics 5 (0.01%) 0 (0%)   
Home Med Pediculicides 24 (0.07%) 0 (0%)   
Home Med Antiparasitics Other 0 (0.%) 0 (0%)   
Home Med Antiseptics Disinfectants 1 (0.%) 0 (0%)   
Home Med Autonomic Medications 995 (2.81%) 0 (0%) X 
Home Med Sympathomimetics 
.adrenergics. 
19 (0.05%) 0 (0%)   
Home Med Sympatholytics 2 (0.01%) 0 (0%)   
Home Med Parasympathomimetics 
Cholinergics 
762 (2.15%) 0 (0%) X 
Home Med Parasympatholytics 220 (0.62%) 0 (0%) X 
Home Med Autonomic Agents Other 9 (0.03%) 0 (0%)   
Home Med Blood Products Modifiers 
Volume Expanders 
3921 (11.07%) 0 (0%) X 
Home Med Anticoagulants 1713 (4.84%) 0 (0%) X 
Home Med Thrombolytics 2 (0.01%) 0 (0%)   
Home Med Antihemorrhagics 26 (0.07%) 0 (0%)   
Home Med Platelet Aggregation 
Inhibitors 
1222 (3.45%) 0 (0%) X 
Home Med Blood Formation Products 1190 (3.36%) 0 (0%) X 
Home Med Blood Derivatives 30 (0.08%) 0 (0%)   
Home Med Volume Expanders 1 (0.%) 0 (0%)   
Home Med Central Nervous System 
Medications 
19537 (55.17%) 0 (0%) X 
Home Med Analgesics 14293 (40.36%) 0 (0%) X 
Home Med Opioid Analgesics 9892 (27.93%) 0 (0%) X 
Home Med Opioid Antagonist 
Analgesics 
46 (0.13%) 0 (0%)   
Home Med Non Opioid Analgesics 7363 (20.79%) 0 (0%) X 
Home Med Antimigraine Agents 38 (0.11%) 0 (0%)   
Home Med Anesthetics 9 (0.03%) 0 (0%)   
Home Med General Anesthetics Other 1 (0.%) 0 (0%)   
Home Med Local Anesthetics Injection 8 (0.02%) 0 (0%)   
Home Med Anesthetic Adjuncts 0 (0.%) 0 (0%)   
Home Med Sedatives Hypontics 4019 (11.35%) 0 (0%) X 
Home Med Barbituric Acid Derivative 
Sedatives Hypnotics 
29 (0.08%) 0 (0%)   
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Home Med Benzodiazepine Derivative 
Sedatives Hypnotics 
2777 (7.84%) 0 (0%) X 
Home Med Sedatives Hypnotics Other 1457 (4.11%) 0 (0%) X 
Home Med Anticonvulsants 4746 (13.4%) 0 (0%) X 
Home Med Antiparkinson Agents 388 (1.1%) 0 (0%) X 
Home Med Antivertigo Agents 138 (0.39%) 0 (0%) X 
Home Med Antidepressants 9435 (26.64%) 0 (0%) X 
Home Med Tricyclic Antidepressants 1187 (3.35%) 0 (0%) X 
Home Med Monamine Oxidase 
Inhibitor Antidepressants 
2 (0.01%) 0 (0%)   
Home Med Antidepressants Other 8764 (24.75%) 0 (0%) X 
Home Med Antipsychotics 2146 (6.06%) 0 (0%) X 
Home Med Phenothiazine Related 
Antipsychotics 
110 (0.31%) 0 (0%) X 
Home Med Antipsychotics Other 2061 (5.82%) 0 (0%) X 
Home Med Lithium Salts 97 (0.27%) 0 (0%) X 
Home Med Cns Stimulants 70 (0.2%) 0 (0%)   
Home Med Amphetamines 6 (0.02%) 0 (0%)   
Home Med Amphetamine Like 
Stimulants 
50 (0.14%) 0 (0%)   
Home Med Cns Stimulants Other 14 (0.04%) 0 (0%)   
Home Med Cns Medications Other 452 (1.28%) 0 (0%) X 
Home Med Cardiovascular Medications 27201 (76.81%) 0 (0%) X 
Home Med Digitalis Glycosides 1423 (4.02%) 0 (0%) X 
Home Med Beta Blockers Related 16825 (47.51%) 0 (0%) X 
Home Med Alpha Blockers Related 4450 (12.57%) 0 (0%) X 
Home Med Calcium Channel Blockers 5194 (14.67%) 0 (0%) X 
Home Med Antianginals 2718 (7.68%) 0 (0%) X 
Home Med Antiarrhythmics 546 (1.54%) 0 (0%) X 
Home Med Antilipemic Agents 6364 (17.97%) 0 (0%) X 
Home Med Antihypertensive 
Combinations 
446 (1.26%) 0 (0%) X 
Home Med Antihypertensives Other 1944 (5.49%) 0 (0%) X 
Home Med Peripheral Vasodilators 2 (0.01%) 0 (0%)   
Home Med Diuretics 21146 (59.71%) 0 (0%) X 
Home Med Thiazides Related Diuretics 2698 (7.62%) 0 (0%) X 
Home Med Loop Diuretics 18419 (52.01%) 0 (0%) X 
Home Med Carbonic Anhydrase 
Inhibitor Diuretics 
14 (0.04%) 0 (0%)   
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Home Med Potassium Sparing 
Combinations Diuretics 
14719 (41.57%) 0 (0%) X 
Home Med Diuretics Other 0 (0.%) 0 (0%)   
Home Med Ace Inhibitors 7725 (21.81%) 0 (0%) X 
Home Med Angiotensin Ii Inhibitor 1504 (4.25%) 0 (0%) X 
Home Med Direct Renin Inhibitor 5 (0.01%) 0 (0%)   
Home Med Cardiovascular Agents 
Other 
613 (1.73%) 0 (0%) X 
Home Med Dermatological Agents 7574 (21.39%) 0 (0%) X 
Home Med Anti Infective Topical 3054 (8.62%) 0 (0%) X 
Home Med Antibacterial Topical 1352 (3.82%) 0 (0%) X 
Home Med Antifungal Topical 1731 (4.89%) 0 (0%) X 
Home Med Antiviral Topical 18 (0.05%) 0 (0%)   
Home Med Anti Infective Topical Other 268 (0.76%) 0 (0%) X 
Home Med Anti Inflammatory Topical 2017 (5.7%) 0 (0%) X 
Home Med Anti Infective Anti 
Inflammatory Combinations Topical 
82 (0.23%) 0 (0%) X 
Home Med Sun Protectants Screens 
Topical 
55 (0.16%) 0 (0%)   
Home Med Emollients 2413 (6.81%) 0 (0%) X 
Home Med Soaps Shampoos Soap Free 
Cleansers 
324 (0.91%) 0 (0%) X 
Home Med Deodorants 
Antiperspirants Topical 
3 (0.01%) 0 (0%)   
Home Med Keratolytics Caustics 
Topical 
30 (0.08%) 0 (0%)   
Home Med Antineoplastic Topical 27 (0.08%) 0 (0%)   
Home Med Analgesics Topical 787 (2.22%) 0 (0%) X 
Home Med Local Anesthetics Topical 562 (1.59%) 0 (0%) X 
Home Med Antiacne Agents 132 (0.37%) 0 (0%) X 
Home Med Antiacne Agents Systemic 0 (0.%) 0 (0%)   
Home Med Antiacne Agents Topical 132 (0.37%) 0 (0%)   
Home Med Antipsoriatic 185 (0.52%) 0 (0%) X 
Home Med Antipsoriatics Systemic 24 (0.07%) 0 (0%)   
Home Med Antipsoriatics Topical 163 (0.46%) 0 (0%) X 
Home Med Dermatologicals Systemic 
Other 
1 (0.%) 0 (0%)   
Home Med Dermatologicals Topical 
Other 
1543 (4.36%) 0 (0%) X 
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Admit IVF Total 350. (0.,1250.) 0 (0%) X 
Admit Octreotide 1803 (5.09%) 0 (0%) X 
Admit Midodrine 478 (1.35%) 0 (0%) X 
Admit Albumin Inf 6042 (17.06%) 0 (0%) X 
Admit Norepinephrine 712 (2.01%) 0 (0%) X 
Admit Vasopressin 153 (0.43%) 0 (0%) X 
Admit Rifaximin 2888 (8.16%) 0 (0%) X 
Admit Med Class Nsaids 806 (2.28%) 0 (0%) X 
Admit Med Class Aminoglycosides 796 (2.25%) 0 (0%) X 
Admit Med Class Betablockers 15805 (44.63%) 0 (0%)   
Admit Med Class Ace 3091 (8.73%) 0 (0%)   
Admit Med Class Arb 684 (1.93%) 0 (0%)   
Admit Med Class Glucocorticoids 2681 (7.57%) 0 (0%) X 
Admit Med Class Ksparingdiuretic 7890 (22.28%) 0 (0%)   
Admit Med Class Benzodiazepines 5798 (16.37%) 0 (0%)   
Admit Med Class Statins 5310 (14.99%) 0 (0%) X 
Admit Med Class Insulin 12004 (33.9%) 0 (0%) X 
Admit Med Class Fluoroquinolones 4147 (11.71%) 0 (0%) X 
Admit Med Class Opioids 19447 (54.92%) 0 (0%) X 
Admit Med Va Class Antidotes 
Deterrents And Poison Control 
0 (0.%) 0 (0%)   
Admit Med Va Class Alcohol Deterrents 21 (0.06%) 0 (0%)   
Admit Med Va Class Heavy Metal 
Antagonists 
6 (0.02%) 0 (0%)   
Admit Med Va Class Antidotes 
Deterrents And Poison Control 
Exchange Resins 
3502 (9.89%) 0 (0%) X 
Admit Med Va Class Antidotes 
Deterrents Other 
188 (0.53%) 0 (0%) X 
Admit Med Va Class Antihistamines 0 (0.%) 0 (0%)   
Admit Med Va Class Antihistamines 
Phenothiazine 
974 (2.75%) 0 (0%) X 
Admit Med Va Class Antihistamines 
Ethanolamine 
1895 (5.35%) 0 (0%) X 
Admit Med Va Class Antihistamines 
Alkylamine 
12 (0.03%) 0 (0%)   
Admit Med Va Class Antihistamines 
Piperazine 
991 (2.8%) 0 (0%) X 
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Admit Med Va Class Antihistamines 
Butyrophenone 
23 (0.06%) 0 (0%)   
Admit Med Va Class Antihistamines 
Piperidine 
61 (0.17%) 0 (0%)   
Admit Med Va Class Antihistamines 
Other 
823 (2.32%) 0 (0%) X 
Admit Med Va Class Antimicrobials 0 (0.%) 0 (0%)   
Admit Med Va Class Penicillin G 
Related Penicillins 
51 (0.14%) 0 (0%)   
Admit Med Va Class Penicillins Amino 
Derivatives 
996 (2.81%) 0 (0%) X 
Admit Med Va Class Penicillinase 
Resistant Penicillins 
125 (0.35%) 0 (0%) X 
Admit Med Va Class Extended 
Spectrum Penicillins 
5186 (14.64%) 0 (0%) X 
Admit Med Va Class Penicillins And 
Beta Lactam Antimicrobials 
0 (0.%) 0 (0%)   
Admit Med Va Class Cephalosporin 1st 
Generation 
695 (1.96%) 0 (0%) X 
Admit Med Va Class Cephalosporin 
2nd Generation 
134 (0.38%) 0 (0%) X 
Admit Med Va Class Cephalosporin 3rd 
Generation 
5955 (16.82%) 0 (0%) X 
Admit Med Va Class Erythromycins 
Macrolides 
1337 (3.78%) 0 (0%) X 
Admit Med Va Class Tetracyclines 350 (0.99%) 0 (0%) X 
Admit Med Va Class Aminoglycosides 753 (2.13%) 0 (0%) X 
Admit Med Va Class Lincomycins 544 (1.54%) 0 (0%) X 
Admit Med Va Class Quinolones 5703 (16.1%) 0 (0%) X 
Admit Med Va Class Antituberculars 80 (0.23%) 0 (0%) X 
Admit Med Va Class Nitrofurans 
Antimicrobials 
19 (0.05%) 0 (0%)   
Admit Med Va Class Sulfonamide 
Related Antimicrobials 
597 (1.69%) 0 (0%) X 
Admit Med Va Class Antifungals 861 (2.43%) 0 (0%) X 
Admit Med Va Class Antivirals 774 (2.19%) 0 (0%) X 
Admit Med Va Class Anti Infectives 
Other 
10306 (29.1%) 0 (0%) X 
Admit Med Va Class Antineoplastics 0 (0.%) 0 (0%)   
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Admit Med Va Class Antineoplastics 
Alkylating Agents 
4 (0.01%) 0 (0%)   
Admit Med Va Class Antineoplastics 
Antimetabolites 
33 (0.09%) 0 (0%)   
Admit Med Va Class Antineoplastic 
Hormones 
6 (0.02%) 0 (0%)   
Admit Med Va Class Antineoplastic 
Other 
227 (0.64%) 0 (0%) X 
Admit Med Va Class Antiparasitics 0 (0.%) 0 (0%)   
Admit Med Va Class Antiprotozoals 0 (0.%) 0 (0%)   
Admit Med Va Class Antimalarials 151 (0.43%) 0 (0%) X 
Admit Med Va Class Antiprotozoals 
Other 
30 (0.08%) 0 (0%)   
Admit Med Va Class Pediculicides 30 (0.08%) 0 (0%)   
Admit Med Va Class Autonomic 
Medications 
0 (0.%) 0 (0%)   
Admit Med Va Class 
Parasympathomimetics Cholinergics 
1022 (2.89%) 0 (0%) X 
Admit Med Va Class 
Parasympatholytics 
221 (0.62%) 0 (0%) X 
Admit Med Va Class Autonomic Agents 
Other 
6 (0.02%) 0 (0%)   
Admit Med Va Class Blood Products 
Modifiers Volume Expanders 
0 (0.%) 0 (0%)   
Admit Med Va Class Anticoagulants 11162 (31.52%) 0 (0%) X 
Admit Med Va Class Antihemorrhagics 25 (0.07%) 0 (0%)   
Admit Med Va Class Platelet 
Aggregation Inhibitors 
1103 (3.11%) 0 (0%) X 
Admit Med Va Class Blood Formation 
Products 
541 (1.53%) 0 (0%) X 
Admit Med Va Class Blood Derivatives 6062 (17.12%) 0 (0%) X 
Admit Med Va Class Volume Expanders 126 (0.36%) 0 (0%) X 
Admit Med Va Class Central Nervous 
System Medications 
0 (0.%) 0 (0%)   
Admit Med Va Class Analgesics 0 (0.%) 0 (0%)   
Admit Med Va Class Opioid Analgesics 14915 (42.12%) 0 (0%) X 
Admit Med Va Class Opioid Antagonist 
Analgesics 
222 (0.63%) 0 (0%) X 
Admit Med Va Class Non Opioid 
Analgesics 
9986 (28.2%) 0 (0%) X 
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Admit Med Va Class Antimigraine 
Agents 
4 (0.01%) 0 (0%)   
Admit Med Va Class Anesthetics 0 (0.%) 0 (0%)   
Admit Med Va Class Local Anesthetics 
Injection 
362 (1.02%) 0 (0%) X 
Admit Med Va Class Sedatives 
Hypontics 
1 (0.%) 0 (0%)   
Admit Med Va Class Barbituric Acid 
Derivative Sedatives Hypnotics 
60 (0.17%) 0 (0%)   
Admit Med Va Class Benzodiazepine 
Derivative Sedatives Hypnotics 
5798 (16.37%) 0 (0%) X 
Admit Med Va Class Sedatives 
Hypnotics Other 
1232 (3.48%) 0 (0%) X 
Admit Med Va Class Anticonvulsants 4889 (13.81%) 0 (0%) X 
Admit Med Va Class Antiparkinson 
Agents 
363 (1.03%) 0 (0%) X 
Admit Med Va Class Antivertigo Agents 48 (0.14%) 0 (0%)   
Admit Med Va Class Antidepressants 0 (0.%) 0 (0%)   
Admit Med Va Class Tricyclic 
Antidepressants 
863 (2.44%) 0 (0%) X 
Admit Med Va Class Antidepressants 
Other 
8512 (24.04%) 0 (0%) X 
Admit Med Va Class Antipsychotics 0 (0.%) 0 (0%)   
Admit Med Va Class Phenothiazine 
Related Antipsychotics 
117 (0.33%) 0 (0%) X 
Admit Med Va Class Antipsychotics 
Other 
2612 (7.38%) 0 (0%) X 
Admit Med Va Class Lithium Salts 82 (0.23%) 0 (0%) X 
Admit Med Va Class Cns Stimulants 0 (0.%) 0 (0%)   
Admit Med Va Class Amphetamine Like 
Stimulants 
35 (0.1%) 0 (0%)   
Admit Med Va Class Cns Stimulants 
Other 
5 (0.01%) 0 (0%)   
Admit Med Va Class Cns Medications 
Other 
425 (1.2%) 0 (0%) X 
Admit Med Va Class Cardiovascular 
Medications 
0 (0.%) 0 (0%)   
Admit Med Va Class Digitalis 
Glycosides 
1118 (3.16%) 0 (0%) X 
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Admit Med Va Class Beta Blockers 
Related 
15805 (44.63%) 0 (0%) X 
Admit Med Va Class Alpha Blockers 
Related 
3815 (10.77%) 0 (0%) X 
Admit Med Va Class Calcium Channel 
Blockers 
3892 (10.99%) 0 (0%) X 
Admit Med Va Class Antianginals 2018 (5.7%) 0 (0%) X 
Admit Med Va Class Antiarrhythmics 702 (1.98%) 0 (0%) X 
Admit Med Va Class Antilipemic 
Agents 
5855 (16.53%) 0 (0%) X 
Admit Med Va Class Antihypertensive 
Combinations 
93 (0.26%) 0 (0%) X 
Admit Med Va Class Antihypertensives 
Other 
2365 (6.68%) 0 (0%) X 
Admit Med Va Class Diuretics 0 (0.%) 0 (0%)   
Admit Med Va Class Thiazides Related 
Diuretics 
1074 (3.03%) 0 (0%) X 
Admit Med Va Class Loop Diuretics 12466 (35.2%) 0 (0%) X 
Admit Med Va Class Carbonic 
Anhydrase Inhibitor Diuretics 
16 (0.05%) 0 (0%)   
Admit Med Va Class Potassium Sparing 
Combinations Diuretics 
7890 (22.28%) 0 (0%) X 
Admit Med Va Class Ace Inhibitors 3091 (8.73%) 0 (0%) X 
Admit Med Va Class Angiotensin Ii 
Inhibitor 
684 (1.93%) 0 (0%) X 
Admit Med Va Class Cardiovascular 
Agents Other 
847 (2.39%) 0 (0%) X 
Admit Med Va Class Dermatological 
Agents 
0 (0.%) 0 (0%)   
Admit Med Va Class Anti Infective 
Topical 
0 (0.%) 0 (0%)   
Admit Med Va Class Antibacterial 
Topical 
1116 (3.15%) 0 (0%) X 
Admit Med Va Class Antifungal Topical 1746 (4.93%) 0 (0%) X 
Admit Med Va Class Antiviral Topical 8 (0.02%) 0 (0%)   
Admit Med Va Class Anti Infective 
Topical Other 
184 (0.52%) 0 (0%) X 
Admit Med Va Class Anti Inflammatory 
Topical 
1260 (3.56%) 0 (0%) X 
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Variable Name n (%) or median 
(IQR) 
Missing, n 
(%) 
Candidate 
Variable 
in Final 
Model 
Admit Med Va Class Anti Infective Anti 
Inflammatory Combinations Topical 
43 (0.12%) 0 (0%)   
Admit Med Va Class Sun Protectants 
Screens Topical 
3 (0.01%) 0 (0%)   
Admit Med Va Class Emollients 1540 (4.35%) 0 (0%) X 
Admit Med Va Class Soaps Shampoos 
Soap Free Cleansers 
138 (0.39%) 0 (0%) X 
Admit Med Va Class Keratolytics 
Caustics Topical 
12 (0.03%) 0 (0%)   
Admit Med Va Class Antineoplastic 
Topical 
19 (0.05%) 0 (0%)   
Admit Med Va Class Analgesics Topical 364 (1.03%) 0 (0%) X 
Admit Med Va Class Local Anesthetics 
Topical 
235 (0.66%) 0 (0%) X 
Admit Med Va Class Antiacne Agents 0 (0.%) 0 (0%)   
Admit Med Va Class Antiacne Agents 
Topical 
57 (0.16%) 0 (0%)   
Admit Med Va Class Antipsoriatic 2 (0.01%) 0 (0%)   
Admit Med Va Class Antipsoriatics 
Systemic 
11 (0.03%) 0 (0%)   
Admit Med Va Class Antipsoriatics 
Topical 
114 (0.32%) 0 (0%) X 
Admit Med Va Class Dermatologicals 
Topical Other 
1122 (3.17%) 0 (0%) X 
Admit Procedure Dialysis 2569 (7.25%) 0 (0%) X 
Admit Proc Liver Transplant 23 (0.06%) 0 (0%)   
Admit Procedure TIPS 84 (0.24%) 0 (0%) X 
Admit Procedure Variceal Control 672 (1.9%) 0 (0%) X 
Admit Procedure Paracentesis 7814 (22.07%) 0 (0%) X 
Admit Procedure Cardiac Cath 165 (0.47%) 0 (0%) X 
Admit Condition SBP 2654 (7.5%) 0 (0%) X 
3 Day Pre Admit Procedure Dialysis 0 (0.%) 0 (0%)   
3 Day Pre Admit Procedure 
Paracentesis 
617 (1.74%) 0 (0%) X 
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Appendix Table 1b: Code definitions for co-morbid conditions used in the model. (ICD-9: 
International Classification of Diseases-Version 9; CPT: Current Procedural Terminology; 
ICDProc: ICD Procedure Code) 
Description ICD-9 CPT ICDProc 
Acute 
Glomerulonephriti
s 
580.*   
Etoh Abuse 291.[0123589],303.*,305.0*   
Amyloidosis 277.3,277.3[019]   
Anemia 280*,281*,282.01,282.2*,282.3*,282.4*, 
282.71,282.8,282.9,283.[019]*,284*,285
*, 
648.2*,776.5* 
  
Angina 413*,411.1   
Arrhythmia 427*,785.0,785.1,779.81,426*,V45.0*,V5
3.3*,746.86 
  
Ascites 789.5* 4908[0-3] 54.91 
Asthma 493.*   
Atrial Fibulation 427.3[12]   
Autonomic 
Neuropathy 
337.9   
Cancer 1[4-9][0-9]*,20[0-8]*,209.[0-3]*,23[0-
3]* 
  
Biliary Cirrhosis 571.6   
Bone Marrow 
Transplant 
996.8[58],V42.8[12] 3824[012] 41.00* 
CABG V45.81,414.04 3351[01234678
9], 
3352[123], 
3353[3-6] 
36.1*, 
36.2* 
Carotid Disease 433.1  38.12 
Cerebrovascular 
Disease 
43[0-8]*,362.34   
Congestive Heart 
Failure 
398.91,402.11,404.01,404.11,404.91,42
8*, 
402.01,402.91,404.13,404.93,425.[1457
89]* 
  
Chronic Kidney 
Disease 
585*,403*,404*   
Colitis 555.[0129],556.,556.[0-6]   
Chronic 
Obstructive 
Pulmonary 
Disease 
491.*,492.*,493.*,496.*,V17.5*,V81.3*   
 160 
Description ICD-9 CPT ICDProc 
Coronary Artery 
Disease 
410.*,411.*,412.*,413.*, 
414.[02-9]*,V45.81,V45.82 
  
Dementia 290.*,294.[1]*,331.[012]*   
Dermatomyositis 710.3   
Diabetes Mellitus 249*,250*,357.2*,362.0*,366.41,V45.85, 
V53.91 
  
Diabetic 
Neuropathy 
357.2   
Dialysis 585.6,V39.27,V39.42,V39.43,V45.1,V56.0
, 
V56.2,V56.31,V56.32,V56.8 
90921,90925, 
90935,90937, 
90945,9096[012
6],G8956,90947, 
90989,9099[39] 
39.9[35], 
54.98 
Dyslipidemia 272.*   
Gastrointestinal 
Bleeding 
530.82,53[1-
4].[0246]0,535.[045]1,578.* 
  
Glomerular 
Nephritis 
(Exclusion) 
580.[049],580.8[19],581.[0123],582.[01
249], 
582.8[19],583.[0124],581.89 
  
Heart Transplant V42.1  37.5[1-5] 
Hemiplegia or 
Paraplegia 
334.1*,342.*,343.*,344.[01234569]*   
Hepatic 
Encephalopathy 
572.2*,070.00,070.2*,070.40,070.41,070
.44, 
070.49,070.60 
  
Viral Hepatitis 070.[23][0-
3],V02.6[12],070.[45][14],070.7[01] 
  
Hepatocellular 
Carcinoma 
155.0   
HIV 04[234]*,079.53,795.71,V08*   
Hospice  9,937,799,378  
Hyperparathyroidi
sm 
252.0*   
Hypertension 401*,402*,403*,404*,405*,437.2*   
Leukemia 202.4*,203.1*,20[4-8].*,V10.6*   
Lung Transplant V42.6  33.50* 
Multiple 
Endocrine 
Neoplasia 
258.0*   
Multiple Myeloma 203.0*   
Multiple Sclerosis 340.   
Myocardial 
Infarction 
410*   
Myopathies 359.8,359.89,425.4   
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Description ICD-9 CPT ICDProc 
Nephrectomy  5022[05], 
5023[046],5024
0, 
50300,50320, 
50340,50370, 
5054[35-8] 
55.4, 
55.5[1-4] 
Glomerular 
Nephritis, NOS 
580.81,58[03].9,583.8[19]   
NAFLD 571.8,571.9   
Obesity 278.0,278.0[01],649.1,278.03   
Osteoarthritis 715.0[049],715.1[0-8],715.2[0-8], 
715.3[0-8],715.8[09],715.9[0-8],V13.4 
  
Pallative Care V66.7*   
Pancreatitis 577.[01]*   
Parkinson’s 
Disease 
332.0   
Peptic Ulcer 
Disease 
531.*,532.*,533.*,534.*   
Peripheral 
Vascular Disease 
440*,441*,442*,444.2*,V43.4   
Porphyria 277.1   
Renal Transplant 996.81,V42.0 5,036,550,360 55.69*, 
00.9[123] 
Rheumatic Disease 
(Charlson 
Comorbidity 
Definition) 
446.5*,710.[01234]*,714.[0128]*,725.*   
Rheumatoid 
Arthritis 
714.0   
Scleroderma 701.0   
Sickle Cell Disease 282.4[1-4]*,282.6*   
Spinal Cord Injury  349.39,806.[0-3][0-9], 806.[4589], 
806.[67][0129],907.2, 
952.[01][0-9], 952.[23489] 
  
Spontaneous 
Bacterial 
Peritonitis 
567.23,567.[0289]0,567.2[19],567.89, 
567.[0289] 
  
STEMI 410.[012345689]*   
Stroke 43[01]*,434.[019],434.[019]1,436*,997.
02 
  
Lupus 286.5,323.81,517.8,58[023].81,695.4,71
0.0 
  
Transient Ischemic 
Attack 
435.[89]   
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Description ICD-9 CPT ICDProc 
Tobacco Use 305.1*,V15.82   
TIPS  3718[23] 39.1 
Tuberculosis 01[0-8].*,137.*,V12.01   
Urinary 
Obstruction 
592.1,593.4,594.[29],596.0,598.[1289],5
99.6, 
599.69,599.82,600.[0129]1,753.[26], 
753.2[129],788.2,788.29,V44.6,V55.6 
  
Valvular Heart 
Disease 
424.[0-3]   
Varices 456.[012][01],456.[012] 4324[34],4320[4
5] 
42.33 
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Appendix Table 2: Variables used in the multiple imputation of laboratory values.  
Multiple imputation was carried out by the mi package for the R statistical programming 
software. Imputation was carried out for 30 iterations using 4 separate chains. 
Imputations were carried out to convergence. Values from the four separate chains 
were averaged together for the final imputed values used in the dataset. 
Variable Name 
Gender 
Race 
Age 
Admit MELD 
Baseline Creatinine 
Admit Avg Creatinine 
Admit Avg Sodium 
Admit Avg Chloride 
Admit Avg Bicarbonate 
Admit Avg Calcium 
Admit Avg Blood Urea Nitrogen 
Admit Avg Glucose 
Admit Avg Hemoglobin 
Admit Avg Hematocrit 
Admit Avg White Blood Cell 
Admit Avg Platelet 
Admit Avg Mean Corpuscular Volume 
Admit Avg Mean Corpuscular Hemoglobin 
Conc. 
Admit Avg Mean Corpuscular Hemoglobin 
Admit Avg Albumin 
Admit Avg Aspartate Aminotransferase 
Admit Avg Alanine Aminotransferase 
Admit Avg Direct Bilirubin 
Admit Avg Total Bilirubin 
Admit Avg Alkaline Phosphatase 
Admit Avg Prothrombin Time 
Admit Avg Partial Thromboplastin Time 
Admit Avg International Normalized Ratio 
Atrial Fibrillation 
Anemia 
Ascites 
Cancer 
Biliary Cirrhosis 
Coronary Artery Disease 
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Congestive Heart Failure 
Chronic Kidney Disease 
Dialysis 
Diabetes Mellitus 
Etoh Abuse 
Gastrointestinal Bleed 
Hepatocellular Carcinoma 
Hepatic Encephalopathy 
Viral Hepatitis 
HIV 
Hypertension 
NAFLD 
Spontaneous Bacterial Peritonitis 
TIPS 
Varices 
# Paracentesis in last 90 days 
Home Med Rifaximin 
Home Med Lactulose 
Home Med Quinolones 
Home Med Anticoagulants 
Home Med Platelet Aggregation Inhibitors 
Home Med Opioid Analgesics 
Home Med Sedatives Hypontics 
Home Med Anticonvulsants 
Home Med Antidepressants 
Home Med Digitalis Glycosides 
Home Med Beta Blockers Related 
Home Med Alpha Blockers Related 
Home Med Calcium Channel Blockers 
Home Med Antiarrhythmics 
Home Med Antilipemic Agents 
Home Med Thiazides Related Diuretics 
Home Med Loop Diuretics 
Home Med Potassium Sparing Combinations 
Diuretics 
Home Med Ace Inhibitors 
Home Med Angiotensin Ii Inhibitor 
Admit Procedure Dialysis 
Admit Procedure TIPS 
Admit Procedure Variceal Control 
Admit Procedure Paracentesis 
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Appendix Table 3: GEE Odds ratios and confidence intervals for the variables selected by 
LASSO yielding the minimum deviance. 
Variable Odds Ratio (95% CI) 
(Intercept) 2.733  
Race White 0.804 (0.67,0.965) 
Race Black 0.639 (0.515,0.793) 
Race Asian 0.481 (0.3,0.772) 
Race Native American 0.644 (0.407,1.02) 
Age 1.012 (1,1.02) 
KDIGO Stage 2 Renal Failure 1.188 (1.04,1.35) 
KDIGO Stage 3 Renal Failure 0.942 (0.774,1.15) 
Admit IVF Total 0.942 (0.898,0.987) 
Admit MELD 1.169 (1.15,1.19) 
Baseline Creatinine 0.77 (0.711,0.834) 
Admit Avg Creatinine 1.066 (1.02,1.11) 
Admit Avg Sodium 0.971 (0.955,0.988) 
Admit Avg Chloride 1.016 (0.999,1.03) 
Admit Avg Bicarbonate 0.992 (0.974,1.01) 
Admit Avg Calcium 0.978 (0.913,1.05) 
Admit Avg Blood Urea Nitrogen 1.005 (1,1.01) 
Admit Avg Glucose 0.998 (0.997,0.999) 
Admit Avg Hematocrit 1 (0.99,1.01) 
Admit Avg Platelet 1 (0.999,1) 
Admit Avg Mean Corpuscular Volume 0.996 (0.99,1) 
Admit Avg Mean Corpuscular Hemoglobin Concentration 1.068 (1.02,1.12) 
Admit Avg Albumin 0.918 (0.836,1.01) 
Admit Avg Alanine Aminotransferase 0.999 (0.999,1) 
Admit Avg Total Bilirubin 0.988 (0.978,0.998) 
Admit Avg Alkaline Phosphatase 1 (1,1) 
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Variable Odds Ratio (95% CI) 
Admit Avg Partial Thromboplastin Time 0.995 (0.989,1) 
Admit Avg International Normalized Ratio 0.568 (0.491,0.657) 
Admit Mean Systolic Blood Pressure 0.985 (0.979,0.992) 
Admit Mean Diastolic Blood Pressure  1.014 (1.01,1.02) 
Admit Mean Temperature 0.942 (0.889,1) 
Admit Mean Pulse 1 (0.993,1.01) 
Admit Mean Weight 1.002 (1,1) 
Admit Min Systolic Blood Pressure 1.006 (1,1.01) 
Admit Max Pulse 0.999 (0.993,1) 
# Paracentesis in last 90 days 1.073 (1.05,1.1) 
Anemia 1.121 (0.997,1.26) 
Arrhythmia 0.951 (0.845,1.07) 
Asthma 0.732 (0.572,0.938) 
Cancer 0.902 (0.804,1.01) 
CABG 0.767 (0.592,0.993) 
Coronary Artery Disease 0.946 (0.824,1.09) 
Congestive Heart Failure 0.94 (0.806,1.09) 
Dialysis 1.04 (0.85,1.27) 
Gastrointestinal Bleed 0.9 (0.802,1.01) 
Hepatic Encephalopathy 1.446 (1.29,1.63) 
Viral Hepatitis 0.951 (0.851,1.06) 
Hypertension 0.922 (0.818,1.04) 
NAFLD 1.083 (0.955,1.23) 
Osteoarthritis 0.969 (0.858,1.09) 
Obesity 1.301 (1.14,1.48) 
Palliative Care 1.183 (1.03,1.36) 
Peptic Ulcer Disease 0.856 (0.725,1.01) 
Peripheral Vascular Disease 0.818 (0.661,1.01) 
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Variable Odds Ratio (95% CI) 
STEMI 1.118 (0.836,1.5) 
Tobacco Use 1.126 (1.02,1.25) 
Urinary Obstruction 0.864 (0.733,1.02) 
Varices 1.03 (0.915,1.16) 
Home Med Lactulose 0.942 (0.837,1.06) 
Home Med Antihistamines Piperazine 0.847 (0.677,1.06) 
Home Med Antihistamines Other 1.024 (0.787,1.33) 
Home Med Cephalosporin 1st Generation 0.448 (0.243,0.826) 
Home Med Quinolones 1.04 (0.91,1.19) 
Home Med Antivirals 1.352 (1,1.82) 
Home Med Anti Infectives Other 0.828 (0.693,0.989) 
Home Med Antineoplastic Other 0.589 (0.365,0.952) 
Home Med Autonomic Medications 0.805 (0.575,1.13) 
Home Med Platelet Aggregation Inhibitors 2.195 (1.61,2.98) 
Home Med Opioid Analgesics 0.915 (0.812,1.03) 
Home Med Non Opioid Analgesics 0.876 (0.758,1.01) 
Home Med Antidepressants Other 0.877 (0.763,1.01) 
Home Med Cardiovascular Medications 1.114 (0.962,1.29) 
Home Med Beta Blockers Related 0.831 (0.741,0.931) 
Home Med Calcium Channel Blockers 1.065 (0.891,1.27) 
Home Med Antianginals 0.837 (0.646,1.08) 
Home Med Antilipemic Agents 1.028 (0.845,1.25) 
Home Med Antihypertensives Other 0.592 (0.406,0.862) 
Home Med Potassium Sparing Combinations Diuretics 1.052 (0.93,1.19) 
Home Med Ace Inhibitors 0.859 (0.733,1.01) 
Home Med Dermatologicals Topical Other 1.184 (0.937,1.5) 
Admit Midodrine 1.459 (0.937,2.27) 
Admit Albumin Infusion 1.37 (1.22,1.54) 
 169 
Variable Odds Ratio (95% CI) 
Admit Norepinephrine 0.913 (0.652,1.28) 
Admit Rifaximin 1.42 (1.16,1.73) 
Admit Med Class Glucocorticoids 0.76 (0.607,0.951) 
Admit Med Class Statins 0.913 (0.569,1.47) 
Admit Med Class Insulin 0.88 (0.769,1.01) 
Admit Med Class Opioids 1.103 (0.994,1.22) 
Admit Med Va Class Antidotes Deterrents And Poison Control 
Exchange Resins 
1.306 (1.13,1.51) 
Admit Med Va Class Antihistamines Phenothiazine 1.126 (0.851,1.49) 
Admit Med Va Class Extended Spectrum Penicillins 0.751 (0.644,0.876) 
Admit Med Va Class Anti Infectives Other 0.924 (0.805,1.06) 
Admit Med Va Class Anticoagulants 1.013 (0.9,1.14) 
Admit Med Va Class Non Opioid Analgesics 0.759 (0.664,0.868) 
Admit Med Va Class Benzodiazepine Derivative Sedatives 
Hypnotics 
1.007 (0.87,1.17) 
Admit Med Va Class Anticonvulsants 1.134 (0.957,1.34) 
Admit Med Va Class Antidepressants Other 1.153 (1,1.33) 
Admit Med Va Class Antipsychotics Other 0.647 (0.508,0.824) 
Admit Med Va Class Beta Blockers Related 1.179 (1.05,1.32) 
Admit Med Va Class Antilipemic Agents 0.829 (0.531,1.3) 
Admit Med Va Class Potassium Sparing Combinations Diuretics 1.007 (0.887,1.14) 
Admit Med Va Class Ace Inhibitors 0.731 (0.524,1.02) 
Admit Med Va Class Cardiovascular Agents Other 1.446 (1,2.08) 
Admit Med Va Class Emollients 0.68 (0.514,0.901) 
Admit Procedure Dialysis 0.765 (0.555,1.05) 
Admit Procedure Paracentesis 1.453 (1.3,1.63) 
Admit Condition SBP 1.631 (1.41,1.88) 
3 Day Pre Admit Procedure Paracentesis 1.573 (1.2,2.06) 
 
 170 
  
 171 
Appendix Table 3b: Overall GEE model performance using the LASSO variables yielding 
the minimum deviance. 
 
Value 
Intercept -0.154 (-0.319, 0.012) 
Slope 0.926 (0.860, 0.993) 
Brier 0.052 (0.050, 0.055) 
AUC 0.843 (0.833, 0.853) 
O/E 0.998 (0.913, 1.083) 
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Appendix 4: Distribution of number of patients as a function of number of admissions. 
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Appendix Table 5: Discrimination and calibration statistics for each cluster along with 
95% confidence intervals obtained by bootstrap sampling.  
Clusters with “N/A” had ≤ 2 observations. When comparing the cluster number with the cluster 
map in Figure 3, cluster #1 starts in the bottom left corner and proceeds row-wise until cluster 
#49 in the top right corner. 
Cl. N Intercept Slope Brier AUC 
1 423 -0.374 (-0.707,-
0.04) 
0.612 (0.387,0.837) 0.17 
(0.15,0.191) 
0.665 
(0.606,0.725) 
2 927 1.647 (-
3.471,6.765) 
1.555 (0.289,2.82) 0.008 
(0.003,0.013) 
0.803 
(0.554,1.051) 
3 1535 0.686 (-
0.552,1.923) 
1.217 (0.883,1.551) 0.016 
(0.01,0.022) 
0.859 
(0.784,0.934) 
4 2026 0.785 (-
0.002,1.572) 
1.214 (0.966,1.461) 0.027 
(0.021,0.033) 
0.821 
(0.767,0.875) 
5 973 0.458 (-
0.637,1.553) 
1.075 (0.731,1.42) 0.033 
(0.022,0.044) 
0.762 
(0.678,0.846) 
6 236 -0.166 (-
0.644,0.312) 
0.82 (0.507,1.132) 0.146 
(0.116,0.176) 
0.749 
(0.672,0.826) 
7 266 -1.001 (-1.747,-
0.255) 
0.381 (-
0.017,0.779) 
0.139 
(0.11,0.168) 
0.617 
(0.52,0.714) 
8 321 -0.615 (-1.144,-
0.087) 
0.682 (0.426,0.937) 0.124 
(0.1,0.149) 
0.757 
(0.702,0.812) 
9 860 0.366 (-
0.196,0.928) 
1.037 (0.807,1.266) 0.08 
(0.066,0.094) 
0.792 
(0.745,0.839) 
10 1332 2.172 (0.58,3.764) 1.665 (1.2,2.13) 0.02 
(0.013,0.028) 
0.865 
(0.794,0.937) 
11 2006 0.104 (-
0.523,0.73) 
1.004 (0.81,1.197) 0.045 
(0.036,0.053) 
0.775 
(0.733,0.817) 
12 1 N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) 
13 327 -0.262 (-
1.273,0.749) 
0.69 (0.281,1.1) 0.101 
(0.071,0.13) 
0.649 
(0.555,0.743) 
14 0 N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) 
15 66 4.122 (-
47.616,55.859) 
4.391 (-
14.986,23.769) 
0.029 (-
0.001,0.059) 
0.515 (-
0.17,1.2) 
16 425 -0.427 (-
1.51,0.656) 
0.865 (0.482,1.247) 0.05 
(0.033,0.067) 
0.819 
(0.722,0.916) 
17 1117 0.757 
(0.207,1.306) 
1.315 (1.092,1.539) 0.053 
(0.043,0.063) 
0.868 
(0.832,0.904) 
18 1223 0.053 (-
0.327,0.433) 
0.975 (0.807,1.144) 0.092 
(0.08,0.104) 
0.78 
(0.743,0.817) 
19 378 0.176 (-
0.421,0.773) 
0.906 (0.656,1.157) 0.109 
(0.083,0.134) 
0.782 
(0.727,0.838) 
20 457 -0.548 (-
1.528,0.431) 
0.963 (0.544,1.382) 0.035 
(0.023,0.048) 
0.801 
(0.712,0.89) 
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Cl. N Intercept Slope Brier AUC 
21 811 -1.029 (-1.621,-
0.437) 
0.541 (0.313,0.769) 0.077 
(0.061,0.092) 
0.665 
(0.603,0.728) 
22 508 1.535 (-
0.659,3.729) 
1.55 (0.883,2.218) 0.02 
(0.009,0.032) 
0.835 
(0.75,0.92) 
23 892 -0.312 (-
2.116,1.492) 
1.022 (0.544,1.5) 0.013 
(0.007,0.02) 
0.768 
(0.665,0.871) 
24 788 -0.435 (-0.77,-0.1) 0.699 (0.496,0.901) 0.137 
(0.122,0.152) 
0.694 
(0.649,0.739) 
25 831 -0.518 (-
1.105,0.07) 
0.888 (0.647,1.13) 0.055 
(0.041,0.068) 
0.783 
(0.728,0.837) 
26 819 0.148 (-
1.106,1.402) 
1.126 (0.642,1.61) 0.037 
(0.027,0.047) 
0.785 
(0.687,0.882) 
27 121 7.581 (-
13.038,28.201) 
4.699 (-
6.656,16.053) 
0.034 
(0.011,0.058) 
0.969 
(0.917,1.02) 
28 1092 0.956 (0.24,1.672) 1.209 (0.955,1.463) 0.054 
(0.043,0.066) 
0.807 
(0.761,0.854) 
29 1256 1.191 (-
1.188,3.571) 
1.573 (0.826,2.321) 0.011 
(0.006,0.016) 
0.785 
(0.661,0.908) 
30 907 0.137 (-
0.709,0.983) 
0.947 (0.636,1.259) 0.061 
(0.048,0.075) 
0.719 
(0.652,0.785) 
31 261 -0.081 (-
0.465,0.302) 
1.02 (0.695,1.344) 0.16 
(0.135,0.185) 
0.761 
(0.699,0.824) 
32 506 -0.316 (-0.544,-
0.089) 
0.584 (0.377,0.791) 0.206 
(0.185,0.226) 
0.667 
(0.612,0.722) 
33 622 -0.043 (-
0.981,0.894) 
1.011 (0.669,1.353) 0.043 
(0.03,0.056) 
0.85 
(0.778,0.923) 
34 1142 1.51 (-
0.911,3.931) 
1.631 (0.868,2.394) 0.012 
(0.008,0.017) 
0.871 
(0.76,0.981) 
35 1493 -0.226 (-
1.705,1.253) 
1.128 (0.703,1.554) 0.012 
(0.007,0.017) 
0.83 
(0.742,0.918) 
36 815 -0.211 (-
1.09,0.668) 
0.87 (0.557,1.183) 0.057 
(0.043,0.07) 
0.714 
(0.644,0.785) 
37 449 -0.219 (-
1.143,0.705) 
1.029 (0.644,1.414) 0.039 
(0.024,0.055) 
0.829 
(0.745,0.913) 
38 813 -0.019 (-
0.633,0.595) 
0.889 (0.631,1.146) 0.083 
(0.068,0.098) 
0.749 
(0.685,0.813) 
39 253 -0.914 (-1.583,-
0.246) 
0.411 (0.162,0.66) 0.124 
(0.091,0.156) 
0.661 
(0.575,0.748) 
40 192 0.566 (-
1.037,2.169) 
1.535 (0.664,2.407) 0.058 
(0.036,0.08) 
0.936 
(0.886,0.986) 
41 562 0.275 (-
3.947,4.496) 
1.457 (0.262,2.653) 0.008 
(0.001,0.014) 
0.85 
(0.636,1.064) 
42 604 -0.296 (-
0.707,0.116) 
0.821 (0.607,1.036) 0.115 
(0.098,0.132) 
0.782 
(0.736,0.827) 
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Cl. N Intercept Slope Brier AUC 
43 1456 0.756 
(0.034,1.479) 
1.23 (0.994,1.466) 0.036 
(0.028,0.044) 
0.819 
(0.774,0.864) 
44 308 1.862 (-
0.798,4.523) 
1.7 (0.767,2.633) 0.023 
(0.01,0.036) 
0.874 
(0.786,0.962) 
45 488 -0.619 (-
1.257,0.018) 
0.696 (0.378,1.014) 0.109 
(0.086,0.133) 
0.676 
(0.602,0.749) 
46 2 N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) N/A (N/A,N/A) 
47 1537 0.181 (-
0.325,0.687) 
1.063 (0.841,1.285) 0.072 
(0.062,0.082) 
0.747 
(0.706,0.788) 
48 131 -1.849 (-
9.556,5.859) 
1.985 (-
5.986,9.957) 
0.031 
(0.012,0.05) 
0.91 
(0.805,1.015) 
49 854 -1.399 (-
4.175,1.376) 
1.168 (0.312,2.024) 0.006 
(0.002,0.01) 
0.908 
(0.802,1.013) 
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Appendix 6: Sensitivity analysis taking patients with HRS who were admitted with acute 
decompensated heart failure or acute myocardial infarction and re-assigning them to the 
no-HRS group. Performed to assess the possibility of misdiagnosing cardiorenal syndrome.  
As cardiorenal syndrome develops in the setting of acute (or acute on chronic) 
decompensated heart failure (ADHF) or acute myocardial infarction (AMI),304–306 we 
performed a sensitivity analysis assigning patients with decompensated  heart failure or 
acute myocardial infarction who had an HRS ICD9 code to the “No HRS” cohort.  
METHODS: We identified patients with decompensated heart failure by an ICD9 code 
for acute or acute on chronic heart failure (428.21, 428.23, 428.31, 428.33, 428.41, 
428.43) occurring any time during the admission or a primary discharge diagnosis of 
heart failure (regardless of chronicity). We identified patients with an acute myocardial 
infarction by an ICD9 code (410.*) any time during the admission. 
There were 11 patients with ADHF and 19 patients with AMI who also had an ICD9 
code for HRS (out of a total of 2258).  
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Appendix Table 6a: Odds Ratios for the GEE model predicting HRS for statistically 
significant variables. 
Risk Factor GEE Odds Ratio 
(95% CI) 
Admit Intravenous Fluids / 1000 mL 0.899 (0.858,0.942) 
Admit MELD 1.154 (1.139,1.169) 
Baseline Creatinine 0.789 (0.749,0.831) 
Admit Sodium 0.982 (0.974,0.99) 
Admit Bicarbonate 0.98 (0.969,0.991) 
Admit Blood Urea Nitrogen 1.006 (1.004,1.008) 
Admit Glucose 0.997 (0.996,0.998) 
Admit Mean Corpuscular Hemoglobin 
Conc. 1.076 (1.024,1.131) 
Admit Mean Corpuscular Hemoglobin 1.003 (0.986,1.02) 
Admit Alanine Aminotransferase 0.999 (0.999,1) 
Admit Alkaline Phosphatase 1 (1,1) 
Admit Partial Thromboplastin Time 0.994 (0.988,1) 
Admit International Normalized Ratio 0.565 (0.493,0.647) 
Admit Systolic Blood Pressure 0.995 (0.993,0.998) 
Admit Temperature 0.954 (0.866,1.051) 
Admit Weight 1.002 (1.001,1.003) 
Admit Maximum Temperature 0.977 (0.907,1.053) 
# Paracentesis in 90 days Pre-Admit 1.104 (1.084,1.125) 
KDIGO Stage II (vs. KDIGO Stage I as 
baseline) 1.243 (1.099,1.406) 
KDIGO Stage III (vs. KDIGO Stage I as 
baseline) 1.005 (0.863,1.171) 
Hepatic Encephalopathy 1.58 (1.424,1.752) 
Home Medication Analgesics 0.859 (0.776,0.95) 
Home Medication Potassium Sparing 
Diuretics 1.072 (0.968,1.188) 
Admit Medication Albumin Infusion 1.474 (1.315,1.651) 
Admit Medication Non Opioid Analgesics 0.7 (0.616,0.796) 
Admit Procedure Paracentesis 1.519 (1.359,1.698) 
Admit Diagnosis SBP 1.56 (1.354,1.796) 
Intercept 10.913 
 
Appendix Table 6b: Overall GEE model performance. 
 
Value 
Intercept -0.039 (-0.206, 0.129) 
Slope 0.983 (0.921, 1.046) 
Brier 0.052 (0.049, 0.055) 
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AUC 0.841 (0.832, 0.850) 
O/E 0.998 (0.913, 1.084) 
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Appendix 7: Hepatorenal Syndrome ICD-9 Code Accuracy Identification 
Study Population 
We analyzed a retrospective cohort of patients hospitalized from among 124 medical 
centers in the Department of Veterans Affairs (VA) between January 1, 2005 and 
December 31, 2013.  We included all hospitalizations for patients who had a cirrhosis 
diagnosis (based on a history of two outpatient or one inpatient) ICD-9 code (571.2 or 
571.5) and had AKI during their hospitalization with a maximum inpatient creatinine of at 
least 1.5 mg/dl. We excluded hospitalizations where the patient was on dialysis prior to 
admission, did not have at least one serum creatinine value within the year prior to 
admission or during the inpatient stay, who had a diagnosis of HRS prior to the 
hospitalization, who had a prior hospitalization with AKI, or who were discharged in less 
than forty eight hours.  
We performed stratified sampling based on presence/absence of an ICD-9 code for 
Hepatorenal Syndrome, level of kidney injury, and level of liver disease.  We sampled in 
blocks of twelve: six patients were selected if they had an ICD-9 code for Hepatorenal 
Syndrome anytime during their hospitalization;   six patients (without an HRS ICD-9 
code) were selected based on two levels of kidney injury (KDIGO Stage I versus KDIGO 
Stage II and III) and three levels of MELD (< 20, >= 20, and unable to calculate). We 
randomly selected a total of 42 blocks (504 inpatient admissions) to serve as the gold 
standard cohort.  
Outcome 
Two physician annotators reviewed the 504 hospitalizations reviewing all clinical notes, 
relevant laboratory values, medications, and radiology reports to assign each 
hospitalization into one of five categories: HRS Type I, HRS Type II, HRS Type 
Indeterminate, Maybe HRS, and Not HRS based on International Ascites Club criteria, 
with the exception that chronic kidney disease did not automatically preclude HRS. We 
employed a training phase where the two annotators worked in blocks of twelve patients 
until the inter-annotator agreement was >= 0.8. Disagreements on the 504 patient set 
were adjudicated by a board certified nephrologist.  
Results 
The sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) of a discharge ICD-9 code for HRS were 57.6%, 88.8%, 78.6%, and 74.6%. 
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Appendix 8: Point Score Model 
A point-based scoring model was developed in line with the Framingham risk study.260 
Points ranged from -12 to 56 (median 13, IQR: 7 – 19). The points based model had an 
AUC of 0.835, intercept and slope of the observed-to-expected calibration line of -4.208 
and 1.043 respectively, and a Brier score of 0.424. 
Appendix Table 8a: Point allocation for statistically significant variables. 
Variable Categories Points 
Admit Intravenous Fluids  <500 1 
Admit Intravenous Fluids  (500,1e+03] 0 
Admit Intravenous Fluids  (1e+03,2e+03] 0 
Admit Intravenous Fluids  > 2000 -2 
Admit MELD < 7 -2 
Admit MELD (7,10] 0 
Admit MELD (10,15] 4 
Admit MELD (15,20] 9 
Admit MELD (20,25] 13 
Admit MELD (25,30] 18 
Admit MELD > 30 26 
Baseline Creatinine <1 1 
Baseline Creatinine (1,1.5] 0 
Baseline Creatinine (1.5,2] -1 
Baseline Creatinine (2,2.5] -2 
Baseline Creatinine (2.5,3] -3 
Baseline Creatinine (3,3.5] -4 
Baseline Creatinine (3.5,4] -4 
Baseline Creatinine > 4 -9 
Admit Sodium <125 2 
Admit Sodium (125,140] 0 
Admit Sodium > 140 -1 
Admit Bicarbonate < 10 1 
Admit Bicarbonate (10,15] 1 
Admit Bicarbonate (15,20] 0 
Admit Bicarbonate (20,25] -1 
Admit Bicarbonate > 25 -2 
Admit Blood Urea Nitrogen < 10 0 
Admit Blood Urea Nitrogen (10,20] 0 
Admit Blood Urea Nitrogen (20,40] 1 
Admit Blood Urea Nitrogen (40,80] 2 
Admit Blood Urea Nitrogen > 80 4 
Admit Glucose < 100 0 
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Admit Glucose (100,200] -1 
Admit Glucose (200,300] -3 
Admit Glucose (300,400] -5 
Admit Glucose > 400 -7 
Admit Mean Corpuscular Hemoglobin Conc. < 25 -1 
Admit Mean Corpuscular Hemoglobin Conc. (30,32] 0 
Admit Mean Corpuscular Hemoglobin Conc. (32,34] 1 
Admit Mean Corpuscular Hemoglobin Conc. (34,36] 2 
Admit Mean Corpuscular Hemoglobin Conc. > 36 3 
Admit Alanine Aminotransferase < 20 0 
Admit Alanine Aminotransferase (20,50] 0 
Admit Alanine Aminotransferase (50,150] 0 
Admit Alanine Aminotransferase (150,300] -1 
Admit Alanine Aminotransferase > 300 -4 
Admit Partial Thromboplastin Time < 30 0 
Admit Partial Thromboplastin Time (30,40] 0 
Admit Partial Thromboplastin Time (40,50] 0 
Admit Partial Thromboplastin Time (50,70] -1 
Admit Partial Thromboplastin Time > 70 -2 
Admit International Normalized Ratio < 1.2 0 
Admit International Normalized Ratio (1.2,1.5] -1 
Admit International Normalized Ratio (1.5,2] -3 
Admit International Normalized Ratio (2,2.5] -5 
Admit International Normalized Ratio > 2.5 -11 
Admit Systolic Blood Pressure < 90 1 
Admit Systolic Blood Pressure (90,120] 1 
Admit Systolic Blood Pressure (120,130] 0 
Admit Systolic Blood Pressure (130,140] 0 
Admit Systolic Blood Pressure > 140 -1 
Admit Weight < 45 -1 
Admit Weight (45,60] 0 
Admit Weight (60,100] 1 
Admit Weight > 100 2 
# Paracentesis in 90 days Pre-Admit < 2 0 
# Paracentesis in 90 days Pre-Admit (2,4] 2 
# Paracentesis in 90 days Pre-Admit (4,7] 3 
# Paracentesis in 90 days Pre-Admit > 7 7 
Hepatic Encephalopathy Present 3 
Home Medication Analgesics Present -1 
Admit Medication Albumin Infusion Present 3 
Admit Medication Non Opioid Analgesics Present -2 
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Admit Procedure Paracentesis Present 3 
Admit Diagnosis SBP Present 3 
KDIGO Stage 2 Renal Failure Present 1 
KDIGO Stage 3 Renal Failure Present 0 
 
Appendix Table 8b: Probability of HRS based on total points. 
Points Probability 
-16 0.039398 
-15 0.044875 
-14 0.051073 
-13 0.058074 
-12 0.065969 
-11 0.074851 
-10 0.084821 
-9 0.095981 
-8 0.108435 
-7 0.122287 
-6 0.137635 
-5 0.15457 
-4 0.173171 
-3 0.193498 
-2 0.215588 
-1 0.239451 
0 0.265064 
1 0.292363 
2 0.321244 
3 0.351561 
4 0.383125 
5 0.415705 
6 0.449039 
7 0.482837 
8 0.516793 
9 0.550595 
10 0.583936 
11 0.616526 
12 0.648102 
13 0.678433 
14 0.707331 
15 0.734648 
16 0.760279 
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17 0.784162 
18 0.806272 
19 0.826617 
20 0.845236 
21 0.862189 
22 0.877554 
23 0.891422 
24 0.903891 
25 0.915064 
26 0.925046 
27 0.93394 
28 0.941845 
29 0.948856 
30 0.955062 
31 0.960546 
32 0.965385 
33 0.969649 
34 0.973403 
35 0.976703 
36 0.979603 
37 0.982148 
38 0.984381 
39 0.986338 
40 0.988053 
41 0.989555 
42 0.99087 
43 0.992021 
44 0.993027 
45 0.993908 
46 0.994678 
47 0.995351 
48 0.995939 
49 0.996453 
50 0.996902 
51 0.997295 
52 0.997638 
53 0.997937 
54 0.998199 
55 0.998427 
56 0.998627 
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Appendix 9: Natural Language Processing pipeline to identify ascites from radiology 
reports. 
To identify ascites, we constructed a natural language processing (NLP) pipeline. To develop the 
pipeline we assembled a gold standard of radiology reports for cirrhotic patients. We filtered all 
available radiology reports to include only computed tomography, magnetic resonance imaging, 
and ultrasound examinations of the abdomen, pelvis, or chest.  Four hundred and fifty-six 
documents were randomly sampled and manually reviewed for assertion of ascites (either 
positive or negative). Of the reviewed documents, 124 were sampled for training and testing of 
the NLP pipeline (64 with at least one positive ascites assertion, 30 with at least one negative 
assertion and no positive assertions, and 30 with zero positive or negative assertions). The 
documents were split into a training (50%) and testing set (50%).  We converted the documents 
into a string of concept unique identifiers (CUIs) mapped to the Unified Medical Language 
System (version 2013AB)84 using the clinical Text Analysis Knowledge Extraction System 
(cTAKES) version 3.2.85 A rule-based algorithm was devised based on the training set using 
CUIs related to ascites. Performance was assessed on the testing set; the sensitivity, specificity, 
positive predictive value, and negative predictive value were 96.5%, 94.0%, 93.3%, and 96.9%, 
respectively. 
 
